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Abstract 
 
This thesis focuses on non-motor symptoms (NMS) of Parkinson’s disease (PD), 
particularly the neuropsychiatric symptoms of visual hallucinations, apathy and impulse 
control disorders. A clinical cohort study and pathology study were performed. PD 
patients (N=94) were recruited and each underwent neurological examination for motor 
aspects of the disease, detailed multi-domain cognitive assessment including executive 
and visuoperceptive function, and a battery of validated non-motor assessments for 
symptoms including mood, apathy, sleep, fatigue, psychosis, autonomic function, 
disability and health-related quality of life (QOL). A subgroup (N=50) also had detailed 
ophthalmological examination. In the autopsy study, the presence of ante-mortem visual 
hallucinations (VH) in PD donors was correlated with Lewy body (LB) density and 
distribution at different cortical locations. The clinical study examined the impact of 
NMS on QOL and found that NMS, particularly depression, had stronger association 
with QOL than motor scores, but despite this NMS were often under-reported by their 
treating neurologist. A significant proportion of pathologically confirmed PD patients 
presented exclusively with NMS and this led to misdiagnosis and, in some cases, 
inappropriate investigations and treatment. An aetiological model of VH was proposed 
and examined; factors investigated included dopaminergic medication, higher cortical 
function, sleep and ophthalmic pathology. Clinical associations of VH were rapid eye 
movement sleep behaviour disorder, autonomic function, and executive and 
visuoperceptive cortical function. There was however no clear association with co-
existing ophthalmic pathology. In the post-mortem analysis, LB involvement at 
corresponding cortical areas was confirmed, including frontal (executive) and temporal 
and trans-entorhinal (visuoperception) cortices. A meta-analysis of studies reporting 
5 
 
pathological gambling was performed and an association with dopaminergic 
medication, particularly dopamine agonist therapy, and co-existing psychopathology 
was confirmed.     
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Chapter 1 
Introduction 
1.1  Range of non-motor features of Parkinson’s disease 
Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by 
motor phenotype of tremor, rigidity, bradykinesia and gait disturbance. However, an 
increasing number of non-motor symptoms (NMS) have been recognised to be of 
clinical importance. These include autonomic dysfunction (gastrointestinal, 
genitourinary, cardiovascular, pupillomotor, thermoregulatory and sexual), sleep 
disturbance (daytime hypersomnolence, nocturnal insomnia, vivid dreaming, and REM 
sleep behavioural disorder), neuropsychiatric complications (cognitive impairment, 
depression, anxiety, apathy, impulse control disorders and dopamine dysregulation, 
visual hallucinations [VH] and delusional thought disorder), pain and fatigue.  NMS in 
PD are often under-recognized by treating physicians yet have significant impact on 
disability and health-related quality of life, particularly in advanced disease (Chaudhuri 
et al., 2006).  
1.1.2   Determinants of quality of life in Parkinson’s disease 
Several clinical determinants of Health-Related Quality of Life (Hr-QOL) in PD have 
been evaluated. Whilst it is clear that severity of motor symptoms and their treatment 
are important predictors of Hr-QoL scores in PD (Global Parkinson’s Disease Survey 
Steering Committee, 2002, Slawek et al., 2005), these factors may only explain a small 
proportion of Hr-QoL scores. Motor fluctuations (end of dose wearing-off, 
unpredictable “off” periods, morning akinesia, biphasic dyskinesia) (Chapuis et al., 
2005), peak-dose dyskinesias (Chapuis et al., 2005, Pechevis et al., 2005), postural 
instability and falls (Michalowska et al., 2005), freezing of gait (Kuopio et al., 2000), 
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bradykinesia, limb rigidity, abnormal posture, impaired speech (Gomez-Esteban et al., 
2007), and dysphagia (Miller et al., 2006) are all associated with reduced Hr-QOL. 
However, non-motor features, in particular depression (Schrag, 2006), but also 
cognitive impairment (Weintraub et al., 2004), fatigue (Yoshii et al., 2006, Martinez-
Martin et al., 2006), sexual dysfunction (Bronner et al., 2004, Moore et al., 2002), 
sweating dysfunction (hypo/hyperhidrosis) (Swinn et al., 2003), sleep quality (Scaravilli 
et al., 2003), excessive daytime somnolence (Weintraub et al., 2004), bladder and bowel 
problems (Sakakibara et al., 2001), and weight loss (Kashihara, 2006) also contribute to 
reduced Hr-QOL in PD. In addition, patient rather than disease related features such as 
psychological adjustment to the disease (Suzukamo et al., 2006), poor patient education 
(Shimbo et al., 2004), and perception of how the diagnosis was told (Global Parkinson’s 
Disease Survey Steering Committee, 2002) play an important role in patients self-rated 
Hr-QoL. Whilst studies differ in their methodology, multiple regression studies 
analysing the relative impact of different parameters on Hr-QOL in PD (Hobson et al., 
1999, Global Parkinson's Disease Survey Steering Committee, 2002, Slawek et al., 
2005, Chapuis et al., 2005, Kuopio et al., 2000, Gomez-Esteban et al., 2007, Weintraub 
et al., 2004, Karlsen et al., 1999, Schrag et al., 2000, Carod-Artal et al., 2007) have 
consistently demonstrated depression and disability as the major non-motor 
determinants of Hr-QOL in PD. Therefore clinical studies and drug trials in PD that 
typically use motor function as the primary outcome measure are unlikely to determine 
the effect on all non-motor aspects of disease or the overall impact on Hr-QOL, 
particularly in subjects where non-motor features predominate. 
1.2  Assessment of non-motor features of Parkinson’s disease 
Research on effective treatment for PD has traditionally concentrated on motor control 
through replacement of nigrostriatal dopamine depletion (Lang & Obeso, 2004). 
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Currently motor function on the Unified Parkinson’s Disease Rating Scale (UPDRS) 
Motor Score (Fahn et al., 1987) is the main outcome measure to determine efficacy of 
pharmacological agents as monotherapy in early PD, often supplemented by UPDRS 
activities of daily living (ADL) score, the Hoehn and Yahr staging system, the Schwab 
and England disability scale, assessment of time to adjunctive levodopa use, latency to 
development of motor complications and clinical global impression (CGI) indices 
(Wheatley et al., 2002). In addition, functional imaging of the dopaminergic system has 
been used as a potential marker of neuroprotection for pharmacological agents in early 
PD ([18]-fluorodopa positron emission tomography with ropinirole (Whone et al., 2003) 
and [123]-I β-CIT and single photon emission computer tomography with pramipexole, 
Parkinson Study Group, 2000). For adjunctive treatment in more advanced PD with 
motor fluctuations, reduction in “off” period (determined from patient diaries) is the 
most commonly used outcome measure. Other outcome measures in advanced disease, 
depending of the aim of the study and the population studied include the UPDRS motor 
score, UPDRS ADL score, L-dopa dose reduction, dyskinesia rating scales, CGI indices 
and health economic evaluations (Wheatley et al., 2002). In recent years, these 
observer-rated outcome measures have been supplemented by patient-rated health status 
scales, which are increasingly incorporated into clinical trials (Den Oudsten et al., 
2007). They have the advantage of including the patients’ perspective into the 
evaluation of newly available treatments, and incorporate multiple aspects of the disease 
for the patient’s well-being, including motor and non-motor symptoms, adverse effects, 
overall disability and the importance in patients overall evaluation of their lives. In 
addition, there has also been more emphasis given to specifically measuring non-motor 
aspects of PD and scales for NMS are increasingly being used as primary or secondary 
outcome measures in clinical trial designs. This has involved revision of existing scales 
that measure overall motor and non-motor aspects of PD (for example, the UPDRS) 
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with more emphasis given to non-motor features of the disease, validation of existing 
non-motor symptom scales developed and used in other neurological and non-
neurological disorders in PD and the development of PD specific non motor scales.  For 
example, a substantial revision of the UPDRS (Movement Disorder Society [MDS] 
sponsored revision of UPDRS, MDS-UPDRS) has been developed and undergone 
validation (Goetz et al., 2007; Goetz et al., 2008), with additional emphasis on non-
motor aspects of the disease that were not included in the original scale. Also, a specific 
non-motor scale, the Non-Motor Symptom Scale (NMSS) has been developed 
(Chaudhuri et al., 2006b) which contains nine dimensions covering the range of non-
motor features found in PD; cardiovascular, sleep/fatigue, mood/cognition, perceptual 
problems, attention/memory, gastrointestinal, urinary, sexual function, and 
miscellaneous symptoms. Other groups have developed specific non-motor scales in 
PD, for example the Scales in Outcome of Parkinson’s group (SCOPA) have validated 
scales for cognition (SCOPA-COG), autonomic function (SCOPA-AUT) and sleep 
(SCOPA-sleep). 
1.2.1  Movement Disorder Society revision of UPDRS 
The UPDRS has been the main outcome measure in clinical and pharmacological 
studies in PD and consists of four sections; Part I - mood, behaviour and mentation, Part 
II - activities of daily living, Part III - motor examination and Part IV - complications of 
therapy. However several criticisms of the UPDRS have been made based on limitations 
of scale structure and clinimetric properties, items encompassed in scale including 
motor and non-motor symptoms and instructions provided to facilitate scale 
administration and consistent scoring. The MDS sponsored a critique of the original 
UPDRS and an international task force was formed to develop and perform clinimetric 
testing of a novel scale (MDS-UPDRS) [Goetz et al., 2007]. Criticisms of the original 
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scale include: (1) Irregular placement of non-motor features throughout the UPDRS 
parts; mood, apathy and cognition in Part I; pain in Part II; and sleep and autonomic 
dysfunction in Part IV. The MDS-UPDRS retains the original four part structure 
however all non-motor items are included together in Part I (Non-motor experiences of 
daily living). These features are further subdivided into complex neuropsychiatric 
symptoms that require physician evaluation (cognition, psychosis, depression, anxiety, 
apathy and dopamine dysregulation), and other non-motor experiences which can be 
quantified using a patient questionnaire (sleep, staying awake during the daytime, pain 
and abnormal sensory sensations, urinary function, constipation, light-headedness on 
standing, and fatigue); (2) Structural inconsistencies in the UPDRS were identified, for 
example a combination of multiple item responses and yes/no answers are employed, 
and a given numeric answer did not always reflect same level of disability across scale 
items. In the MDS-UPDRS a consistent structure has been proposed throughout; all 
items scored 0 to 4 (normal, slight, mild, moderate, or severe), reflecting the impact of 
intensity and frequency of symptoms on everyday functioning; (3) Several important 
non-motor features are not included in the UPDRS and have been included in the 
revised version: anxious mood, impulse control disorders (ICD) and dopamine 
dysregulation syndrome (DDS), urinary problems, constipation problems, and impact 
on hobbies and other activities; (4) The UPDRS has particular emphasis on severe 
disability and is therefore unable to differentiate mild gradations in symptom severity, 
particularly in early disease. The MDS-UPDRS has more emphasis on rating mild 
disability or impairment, to reduce the liability to statistical floor effects; (5) The 
UPDRS was first published in book format, instructions for use were never readily 
available, and several items are ambiguous or are phrased in an unclear manner. To 
address these issues, the MDS-UPDRS will include instructions that guide raters on the 
overall scale, each section, and individual items with a short explanation for each 
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response that describes the exact criteria for that response. An effort was made to avoid 
medical jargon and the MDS-UPDRS questionnaire was reviewed for clarity by non-
physicians, including patients and their carers. In order to ensure uniformity among 
raters, a MDS-UPDRS formal teaching tape and certification programme will be 
available and the scale will be translated into a range of different languages; (6) an 
MDS-UPDRS appendix of suggested and recommended clinical scales will be provided, 
which will be available online and continuously updated, to allow more in depth 
measurement of the motor and non-motor symptoms identified (Goetz et al., 2008). 
1.3  Neuropathology of non-motor features of Parkinson’s disease 
The classical motor features of idiopathic PD result from depletion of dopaminergic 
neurons in the substantia nigra pars compacta. The pathogenesis of PD is complex and 
postulated mechanisms include involvement of ubiquitin proteasome system, 
mitochondrial dysfunction, oxidative stress and free radical mediated neuronal damage, 
excitotoxic cell damage, oligodendrocytic interaction and nerve trophic factor depletion 
(Olanow, 2007). Pathologically, PD is characterized the presence of ubiquitinated 
inclusions, Lewy bodies (LB) and Lewy neurites, which can also occur at a number at a 
number of extra-nigral locations and involve non-dopaminergic neurotransmitter 
systems (Braak et al., 2006). The exact role of LB in the pathogenesis of PD, whether 
toxic, neuroprotective or an epiphenomenon, remains unclear. Over 70 molecular 
constituents have been identified in LB, including alpha-synuclein, microtubule-
associated proteins, cell cycle proteins, kinases and components of the ubiquitin 
proteasome system (Wakabayashi et al., 2007). However, alpha-synuclein has received 
closest attention and immunohistochemistry to alpha-synuclein has become an integral 
part of the neuropathological diagnosis of PD (Dickson et al., 2009). Evidence for a role 
for alpha-synuclein has been suggested by an association of synuclein gene (SNCA) 
29 
 
mutations or dysregulation of wild type SNCA gene expression (for example 
multiplications, Ross et al., 2008) with Parkinsonism. Potential mechanisms of alpha-
synuclein-related toxicity include an effect on calcium homeostasis, cytoskeletal effects 
(including phosphorylation of tau), influence on lysosomal and mitochondrial function, 
including mitochondrial complex activity, mitochondrial lysis and fusion, and 
mitochondrial autophagy (mitophagy) (Vekrellis et al., 2011). LB are characteristically 
found in PD and related disorders, Dementia with Lewy Bodies (DLB) and Multisystem 
Atrophy (MSA). However LB pathology is not unique to these disorders and can occur 
in several other degenerative neurological conditions including Neurodegeneration with 
Brain Iron Accumulation (NBIA, Sneider et al., 2012), Subacute Sclerosing 
Panencephalitis (SSPE, Gibb et al., 1990), and Alzheimer’s disease. Therefore LB may 
represent a non-specific downstream process, encountered in different 
neurodegenerative disorders. In addition, autopsy studies have demonstrated a high 
burden of incidental LB pathology in some elderly individuals with no clinical evidence 
of an extrapyramidal disorder (Lees, 2009). Also, in certain subtypes of genetic 
Parkinsonism, for example autosomal recessive juvenile Parkinsonism, LB pathology 
may not be found, demonstrating that degeneration of dopaminergic neurons and 
Parkinsonian phenotype can occur in absence of LB. In PD the presence of extra-nigral 
LB is not always associated with neuronal loss (Lees, 2009). However post-mortem 
studies have demonstrated a correlation between cortical Lewy body counts and some 
non-motor features, including cognitive impairment (Mattila et al., 2000) and visual 
hallucinations (Harding et al., 2002).  
1.3.1  Braak staging hypothesis 
Autopsy studies of the topographic distribution of α-synuclein pathology provide 
important insights into neuroanatomical correlates of NMS in PD and their temporal 
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relationship to onset of motor symptomatology. Braak and colleagues have proposed a 
sequential staging of LB pathology in PD (Braak et al., 2006). Stage 1 involves the 
anterior olfactory structures and dorsal motor nucleus of the vagus (DMV) in the lower 
medulla. Involvement of the olfactory bulb and vagal nucleus have been proposed as 
pathological correlates for olfactory impairment and autonomic dysfunction 
(particularly gastrointestinal) respectively, which occur commonly in early PD and 
during the pre-motor phase of the disease. Stage 2 involves LB deposition in a number 
of brainstem nuclei including the locus coeruleus, lower raphe nuclei and reticular 
formation but confined to the medulla and pontine tegmentum. These pathological 
changes have been implicated in the development of REM sleep behavioural disorder 
(RBD) and mood disorders in early PD. According to this hypothesis, it is only during 
stages 3 to 4 that LB appear in the substantia nigra, and motor symptoms become a 
prominent feature of the disease. In more advanced disease (stages 5 to 6) diffuse 
deposition of LB in neocortical structures occur and this is proposed to account for the 
cognitive, behavioural and neuropsychiatric features that are encountered particularly in 
advanced disease. However, methodological aspects of the detailed pathological study 
by Braak have been criticised. In particular, post-mortem cases that were included in the 
study were selected by the presence of LB in the dorsal motor nucleus of vagus and in 
patients in whom LB were present in the substantia nigra but absent DMV were 
excluded. This selection bias makes it difficult to make the assertion that pathology 
begins in the medulla, if cases without DMV involvement are excluded. In addition, the 
Braak hypothesis has been independently examined by pathologists at other research 
centres, and this staging scheme does not apply to all patients. For example, a study by 
Halliday and colleagues identified three clinicopathological phenotypes in PD; (1) a 
malignant syndrome characterised by early dementia and severe neocortical LB 
involvement at an early stage, consistent with DLB, (2) younger onset patients with a 
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more typical clinical PD course and slow progression of LB pathology in a distribution 
compatible with the Braak staging system and (3) an older onset group, with shorter 
survival, higher LB loads and more frequent co-existing (for example tau) 
neuropathology (Halliday et al., 2008). In another study, Kalaitzakis and others 
examined 71 autopsy specimens (Kalaitzakis et al., 2008) with PD. The substantia nigra 
and nucleus basalis of Meynert were most commonly affected (100% and 98.5% 
respectively) and in 53% of cases the pattern of LB pathology was consistent with 
Braak staging, whereas in the remaining 47% this pattern was not evident and in 7% 
there were no alpha-synuclein inclusions in the DMV. In another study (Attems and 
Jellinger, 2008) 18.3% did not conform to the Braak distribution and in 8.3% there was 
no LB pathology in the DMV despite higher brainstem and cortical involvement. These 
studies suggest that the caudal to rostral spread of LB pathology, according to Braak, 
does occur in a significant proportion of PD patients but other patterns can be found, 
including neocortical involvement in early disease. The exact role of LB in the 
pathogenesis of PD is not completely elucidated, however these studies demonstrate 
that pathology in PD is not confined to the substantia nigra or dopaminergic 
neurotransmitter systems, with widespread brainstem, limbic and cortical involvement 
and this may be basis for the diverse non-motor phenotype of the disease.     
1.4  Early non-motor features of Parkinson’s disease 
1.4.1  Sleep disorders 
REM sleep behavioural disorder (RBD) is a parasomnia commonly occurring in PD and 
characterized by dream enactment and loss of muscle atony during REM sleep. Insights 
into the pathophysiology of RBD have been gained from brainstem structural lesions in 
humans, post-mortem autopsy studies and animal models. RBD has been described in 
case reports in association with demyelination of the dorsal pontine tegmentum, 
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ischaemic pontine lesions, ponto-mesencephalic cavernoma and brainstem neurinoma 
(Boeve et al., 2007). Incidental brainstem LB pathology has been demonstrated in an 
autopsied case of idiopathic RBD (iRBD) (Uchiyama et al., 1995). Proposed anatomical 
loci of RBD in humans, extrapolated from animal models, include the pre-coeruleus, 
sublaterodorsal nucleus and lateral pontine tegmentum (Boeve et al., 2007). These 
topographical locations correspond to brainstem regions that are involved before the 
development of striatal LB pathology (stages 1 to 2) according to the Braak hypothesis. 
This may provide an explanation for the high prevalence of RBD in PD and its 
occurrence prior to motor impairment.  
There have been a number of epidemiological studies showing an association between 
RBD and the development of PD or other neurodegenerative disorders. For example, in 
one study of 44 patients presenting to a sleep centre with iRBD confirmed by 
polysomnography, 20 (45%) subsequently developed a neurodegenerative disorder (PD 
in nine, DLB in six, and MSA in one) at a mean 11.5 years after symptom onset and 5.1 
years after formal diagnosis of RBD (Iranzo et al., 2006). In a second study, 57% of 
patients presenting to a sleep clinic with RBD had an underlying neurological disorder, 
and of those with PD, 52% had symptoms of RBD preceding the development of motor 
symptoms (Olson et al., 2000).  
Several imaging studies in iRBD have demonstrated early pre-motor basal ganglia 
changes. An imaging study assessing pre-synaptic dopamine transporter (DAT) using 
[123]IPT single photon emission computer tomography (SPECT) has revealed 
significantly reduced striatal uptake in iRBD patients compared with controls, but less 
than in symptomatic PD (Eisensehr et al., 2000). [13C]dihydrotetrabenazine positron 
emission tomography (PET) in patients with iRBD has demonstrated reduced binding in 
all striatal nuclei, particularly the posterior putamen (Albin et al., 2000), and a cerebral 
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perfusion study (99m-Tc ethylene cysteinate dimer, [ECD] SPECT) in iRBD has shown 
increased perfusion bilaterally in the pons and putamen with reduced perfusion of the 
frontal and temporo-parietal cortices, a metabolic picture consistent with that found in 
idiopathic PD (Mazza et al., 2006).  
These studies suggest that there is a predisposition to future development of PD in 
patients with iRBD and that early striatal and cortical metabolic changes may already be 
present, even years before the appearance of motor symptoms or clinical presentation of 
PD. Other disorders of sleep may also predict subsequent development of PD. A large 
population-based study (Honolulu-Asia Aging Study, n = 3078) revealed that daytime 
excessive somnolence was a risk factor (odds ratio [OR] 2.8, p = 0.014) for 
development of PD (Abbott et al., 2005).  
1.4.2  Neuropsychiatric illness and cognitive impairment 
LB deposition occurs in brainstem loci implicated in affective disorders, such as the 
noradrenergic locus coeruleus and serotoninergic dorsal raphe nuclei, and this can 
precede basal midbrain involvement. This may explain the high prevalence of 
depression in early PD, often preceding the development of motor symptoms (Shiba et 
al., 2000). In a recent systematic review of psychiatric illness preceding motor 
symptoms in PD (Ishihara & Brayne, 2006), two cohort studies, one nested case-control 
(NCC) study and six case-control studies were identified for depression and PD. Five of 
six case-control studies, both cohort studies and the NCC showed a statistically 
significant association between a history of depression and subsequent development of 
PD. These studies included a large retrospective cohort study (NCC, N = 105 416) 
(Leentjens et al., 2003) using a general practice based register which found that at 
diagnosis of PD, 9.2% of patients had a history of depression compared with 4.0% of 
controls (odds ratio 2.4, 95% confidence interval [CI] 2.1 to 2.7).  
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The retrospective cohort study by Schuurman and colleagues found that compared with 
controls, depressed subjects had a relative risk of 3.13 (95% CI 1.95 to 5.01) of 
subsequently developing PD (Schuurman et al., 2002). Meanwhile, a similar study to 
assess the likelihood of developing PD found that depressed subjects had a relative risk 
of 2.20 (95% CI 1.70 to 2.84) and 2.24 (95% CI 1.72 to 2.93) compared with a diabetes 
cohort and osteoarthritis cohort respectively (Nilsson et al., 2001). A case-control study 
has identified increased prevalence of pre-morbid anxiety disorders in PD compared 
with controls (Shiba et al., 2000), and in a large prospective study (n = 35 815) using 
the Crown-Crisp phobic anxiety index there was an increased risk of developing PD 
(RR 1.5, 95% CI 1.0 to 2.1) in those with highest level of anxiety at baseline 
(Weisskopf et al., 2003).  
Therefore, depression and anxiety may be predictive of future development of PD. 
Several functional imaging studies in PD have demonstrated signal change in the 
brainstem (corresponding to loci of early LB deposition), which correlate with 
clinimetric indices of mood. For example, in a study using 123I-βCIT SPECT, dorsal 
midbrain binding reflecting serotoninergic function, was significantly correlated with 
UPDRS mood and mentation scores but not motor function (Murai et al., 2001). 
Additionally, trans-cranial sonography (TCS) has shown hypo-echogenicity of the 
dorsal raphe in PD patients in whom depression preceded motor symptoms (Walter et 
al., 2007). These imaging studies suggest that degeneration of serotoninergic and 
noradrenergic brainstem nuclei can occur in parallel or precede substantia nigra 
degeneration leading to affective disorders in the early and pre-motor phase of PD. 
Development of dementia is common in PD, particularly in the later stages. However, a 
number of studies using detailed neuropsychological assessments, including tests 
sensitive to frontal lobe function, have revealed that cognitive impairment, particularly 
35 
 
dysexecutive, can occur early in PD (Lees & Smith, 1983). PD dementia (PDD) and 
DLB are distinguished by whether dementia occurs within one year of onset of motor 
symptoms, but this is perhaps an arbitrary distinction given the common 
neuropathology (α-synuclein containing LB deposition) and overlapping non-motor 
symptomatology of the two diseases. Imaging studies in PD have revealed that 
disruption of frontal-striatal dopaminergic connections can occur early in PD and is 
associated with abnormalities in frontal executive cognitive function. In a study using 
[18F] fluorodopa PET in patients with early PD (mean disease duration 1.3 years) 
fluorodopa uptake was, as expected, decreased in the striatum compared with controls 
(Brück et al., 2005). However, in PD there was also increased cortical fluorodopa 
activity and uptake in the right dorsolateral prefrontal cortex (DLPFC) which was 
correlated with tests of sustained attention (vigilance test) and increased uptake in the 
medial frontal and anterior cingulate cortices which was negatively correlated with the 
Stroop test. In a functional magnetic resonance imaging (fMRI) study, comparing PD 
patients with and without selective executive impairment (Lewis et al., 2003), 
significantly more hypoactivation in the DLPFC, ventrolateral PFC and putamen during 
working memory testing was demonstrated in the executively impaired group. These 
cognitive changes may in part be L-dopa responsive given their associated with striatal 
changes on functional imaging, the association of cognitive and attentional deficits with 
‘on’/ ‘off’ motor fluctuations in some patients, and evidence of exacerbation of 
executive dysfunction secondary to L-dopa withdrawal in some studies (Lange et al., 
1993). While there has been no systematic analysis of cognitive impairment in patients 
with PD susceptibility in the pre-motor phase, the association of cognitive impairment 
with striatal dopamine depletion and impairment of striato-frontal cortical projections, 
suggests executive function may be an early pre-motor feature of PD. 
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1.4.3  Olfaction 
Several epidemiological studies have suggested that impaired olfaction is an early 
marker of idiopathic PD. In the Honolulu-Asia Aging Study, 2267 participants had 
olfactory testing at baseline and those in the lowest quartile of olfaction had a 
significantly increased age-adjusted risk of subsequently developing PD (OR 5.2, 95% 
CI 1.5 to 25.6) compared with the top two quartiles (Ross et al., 2008). In a two-year 
longitudinal study of first-degree relatives of patients with PD, olfactory testing was 
used to select normosmic and hyposmic individuals who then underwent DAT SPECT 
(Ponsen et al., 2004). At two years, 10% of the hyposmic group who had shown 
markedly reduced DAT binding on SPECT imaging at baseline had developed clinical 
PD. In the remainder of the hyposmic group, despite no clinical evidence of 
parkinsonism, DAT binding had decreased more than normosmic controls. In a further 
study of 30 subjects with idiopathic hyposmia, 11 demonstrated hyper-echogenicity of 
the substantia nigra on transcranial sonography (a potential diagnostic tool for early 
dopamine depletion in PD), yet the majority had no motor features or signs suggestive 
of PD. Despite this, DAT SPECT was abnormal in five and had borderline binding 
ratios in two (Sommer et al., 2004), suggestive of possible pre-motor PD.  
The University of Pennsylvania Smell Identification Test (UPSIT), a 40-item odour 
identification test, has been extensively studied in PD. In a study of early PD (mean 
Hoehn and Yahr stage 1.4), a strong correlation between UPSIT scores and DAT 
SPECT imaging indices in the striatum as a whole (regression coefficient 0.66, p = 
0.001), and particularly the putamen (0.74, p < 0.001) (Siderowf et al., 2005) was 
demonstrated. Extrapolation of these findings into the pre-motor phase of PD is 
consistent with epidemiological studies of smell loss antecedent to clinical PD, and is 
supported by the topographical distribution of LB in anterior olfactory structures in 
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autopsy studies of early PD, and suggests a potential role of smell testing in the early 
diagnosis of PD.  
The use of self-administered smell identification kits (such as UPSIT) in the diagnosis 
of early or pre-motor PD, to differentiate PD from other extrapyramidal disorders, and 
to differentiate tremor-dominant PD from essential tremor has undergone extensive 
research. For example, olfactory function has been used to distinguish vascular 
parkinsonism (diagnosis based on localization of MRI lesions and vascular risk factors) 
and idiopathic PD (Katzenschlager et al., 2004). UPSIT scores were significantly lower 
in PD than in both vascular parkinsonism and controls. In a study where olfaction in PD 
was compared with atypical parkinsonian syndromes (Wenning et al., 1995), UPSIT 
scores were normal in progressive supranuclear palsy (PSP) and corticobasal 
degeneration (CBD) compared with controls, and there was only mild impairment in 
MSA. However, UPSIT scores were markedly reduced in the PD group and 
demonstrated good sensitivity (77%) and specificity (85%) in differentiating PD from 
atypical parkinsonism. Smell testing can be used to differentiate essential tremor and 
tremor-dominant PD, particularly in the early stages when other akinetic-rigid 
extrapyramidal features are not present (Ondo & Lai, 2005).  
Methods of smell testing include smell identification (such as the UPSIT), threshold 
detection, smell discrimination and odour memory (Hawkes, 2003). Olfactory 
identification tests may have reduced diagnostic utility in those with cognitive 
impairment or depression, features which can occur commonly in early PD. 
Additionally, local nasal disease should be actively sought (tests do not discriminate 
between conductive and sensorineural olfactory loss), as should lifestyle factors such as 
smoking history. Olfactory loss also occurs in the context of other neurodegenerative 
disorders such as Alzheimer’s disease (Hawkes, 2003). Nonetheless, given these 
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caveats, olfactory testing may provide an important screening tool in PD to allow risk 
stratification in combination with other pre-motor symptoms and direct use of 
diagnostic imaging (DAT SPECT scanning, transcranial sonography).  
1.4.4  Autonomic dysfunction 
Early and prominent autonomic dysfunction in the context of an akinetic-rigid 
syndrome (particularly if pyramidal or cerebellar features are also present) raises the 
possibility of MSA. However, autonomic features occur commonly in PD and often 
predate the onset of motor features. Epidemiological evidence suggests that constipation 
in particular may be an early pre-motor feature of PD. In the Honolulu Heart Program, 
6790 subjects were questioned about their bowel habits and in a 24-year follow-up 
period fewer than one bowel movement per day was associated with greater risk of 
developing PD (Relative Risk 4.1, 95% CI 1.7 to 9.6, p = 0.001) compared with those 
whose bowels were opened twice per day (Abbott et al., 2001). In a retrospective study, 
44.6% of respondents described onset of constipation preceding motor symptoms with a 
mean latency of 18.7 years (Ueki & Otsuka, 2004).  
Sexual dysfunction is common in PD and includes difficulties with sexual arousal, 
reduced libido, erectile dysfunction, and anorgasmia (Bronner et al., 2005). In a large 
retrospective epidemiological study (32,616 participants), men with erectile dysfunction 
had increased risk of subsequently developing PD (Relative Risk 3.8, 95% CI 2.4 to 6.0, 
p < 0.0001) (Gao et al., 2007). In another study, 23.3% of men and 21.9% of women 
reported that pre-morbid sexual dysfunction contributed to cessation of sexual activity 
following diagnosis of PD (Bronner et al., 2004).  
Orthostatic hypotension is common in PD, particularly in later disease, and can be a 
consequence of dopaminergic medication. However, in a study of patients with a 
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clinical diagnosis of PD, in whom MSA had been excluded using imaging of 
myocardial sympathetic function (cardiac [18F]-fluorodopa SPECT), orthostatic 
hypotension was of early onset (within 1 year of onset of motor symptoms) in 60% and 
in 13% preceded motor involvement (Goldstein, 2006). Autopsy examinations have 
revealed early involvement (LB deposition) of central (medulla oblongata) and 
peripheral (sympathetic and parasympathetic) neurons that control autonomic function 
in PD, which may represent a pathological basis for early autonomic symptoms (Braak 
et al., 2007).  
1.4.5  Sensory disturbance and pain syndromes 
Pain is a common and often early feature of PD. An autopsy study has demonstrated 
immunoreactive α-synuclein inclusion bodies in the spinal cord lamina I neurons in PD 
and these changes can occur early in the disease (Braak et al., 2007). These neurons are 
important in transmission of painful sensations and may represent a pathological basis 
for this pre-motor symptom. In addition, the emerging increase in tone that denotes 
substantia nigra par compacta cell loss often leads to pain, typically presenting as a 
‘frozen shoulder’. 
1.5  Neuropsychiatric features of Parkinson’s disease 
1.5.1   Visual hallucinations 
1.5.1.1  Epidemiology of visual hallucinations  
VH are common in PD and can involve extracampine hallucinations (illusions of 
presence and passage), illusional misinterpretations and formed VH with or without 
retained insight. Cross-sectional estimates of VH prevalence in PD range from 16-75 
percent (Goetz et al., 2009), with higher prevalence in studies using sensitive screening 
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questionnaires or structured psychiatric assessments (Williams et al., 2008). Lifetime 
prevalence of VH was a 50% in a large retrospective autopsy study in pathologically 
proven PD (445 patients) (Williams & Lees, 2005). The occurrence of VH may predict 
progression to more severe forms of psychosis including loss of insight and delusions, 
increased risk of nursing home placement and development of dementia (Fenelon and 
Alves, 2010). VH in PD have been associated with older age and longer disease 
duration (Fenelon and Alves, 2010, Papapetropoulos et al., 2005, Sanchez-Ramos et al., 
1996) and greater disease severity (Holroyd et al., 2001, Papapetropoulos et al., 2005). 
The role of dopaminergic medication in development VH is unclear. A majority of 
cross-sectional studies have shown no clear association between L-dopa and 
development of VH (Aarsland et al., 1999, Fenelon et al., 2000, Holroyd et al., 2001, 
Merins et al., 2004, Papapetropoulos et al., 2005, Williams et al., 2005, Benbir et al., 
2006, Fenelon and Alves, 2010). However in a large community based 12 year 
prospective study, development of VH was associated with higher L-dopa-equivalent 
doses at baseline (Forsaa et al., 2010). There is also stronger evidence for a positive 
association with dopamine agonist use than with levodopa preparations (Rascol et al, 
2000; Holloway et al, 2004; Onofrj et al., 2006, Stowe et al., 2008, Baker et al., 2009, 
Williams et al., 2005). Anti-cholinergic drug use has been implicated in development 
and exacerbation of VH but this association has not been clearly confirmed in clinical 
studies (Williams et al., 2005, Benbir et al., 2006). Some studies have shown an 
association of VH with co-existing psychiatric disorders, including depression 
(Sanchez-Ramos et al., 1996, Holroyd et al., 2001, Marsh et al., 2004) and apathy 
(Reijnders et al., 2009, Mosimann et al. 2006); however results are inconsistent and 
when other factors are considered, co-existing psychiatric comorbidity appears less 
important (Fenelon et al., 2000). Autonomic dysfunction has also been associated with 
the presence of VH in PD (Kitayama et al., 2008, Oka et al., 2007, Williams and Lees, 
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2005). VH have been associated with cardiac sympathetic denervation on [123]-
metaiodobenzylguanidine (MIBG) imaging (Kitayama et al., 2008, Oka et al., 2007) 
and with greater fall in systolic blood pressure and impaired norepinephrine response 
during tilt table testing (Oka et al., 2007).  
1.5.1.2  Diagnosis and assessment 
Psychotic features found in PD differ from those encountered in primary psychiatric 
conditions and other neurological disorders, for example visual illusions and 
hallucinations predominate whereas delusions and hallucinations in other modalities, 
such as auditory hallucinations, are less common. A number of rating scales are 
available to assess psychotic symptoms and many of these have been applied in PD. 
However the majority of scales were developed in general psychiatry populations and 
have not been validated specifically in PD and do not cover the range of psychotic 
features in PD. In a review of available rating scales, The Neuropsychiatric Inventory 
(NPI), Brief Psychiatric Rating Scale (BPRS), Positive and Negative Symptom Scale 
(PANSS) and the Schedule for Assessment of Positive Symptoms have been 
recommended as these scales have been applied in PD, have been used in studies other 
than by the original authors and have undergone successful clinimetric testing (Goetz, 
2009). However, none of these scales has been validated in PD or cover the entire 
spectrum of PD psychosis. This highlights the importance of developing specific, well 
validated psychosis scales in PD.  
Formal diagnostic criteria for psychosis in PD have been proposed (Ravina et al., 2007). 
These criteria include (1) presence of at least one characteristic symptom, including 
visual illusions, false sense of presence, hallucinations or delusions; (2) primary 
diagnosis of PD according to UK Brain Bank criteria; (3) symptoms occurring after the 
onset of PD; (4) symptoms that are recurrent or continuous for more than one month 
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and (5) exclusion of other causes, for example other causes of Parkinsonism such as 
DLB, psychiatric disorders such as schizophrenia, schizoaffective disorder, delusional 
disorder, or mood disorder with psychotic features, or a general medical condition 
including delirium (Ravina et al., 2007).    
1.5.1.3  Pathophysiology 
The exact aetiology of VH in PD is unknown but several factors have been implicated 
in the aetiopathogenesis in clinical, polysomnographic, functional imaging and 
histopathological studies. On the basis of these, attempts have been made to formulate 
an integrated model based on an imbalance of external and internal inputs (Diederich et 
al., 2005, Diederich et al., 2009, Goetz et al., 2009). This includes (a) impaired visual 
input and central visual processing through aberrant activation of primary and 
associative visual cortices, (b) impaired brainstem regulation of the sleep-wake cycle 
with fluctuating vigilance, intrusion of REM dream imagery into wakefulness and 
emergence of internally generated imagery, (c) cognitive dysfunction and (d) influence 
of dopaminergic drugs on mesolimbic and visual processing pathways (Goetz et al., 
2009).  
1.5.1.3.1 Visual input and central visual processing  
Impaired visual input in PD can result from disease-related pathophysiological changes 
such as retinal dysfunction, diminished visual acuity, reduced contrast sensitivity, 
colour discrimination and motion perception, and impairment of central visual 
processing pathways (Archibald et al., 2009), or coexisting, particularly age-related, 
ophthalmic factors or environmental considerations such as poor luminance. Evidence 
for abnormal retinal processing in PD includes reduced visual acuity, delayed visual 
evoked potentials and abnormal pattern electroretinograms (Nightingale et al., 1986), 
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and decreased colour discrimination and contrast sensitivity (Pieri et al., 2000), and 
these ophthalmic factors have been reported to be associated with VH in PD (Matsui et 
al., 2006, Holroyd et al., 2001, Diederich et al., 1998, Matsui et al., 2005). VH in PD 
have also been associated with ophthalmological disease such as cataracts (Matsui et al., 
2004) and retinitis pigmentosa (Hermanowicz, 2002) in a Charles Bonnet-type 
phenomenon (Schadlu et al., 2009).  
Visual inputs project to multiple cortical areas specialized for different visual attributes 
(Zeki et al., 1991). The temporal lobe, particularly parahippocampal and  entorhinal 
cortices and amygdala are thought to be important processing centres of the ventral 
visual processing stream (identification and discrimination) (Papapetropoulos, 2006a) 
and are involved in emotional visual processing (Morris et al., 2001). There is evidence 
of abnormal cortical visual processing in PD patients with VH from clinical, imaging 
and pathological studies: Neuropsychological studies of visuoperceptive function in PD 
patients with VH have demonstrated significantly slower image recognition (Meppelink 
et al., 2008), worse facial recognition and visual form discrimination (Ramirez-Ruiz et 
al., 2006, Ramirez-Ruiz et al., 2007) and abnormalities in subsets of the Visual Object 
Space Perception battery (Barnes et al., 2003). fMRI (Holroyd and Wooten, 2006, 
Meppelink et al., 2009), PET (Boecker et al., 2007), SPECT (Oishi et al., 2005) and 
MRI voxel based morphometry studies (Ramirez-Ruiz et al., 2007b) have also 
demonstrated abnormalities in areas involved in visual processing, and pathological 
studies have demonstrated high density of LB in the amygdala and temporal lobes, 
including parahippocampal cortex, in association with VH in LB disorders (Harding et 
al., 2002a, Kalaitzakis et al., 2009, Papapetropoulos et al., 2006). In addition 
significantly higher LB burden has been demonstrated in frontal, temporal and parietal 
cortices (Papapetropoulos et al., 2006).  
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1.5.1.3.2 Impairment of the brainstem-regulated sleep-wake cycle  
It has been hypothesized that altered visual input is counterbalanced by increased 
internal inputs resulting from impaired regulation of the brainstem sleep-wake cycle and 
intrusion of episodes of REM sleep during wakefulness (Diederich et al., 2005, Goetz et 
al., 2009). Clinical studies have demonstrated that RBD is more frequent among PD 
patients with VH than without (Benbir et al., 2006, Pacchetti et al., 2005, Sinforiani et 
al., 2008, Onofrj et al., 2006), and daytime somnolence has been shown to be an 
independent predictor of VH in PD (Fenelon et al., 2000).  In longitudinal studies, RBD 
has been associated with subsequent development of VH (Sinforiani et al., 2008, Onofrj 
et al., 2006, Onofrj et al., 2002). Polysomnography (PSG) studies in PD patients with 
VH have demonstrated significantly greater REM sleep aberration (Comella et al., 1993, 
Manni et al., 2002), significantly increased stage 1 REM sleep with tonic 
electromyogram (neurophysiological correlate of RBD) with these periods 
corresponding to occurrence of nocturnal hallucinations in most patients (Nomura et al., 
2003) and increased sleep onset REM periods (SOREMP) on multiple sleep latency 
testing (MSLT), with dream content during MSLT similar to regular hallucinations 
(Nomura et al., 2003). It has been suggested that VH in PD resemble hypnogogic 
hallucinations in narcolepsy (Nomura et al., 2003). A narcolepsy type phenotype with 
reduced sleep latency and high frequency of SOREMP (Arnulf et al., 2002) has been 
demonstrated in PD patients referred for excessive sleepiness. Furthermore, in a study 
using wrist-worn actigraphy, subjects with VH demonstrated significantly altered rest-
activity rhythms and unpredictable circadian patterns (Whitehead et al., 2008), 
implicating disruption of the brainstem-regulated sleep-wake cycle.  
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1.5.1.3.3 Cognitive Function 
Global cognitive impairment and dementia have been consistently associated with VH 
in PD (Papapetropoulos et al., 2005, Merims et al., 2004, Fenelon and Alves, 2010, 
Goetz et al., 2009, Holroyd et al., 2001). Abnormal visuoperception and frontal 
cognitive dysfunction in particular have been hypothesized to predispose to VH in PD. 
VH are associated with impairment of frontal sensitive tasks, for example reduced 
verbal fluency (Santangelo et al., 2007, Ramirez-Ruiz et al., 2006, Ozer et al., 2007, 
Grossi et al., 2005), Stroop duration and errors (Ozer et al., 2007) and poorer scores on 
Wisconsin Card Sorting Task (Sinforioni et al., 2008).  Functional imaging studies have 
also shown frontal cortical abnormalities in association with VH in PD (Nagano-Saito et 
al., 2004, Ramirez-Ruiz et al., 2008) and pathological studies have demonstrated 
significantly increased LB pathology in frontal cortical areas (Papapetropoulos et al., 
2006). It has therefore been proposed that impaired visual input and central 
visuoperceptive processing disinhibit release of stored visual memories resulting in VH, 
and that cognitive impairment, reduced vigilance and sleep-wake cycle all contribute to 
impairment in filtering these external and internal perceptions (Goetz et al., 2009). 
1.5.1.3.4 Dopaminergic transmission in limbic and visual processing pathways 
Dopamine acts as a neurotransmitter in the retina at multiple levels. Dopaminergic 
amacrine cells receive input from rod and possibly cone bipolar cells, dopamine has a 
direct effect on gap junction permeability between rods and cones and horizontal cells, 
and a diurnal variation of retinal dopamine has been demonstrated (Archibald et al., 
2009). The mesolimbic system is a dopaminergic pathway projecting from the midbrain 
ventral tegmental area via the striatal nucleus accumbens to the limbic system, 
amygdala and prefrontal cortex (Tisch et al., 2004). Dopaminergic neurotransmission in 
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these areas important for visual processing is a potential target for aberrant stimulation 
by dopaminergic drugs and this has been implicated in the pathogenesis of VH in PD 
1.5.2  Impulse control disorders 
ICD are manifest as reduced ability to resist pleasurable impulses and include 
pathological gambling, sexual dysfunction such as hypersexualtiy and paraphilia, 
excessive shopping and eating, and other compulsive activities such internet use. ICD 
have been estimated to occur in between 3.5 to 19% of PD patients (Weintraub et al., 
2010, Lee et al., 2010, Fan et al., 2009, Verbaan et al., 2009, Voon et al., 2006, 
Weintraub et al., 2006). ICD in PD are associated with dopaminergic medication, 
particularly dopamine agonist use (Ambermoon et al., 2011, Weintraub et al., 2010, Fan 
et al., 2009), with a possible dose relationship in some studies (Ambermoon et al., 2011, 
Lee et al., 2010). Early onset PD and younger age, but not disease severity, have also 
been implicated (Ambermoon et al., 2011). Other associations include previous history 
of ICD, family or personal history of substance misuse, personality traits (impulsivity, 
novelty and risk seeking) (Voon et al., 2011a, Voon et al. 2011b), and in some studies 
male sex, (Ambermoon et al., 2011), suggesting that these are predisposing factors to 
develop ICD on dopaminergic medications.  
1.5.2.1  Pathogenesis 
Striatal dopaminergic transmission has an important role in novelty seeking and reward 
(Wittmann et al., 2008, Balleine et al., 2007, Bodi et al., 2009) and this has been 
demonstrated in imaging studies assessing ventral striatal dopamine release using the 
dopamine D2 ligand [(11)C] raclopride. For example, increased ventral striatal 
dopamine release has been shown in PD patients with ICD in response to reward related 
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cues [Steeves et al., 2009, O’Sullivan et al., 2011] and in patients with dopamine 
dysregulation in relation to L-dopa use [Evans et al., 2006]. 
More marked dopaminergic loss has been reported in the dorsal compared to the ventral 
striatum in PD (Kish et al., 1988), with dopaminergic replacement therapy leading to 
improved motor function but tonic stimulation of less affected brain regions, including 
the ventral striatum, limbic system and prefrontal areas (Cilia et al., 2011). Resting over 
activity in these brain areas has been demonstrated in functional imaging studies in 
pathological gambling (PG) (Cilia et al., 2008). The effect of dopaminergic medication 
may be particularly important for agonists such as pramipexole and ropinirole, with 
greater affinity for dopamine D3 receptors, which occur at higher density in the ventral 
striatum and limbic system (Sokoloff et al., 1990). Dopaminergic stimulation is 
proposed to facilitate learning from positive feedback (reward mechanisms, thus leading 
to increased novelty and reward seeking behaviour) and to disrupt negative feedback 
(punishment learning) (Bodi et al., 2009). In addition, genetic polymorphisms in 
dopaminergic neurotransmission (DAT and dopamine receptor genes) have been 
implicated in impulse control disorders and addiction in PD and non-PD subjects (Cilia 
et al., 2011). 
1.5.3   Depression, anxiety and apathy 
1.5.3.1  Prevalence  
Establishing the prevalence of disorders of mood, motivation and anxiety in PD is 
complicated by the symptomatic overlap between the somatic features of the 
neuropsychiatric and underlying movement disorder, differences in the phenomenology 
of these disorders in PD (dPD) and the general population, frequently coexisting 
cognitive problems, psychiatric side effects of dopaminergic medication, the presence of 
48 
 
motor and non-motor fluctuations and the different diagnostic frameworks available (eg, 
Diagnostic and Statistical Manual [DSM], version IV [DSM-IV], applied with or 
without Structured Clinical Interview for DSM disorders and clinical rating scales) 
(Gallagher & Schrag, 2009). Thus estimates of prevalence of neuropsychiatric disorders 
in PD vary considerably in published studies (e.g. 2.7-90% for depression) (Reijnders et 
al., 2008). However, in a large systematic review of the prevalence of depression in PD, 
36 studies met criteria for inclusion and the weighted prevalence of major depressive 
disorder was 17%, minor depression 22%, dysthymia 13% and clinically significant 
depression in 35% (Reijnders et al., 2008). The prevalence of anxiety disorders in cross-
sectional studies has been estimated at between 20-49% (Chen et al., 2010, Dissanayaka 
et al., 2010, Riedel et al., 2010, Negre et al., 2010, Pontone et al., 2009, Kulisevsky et 
al., 2008, Nuti et al., 2004, Stein et al., 1990), with generalised anxiety disorder, panic 
disorder, agoraphobia and social phobia being most common. Apathy has an estimated 
prevalence of up to 60% in PD (Pedersen et al., 2009, Oguru et al., 2010). It frequently 
co-exists with depression, cognitive impairment, particularly dysexecutive syndromes, 
which may impact on motivation and make primary apathetic disorders difficult to 
differentiate.  
1.5.3.2  Pathophysiology of depression, anxiety and apathy 
Endogenous (e.g. involvement of monoamine neurotransmitter systems), environmental, 
genetic and psychological factors (e.g. personality, psychological adjustment to disease) 
are likely to be important in the development of mood disorders in PD (Schrag et al., 
2001). Thus, rates of depression are increased in several neurological and other chronic 
conditions. However, they are higher in PD and may predate the onset of motor 
symptoms (Shiba et al., 2000), suggesting that depression is a manifestation of PD. 
Several endogenous neurobiological factors are thought to underlie the development of 
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psychiatric features of PD. The loss of dopaminergic neurons particularly in the 
substantia nigra underlies the motor phenotype of the disease (tremor, rigidity, 
bradykinesia and gait disturbance). However, the epidemiological association of PD 
with higher rates of depression and anxiety, the association of dopaminergic medication 
with improvement of mood disorders (including in non-PD subjects [Corrigan et al., 
2000]) and the potential development of neuropsychiatric complications (mania, 
psychosis, ICD and DDS) on dopaminergic medication in some patients suggests a role 
of dopaminergic transmission in mood, motivation and reward (Voon et al., 2009). In a 
study using DAT SPECT in PD, anxiety and depression were correlated with left 
anterior putamen DAT availability (Weintraub et al., 2005), suggesting a role for 
dopaminergic pathways. This non-motor role of dopamine is also supported by 
experimental, pathological and functional imaging studies in neuropsychiatric disorders 
in non-PD subjects (Dunlop & Nemeroff, 2007). For example, post-mortem studies in 
depressed patients have demonstrated altered dopamine receptor gene expression in the 
amygdala and pre-synaptic DAT downregulation suggesting deficiency in mesolimbic 
dopamine (Klimek et al., 2002, Xiang et al., 2008), chronic antidepressant treatment 
may result in altered dopamine receptor gene expression (Lammers et al., 2000; Rocc et 
al., 2002) and polymorphisms in genes involved in dopamine metabolism and 
signalling, have been implicated in major depression (Opmeer et al. 2010). In addition, 
dopamine receptor polymorphisms have been implicated in anxiety disorders, including 
Obsessive Compulsive Disorder (Light et al., 2006), and fMRI has demonstrated striatal 
involvement in patients with generalized social phobia (Sareen et al., 2007).  
The involvement of extra-striatal and non-dopaminergic neurotransmitter systems in the 
disease course of PD has also become increasingly recognized (Braak et al., 2006). LB 
deposition in brainstem areas implicated in depression, including the serotoninergic 
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raphe nuclei and the noradrenergic locus coeruleus (Lowry et al., 2008; Itoi K & 
Sugimoto N, 2010), can precede basal midbrain involvement in PD (Braak et al., 2006). 
This may explain the occurrence of depression and anxiety in PD occurring during the 
pre-motor phase (Shiba et al., 2000). A PET study using serotonin transporter specific 
ligands has shown reduced caudate and putaminal serotonin transporter distribution 
volumes, similar to reduced striatal DAT density, reflecting loss of both serotonergic 
and dopaminergic innervation in PD (Kerenyi et al., 2003). In another recent PET study, 
depressive symptoms in PD correlated with relatively higher serotonin transporter 
binding in the median raphe nuclei and limbic structures, interpreted as reflecting lower 
extracellular serotonin levels in these areas (Politis et al., 2010). However other studies 
have shown no correlation between depressive symptoms and serotonin transporter 
availability (Strecker et al., 2011). A study using trans-cranial sonography has shown 
hypo-echogenicity of the dorsal raphe to be associated with onset of depression 
preceding motor deficit in PD (Walter et al., 2007). These studies support the 
involvement of serotonergic systems in depression in PD. Other studies have implicated 
cholinergic and noradrenergic pathways. A PET study examining cortical 
acetylcholinesterase activity demonstrated that depressive symptoms in PD are 
associated with cortical cholinergic denervation (Bohnen et al., 2007). A pathological 
study in PD showed involvement of catecholamine areas of the brain, particularly 
neuronal loss and gliosis in the noradrenergic locus coeruleus (Frisina et al., 2009) and a 
PET study showed reduced dopaminergic and noradrenergic innervation in the locus 
coeruleus and limbic system in depressed PD patients (Remy et al., 2005). 
A recent literature review examining the nosological validity of dPD (Even & 
Weintraub, 2011), identified three potential subtypes of depression in PD, (1) 
nonspecific casual comorbid dPD, patients who would have developed depression even 
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if they didn’t develop PD, (2) nonspecific reactive comorbid dPD, patients who are 
likely to have become depressed if they had another chronic debilitating illness, not 
necessarily PD and (3) specific comorbid dPD, directly related to the pathophysiology 
of PD. 
Reduced limbic and ventral striatal dopamine has been suggested a cause of apathy in 
PD, and there is evidence that apathetic symptoms may be at least partially responsive 
to dopaminergic medication (Czernecki et al., 2008). Imaging studies have shown 
reduced grey matter density in several cortical areas, including inferior frontal gyrus, 
insula and cingulate gyrus (Reijnders et al., 2010). Apathy is closely related to cognitive 
impairment, and may respond to cholinesterase inhibitors (McKeith et al., 2000a; 
McKeith et al., 2000b), suggesting cholinergic mechanisms are also important. 
1.5.3.3  Assessment of psychiatric Disorders in PD 
1.5.3.3.1 Depression 
Diagnostic frameworks for depression include DSM criteria for major, minor or 
subsyndromal depression and the International Statistical Classification of Diseases and 
Related Health Problems (ICD) criteria for a mild, moderate or severe depressive 
episode. DSM-IV-R diagnosis of major depression requires one or more of the two core 
criteria (depressed mood, loss of interest or pleasure), and a total of five or more 
symptoms including significant weight change, insomnia or hypersomnia, psychomotor 
retardation or agitation, fatigue, expression of worthlessness or guilt, reduced 
concentration or decisiveness or recurrent thoughts of death, with exclusion of 
symptoms attributable to medication or an underlying medical condition. However the 
diagnosis of depression in PD provides conceptual difficulties (Gallagher & Schrag, 
2009). A National Institute of Neurological Disorders and Stroke/ National Institute of 
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Mental Health working group examined the use of DSM-IV in PD (Marsh et al., 2006) 
and suggested that use of these criteria in PD may miss up to half of patients with 
clinically significant depression. Several recommendations were made: (1) the diagnosis 
should be made using an inclusive approach to include all symptoms, irrespective of 
potential aetiological basis, as it has the greatest sensitivity and reliability and does not 
require clinical judgment; (2) subsyndromal depression should be included as a 
diagnostic category in research studies; (3) the timing of assessment should be specified 
in patients with motor fluctuations, as a significant proportion of these patients describe 
prominent mood fluctuations; (4) informants should be used for cognitively impaired 
patients; and (5) anhedonia should only be diagnosed based on loss of pleasure rather 
than loss of interest for diagnosis of minor depression or subsyndromal depression, as it 
overlaps with apathy. In a recent large study there was a significant association between 
the severe depression and co-morbid apathy and anxiety and it has therefore been 
proposed that these features, particularly psychic anxiety, be added to the DSM 
diagnostic criteria but this will require further clarification (Starkstein et al, 2011). 
Some studies (Starkstein et al, 2011) reported that all items in the DSM-IV criteria 
identify severe depression with high statistical significance. However, others (Leentjens 
et al., 2003) reported that some somatic items (psychomotor slowing, tiredness, physical 
anxiety) are much poorer discriminators between depressed and non-depressed PD 
patients than core symptoms (low mood or loss of interest) or other non-somatic 
symptoms (guilt, suicidal ideation and psychic anxiety). Thus, whilst somatic symptoms 
are an important aspect of depression, particularly at the severe end, these may be less 
useful in distinguishing depressed from non-depressed patients with PD.  
Clinimetric rating scales are often used in large epidemiological studies and as outcome 
measures in therapeutic trials because they are quantifiable and do not require clinical 
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judgment. A systematic review of depression rating scales in PD has highlighted their 
diverse properties and clinical applicability (Schrag et al., 2007). Diagnosis of 
depression should only be made using validated clinical criteria, and where possible 
using structured interview, as false negatives can occur in patients with low mood and 
anhedonia but with few somatic symptoms and conversely, false positives can occur in 
the absence of low mood but with a large number of overlapping somatic symptoms in 
PD. Additionally, depressive symptoms in PD that present in atypical circumstances, 
such as in the context of motor fluctuations or dysphoric episodes in DDS, are not 
suitable for assessment by rating scales. Similar caveats apply to other neuropsychiatric 
diagnoses in PD. 
1.5.3.3.2 Anxiety 
DSM-IV-R categories for anxiety include panic attacks, agoraphobia, specific phobias, 
social phobias, obsessive compulsive disorder, post-traumatic stress disorder, acute 
stress disorder and general anxiety disorder. The application and clinical validity of 
DSM-IV-R criteria for anxiety in PD has not undergone the same in depth analysis as 
depression but suffers the same conceptual difficulties, particularly somatic symptom 
overlap, for example, DSM-IV criteria for general anxiety disorder include fatigability, 
impaired concentration, sleep disturbance and muscular tension, which are all very 
common in PD. In addition autonomic dysfunction, including cardiac, respiratory and 
gastro-intestinal involvement, is common in PD and these phenomena have substantial 
overlap with diagnostic items on anxiety criteria and rating scales. Anxiety disorders are 
also often co-morbid with depression in PD and can occur in the context of motor and 
non-motor fluctuations.  
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1.5.3.3.3 Apathy 
There is no definition or diagnostic framework for apathy in DSM-IV. Reduced interest 
and motivation can occur as a component of cognitive impairment or depression, and a 
full neuropsychological assessment should be made to exclude apathy in the context of 
cognitive impairment or depression. Diagnosis has previously been made using clinical 
judgement or rating scales, including the NPI and the Marin Apathy Evaluation Scale. 
More recently the Lille Apathy Rating Scale (LARS) has been developed and validated 
to assess apathy in PD (Sockeel et al., 2006). Two groups have recently proposed and 
validated diagnostic criteria that can be applied to PD. Diagnostic items include (1) 
diminished motivation compared to baseline level of functioning, (2) involvement of 
goal-directed behaviour, cognition and emotional domains, (3) symptoms sufficiently 
severe to cause significant impairment of personal, social or occupational function and 
(4) reduced motivation not attributed to the effects of physical disability, level of 
consciousness or medication (Robert et al., 2009, Starkstein et al., 2009). The first 
group formulated consensus criteria for apathy in Alzheimer’s disease and other 
neuropsychiatric disorders [Robert et al., 2009] and these have been validated in PD, 
showing good internal consistency, concurrent validity with the LARS and the apathy 
section of the NPI and discriminant validity against the depression section of the NPI 
(Drijgers et al., 2010). The second group performed a study to validate criteria 
specifically for diagnosis of apathy, based on modified Marin’s criteria for apathy and 
validated in other neurodegenerative disorders, which showed high sensitivity and 
specificity compared to an expert neuropsychiatrist’s clinical judgement (Starkstein et 
al., 2009). In this study 83% of patients with apathy had depression and 56% had 
dementia however 13% had neither depression or dementia, suggesting that apathy can 
exist as a distinct nosological entity (Starkstein et al., 2009).   
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1.6  General aims and objectives 
The aim of this thesis is to examine important non-motor aspects in PD. The impact of 
NMS on quality of life and disability in PD patients overall, and in sub-groups based on 
disease duration and Hoehn-Yahr stage, using detailed clinical rating scales for each 
non-motor feature will be examined. The detection and documentation of individual 
NMS, in the same PD cohort, using retrospective case notes audit will be made and 
compared to their relative importance on quality of life. NMS at PD diagnosis will be 
assessed in pathologically proven PD cases from the UK Brain Bank, and patients 
presenting with classical motor features (tremor, rigidity, bradykinesia, and gait 
disturbance) versus predominantly non-motor symptoms will be compared to determine 
whether this has impact on diagnostic accuracy in primary care or hospital setting, or 
influence on disease treatment and outcome. This part of the thesis led by Dr Sean 
O’Sullivan and was done in collaboration with the UK Brain Bank research team (Dr 
David Williams, Dr Luke Massey and Dr Laura Silveira-Moriyama) and Brain Bank 
pathologists (Professor Tamas Revesz and Dr Laura Parkinnen). The clinimetric 
assessment of NMS in PD will also be examined, with particular reference to the MDS-
UPDRS.  
This thesis has particular emphasis on neuropsychiatric phenomena, including VH, ICD 
and DDS, and disorders of mood and apathy. A detailed study of the aetiology of VH in 
PD will be made with particular emphasis on cognitive and visuoperceptive cortical 
function (based on bedside psychometric evaluation), ophthalmic factors (examined by 
an ophthalmologist) and in a separate pathological study, LB distribution in different 
cortical areas implicated in visual processing and hallucinations will be examined. A 
detailed literature review and meta-analysis will be performed on pathological gambling 
in PD, the archetypal ICD in PD and be used to determine potential demographic, 
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pharmacological and clinical associations, and a further exploratory analysis will be 
performed in our PD cohort. An assessment of the clinical determinants of apathy in PD 
will be made, including the relationship of apathy with depression and cognitive factors.         
1.7  Conclusion   
NMS are common in PD and occur throughout the course of the disease, including in 
the pre-motor phase, and have consistently been shown to have a significant impact on 
Hr-QOL. The pathophysiology of these disorders is likely to relate to widespread 
brainstem and cortical LB deposition, with involvement of different neurotransmitter 
systems, including dopaminergic, serotonergic, cholinergic and adrenergic transmission. 
The pathology of non-motor features in PD appears to be distinct from other 
neurological or primary psychiatric disorders, and there are particular challenges in the 
diagnosis of these disorders due to the comorbid physical, cognitive and psychiatric 
features found in PD. Therapeutic options are available for most NMS in PD, mainly 
based on treatments used in the non-PD context, but these interventions will require 
further evaluation and may have different clinical efficacy, due to distinct 
pathophysiological mechanisms in PD.   
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Chapter 2 
Data acquisition and clinical measures 
 
2.1   Clinical Study 
Patients with idiopathic PD attending out-patient clinics at University College London 
Hospital, The Royal Free Hospital and Luton and Dunstable Hospital were recruited 
into the clinical study. This study received ethical approval by The Royal Free Hospital 
and Medical School Research Ethics Committee, The National Hospital for Neurology 
and Neurosurgery and Institute of Neurology Joint Research Ethics Committee and 
Luton and Dunstable Research Ethics Committee. The research governance sponsor of 
this study was University College London Hospitals/University College London Joint 
Biomedical Research Unit, R&D Directorate. All patients fulfilled UK Brain Bank 
criteria for PD, and patients with other parkinsonian disorders were excluded. Any PD 
patient was eligible for inclusion, including those with cognitive impairment or 
dementia, provided they were felt able to complete the physician assessment, complete 
questionnaires at home, alone or with help from their partner or carer and to give 
consent for the study. All patients received a detailed patient information sheet and 
informed written consent was obtained. During the clinical interview assessments were 
performed in a standard sequence. Physician interview was performed in hospital or if 
there were mobility, transport or general medical issues, at the patients’ request in their 
own homes. Arrangements were made to interview patients at a time when they were 
most likely to be in an “on” motor state in relation to the timing of their dopaminergic 
medication.  In circumstances where there were cognitive or attentional difficulties, 
excessive somnolence or fatigue, or if during the interview the subject developed motor 
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or non-motor wearing “off” that had potential to compromise accurate scoring, 
interview was held over two or more separate sessions.   
 
Patients underwent a detailed clinical interview to record demographic details 
(occupational history, handedness, educational attainments, marital status, domestic 
living arrangements [alone, with partner or family, warden controlled accommodation, 
residential home or nursing home]), smoking, alcohol and recreational drug use history, 
PD history (symptom onset date, laterality of onset, disease duration and predominant 
clinical phenotype [tremor dominant, akinetic-rigid or mixed]), PD medication history 
(start date, treatment duration, maximum dose of each potential medication [levodopa, 
ergot and non-ergot dopamine agonists, monoamine oxidase inhibitors, catechol-o-
methyltransferase inhibitors, amantadine, or subcutaneous apomorphine], record of any 
neurosurgical interventions [for example, subthalamic nucleus or globus pallidus deep 
brain stimulation or pallidotomy],  history of cardiac, respiratory, gastrointestinal, 
endocrine or other medical comorbidities and medication. Each patient underwent full 
neurological examination and a battery of clinimetric tests, which included physician-
administered assessments and self-completed questionnaires, covering a wide range of 
motor and non-motor aspects of the disease. Non-motor assessments included cognitive 
scales (SCOPA-cognitive scale, SCOPA-COG, Marinus et al., 2003a, Addenbrooke’s 
Cognitive Examination [ACE], Larner et al., 2007, Frontal Assessment Battery [FAB], 
Dubois et al., 2000, and Birmingham Object Recognition Battery [BORB]), assessment 
of mood, motivation and anxiety (Hamilton Depression Rating Scale [HDRS], Schwab 
et al., 1967, Hospital Anxiety Depression Scale [HADS], Upadhyaya & Stanley, 1993 
and LARS, Sockeel et al., 2006), scales to assess nocturnal and daytime sleep and 
fatigue (Pittsburgh Sleep Quality Index [PSQI], Buysee et al., 1989, Epworth Sleepiness 
Scale [ESS], Johns et al., 1991, SCOPA-sleep scale, Marinus et al., 2003b, Fatigue 
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Severity Scale [FSS], Krupp et al., 1989, International Classification of Sleep Disorders, 
Revised (ICSD-R) diagnostic criteria for RBD, American Academy of Sleep Medicine, 
2001, International Restless Leg Syndrome Study Group Criteria for the diagnosis of 
Restless Leg Syndrome, Walters et al., 2003), quality of life scale (Parkinson’s Disease 
Questionnaire, 39 item version [PDQ-39], Fitzpatrick et al., 1997), assessment of 
autonomic function (SCOPA-autonomic scale [SCOPA-AUT], Visser et al., 2004), 
assessment of VH and psychosis (Parkinson’s Psychosis Rating Scale [PPRS], 
Friedberg et al., 1998, University of Miami Parkinson’s disease hallucinations 
questionnaire [UM-PDHQ], Papapetropoulos et al., 2008), Visual Analogue Scale 
[VAS] of Pain and Non-Motor Symptoms Questionnaire (NMSQ), Martinez-Martin et 
al., 2007. Motor measures were the UPDRS, Fahn et al., 1987, and MDS-sponsored 
revision of the UPDRS, Goetz et al., 2008.  
 
2.1.1  Cognitive Assessments 
2.1.1.1  Scales for Outcome in Parkinson’s, cognitive scale 
The SCOPA-COG is a cognitive scale developed specifically for use in PD (Marinus et 
al., 2003). In formulating this scale, the development team performed an extensive 
literature review of studies measuring cognitive function in PD and selected the 
cognitive domains most frequently affected in PD and within those domains selected 
items that most consistently distinguished PD from control subjects. Cognitive domains 
most frequently affected were attention, memory, executive and visuospatial function 
whereas verbal function and reasoning were excluded as these tended to be normal. The 
proposed scale items were applied to 85 PD patients and 75 age, sex and education 
matched controls.  Items were selected based on reproducibility and tests that 
significantly discriminated between patients and controls (P<0.05). Ten items were 
60 
 
retained which fulfilled criteria of eligibility; (1) four items were included in the 
memory domain including tests for both visual memory (copying the order in which 
cubes are pointed to) and verbal memory (backward digit span; reading and recalling 10 
words, with immediate and delayed recall), (2) two items in the attention domain were 
naming the months of the year in reverse order and counting backwards from 30 in steps 
of three, (3) the three items included in the executive domain were categorical verbal 
fluency (number of animals named in one minute), a set shifting task and test of motor 
planning (Luria sequencing task) and (4) one visuospatial test, figure assembly (patient 
asked to determine which shapes are needed to construct another figure). The maximum 
total scale score is 43 (Range 0-43), with lower scores indicating higher degrees of 
cognitive impairment. Individual domains are scored as follows: memory and learning 
0-22, attention 0-4, executive functions 0-12 and visuospatial functions 0-5. The scale 
showed high test-retest reliability (intraclass correlation coefficient 0.78) and internal 
consistency (Cronbach’s alpha 0.83). Convergent validity has been demonstrated by 
high correlation with the Cambridge Cognitive Examination (rho = 0.83, p < 0.001), 
Mini-Mental State Examination (MMSE, rho = 0.72, p < 0.001) (Marinus et al., 2003), 
and ACE (rho = 0.93, p < 0.0001) (Reyes et al., 2009). The SCOPA-COG had higher 
coefficient of variability than either Cambridge Cognitive Examination or MMSE, 
indicating better ability to detect cognitive differences between patients (Marinus et al., 
2003). In another study, a higher coefficient of variability was also demonstrated 
compared to the Mini-Mental Parkinson (Serrano-Duenas et al., 2010). In a further 
analysis (Verbaan et al., 2007), SCOPA-COG was applied to a large cohort of PD 
patients (N=400) and age, sex and education matched controls (N=150). PD patients 
scored significantly lower compared to controls on all SCOPA-COG domains, 
particularly executive and memory subscores. The total SCOPA‐COG score showed 
moderate correlation with motor function (rho = −0.35), psychotic symptoms (rho = 
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−0.33), autonomic function (rho = −0.28), and depressive symptoms (rho = −0.24). A 
regression analysis was performed to determine the influence of clinical and 
demographic variables on cognitive function and found that age and years of education 
had the largest effect (29% of variance), with levodopa dose and motor function (6%) 
and psychotic symptoms (6%) only having a small influence, suggesting that the scale is 
relatively independent of motor and other confounding neuropsychiatric features. In 
another study (Reyes et al., 2009), with receiver operating characteristic (ROC) analysis 
using The Mattis Dementia Rating Scale as a diagnostic reference, the area under the 
curve (AUC) was high, 0.92 (95% CI 0.83-1.00) demonstrating excellent discriminant 
validity, with high sensitivity (92%) and specificity (87%). Therefore the SCOPA-COG 
has been developed and validated specifically for patients with PD, has acceptable scale 
properties (high test-retest reliability and internal consistency), has demonstrated high 
convergent validity with currently available cognitive rating scales (Cambridge 
Cognitive Examination, MMSE, ACE), has shown excellent ability to detect cognitive 
differences between PD patients (high coefficient of variability), has high sensitivity 
and specificity to detect cognitive impairment in PD (discriminant validity), and in a 
logistic regression study only a small proportion of SCOPA-COG total score variance 
was accounted for by other disease-related factors, such as motor function, 
dopaminergic medication and psychosis.        
2.1.1.2  Addenbrooke’s Cognitive Examination  
The ACE is a cognitive scale that was developed for use in Alzheimer’s disease and 
Frontotemporal Dementia (total score 0-100), and contains six domains: (1) orientation 
(scored 0-10), testing orientation to time (5 items) and place (5 items); (2) 
attention/concentration (scored 0-8), testing three item registration and serial seven 
subtraction; (3) memory domain (scored 0-35) testing immediate and delayed 
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anterograde memory (recall of objects, and a fictional person’s name and address) and 
retrograde memory (naming important historical and political figures); (4) verbal 
fluency (scored 0-14), testing phonemic (words beginning with the letter “P”) and 
semantic (animals) verbal fluency; (5) language domain (scored 0-28) testing 
confrontational object naming, comprehension including three stage command and 
comprehension of complex grammar, single word and phrase repetition, reading regular 
(phonetic) and irregular (non-phonetic) words and writing, and (6) visuospatial function 
(scored 0-5) testing drawing of intersecting pentagons, Necker’s cube (three 
dimensional representation of cube) and clock face task (Mathuranath et al., 2000). Use 
of the ACE as a cognitive measure in PD has been examined by several groups. For 
example, in one study (Chade et al., 2008) ACE was administered to 22 patients with 
PD, 53 with Alzheimer’s disease, 24 with Frontotemporal dementia and 53 control 
subjects. PD patients scored significantly lower than controls on ACE total score, 
memory score, and verbal fluency (particularly semantic fluency). ACE total score 
demonstrated better sensitivity at detecting cognitive impairment than MMSE. 
Convergent validity of ACE has been demonstrated with high correlation with SCOPA-
COG (rho = 0.93, P < 0.0001), MDRS (rho = 0.91 P < 0.0001) and MMSE (rho = 0.84, 
P < 0.001) in one study (Reyes et al., 2009) and significant correlation with MMSE (rho 
= 0.72, P < 0.01) and FAB (rho = 0.56, P < 0.01) in another study (Kaszás et al., 2012). 
In ROC analysis, using MDRS as the reference, the AUC was higher for ACE (0.97) 
than for SCOPA-COG (0.92) or MMSE (0.91) and ACE demonstrated high sensitivity 
(92%) and specificity (91%) for diagnosing dementia at the optimal cut-off score (Reyes 
et al., 2009). Therefore ACE is a cognitive scale which has been used in PD and has 
demonstrated high convergent validity with currently available cognitive rating scales 
(SCOPA-COG, MMSE, MDRS) and has high sensitivity and specificity to detect 
cognitive impairment in PD (discriminant validity). 
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2.1.1.3  Frontal Assessment Battery 
The FAB is a short bedside test to examine frontal executive function (Dubois et al., 
2000) and contains six domains: (1) Similarities task, testing conceptualization where 
patient is asked to provide categorical responses to objects presented (fruits, furniture 
and flowers); (2) Lexical fluency testing phonemic verbal fluency (words beginning 
with the letter “S”); (3) Motor series using Luria sequencing task ; (4) Conflicting 
instructions task testing sensitivity to interference on a tapping test (subject is asked to 
tap once when examiner taps twice and vice versa), (5) Go-No Go task, testing 
inhibitory control (withholding a response that was previously given to the same 
stimulus) and (6) Prehension behaviour testing response to environmental cues which 
are inhibited in normal individuals (utilization behaviour). Each item is scored 0-3, with 
total maximum score 18. The study authors (Dubois et al. 2000) administered their scale 
to patients with various neurodegenerative disorders, including PD (N=42), MSA 
(N=6), CBD (N=21), PSP (N=47) and Frontotemporal Dementia (N=23) and healthy 
controls (N=42). FAB scores had high correlation with MDRS scores (rho = 0.82) and 
with Wisconsin Card Sorting Task (WCST) correct categories (rho = 0.77) and 
perseverative error (rho = 0.68) scores. Convergent validity was further demonstrated in 
a study where the FAB was applied in MSA (N=11), PSP (N=17) and PD (N=12) 
(Paviour et al., 2005). This study included detailed neuropsychological assessments and 
FAB had high correlation with tests specific for executive function and also tests of 
general cognitive function. For example, FAB had significant correlation with frontal-
executive scores, including Wechsler Adult Intelligence Scale – Revised (WAIS-R) 
similarities score (rho = 0.68), WCST correct categories score (rho = 0.48), phonemic 
(rho = 0.70), semantic (rho = 0.59) and alternating semantic (rho = 0.75) verbal fluency, 
Paced Auditory Serial Addition Test score (rho = 0.65), MDRS Initiation/Perseveration 
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(rho = 0.60) and conceptualisation (rho = 0.39) subscores. FAB also had significant 
correlation with scores for general cognitive function, including National Adult Reading 
Test (rho = 0.61), WAIS-R verbal IQ (rho = 0.71), WAIS-R vocabulary score (rho = 
0.78), WAIS-R digit span (rho = 0.67), MMSE (rho = 0.62), and MDRS total (rho = 
0.67) and initiation (rho = 0.60), construction (rho = 0.44), memory (rho = 0.36) and 
attention (rho = 0.33) subscores. This study also demonstrated that the FAB could 
differentiate between types of extrapyramidal disorder, with FAB score significantly 
lower in PSP compared to MSA (p=0.02) or PD (P<0.001) and significantly lower in 
MSA than in PD (P=0.047) (Paviour et al., 2005). In another study, FAB was 
administered to PD patients (N=50) and healthy controls (N=122) (Lima et al., 2008), 
and FAB had significant correlation with general cognitive scales, MMSE (rho = 0.50) 
and Raven’s Coloured Progressive Matrices (a non-verbal test of reasoning, rho = 0.43) 
and executive scales, phonemic verbal fluency (rho = 0.41), WCST perseverative errors 
(rho = 0.43) and Trail Making Test parts A and B (rho = 0.41). FAB scores were 
significantly lower in PD, particularly the Similarities (P<0.02) and Go-No-Go 
(P<0.0001) subscales, and on discrimination analysis correctly classified PD and normal 
controls in over 70% of cases (P<0.00001) (Lima et al., 2008). Therefore, the FAB is a 
simple bedside test of executive cognitive functioning, which has been applied to PD 
and related neurodegenerative disorders, and has demonstrated high convergent validity 
with a number of executive and global cognitive scales, in several studies, and has 
potential to differentiate between extrapyramidal disorders. 
2.1.1.4  Birmingham Object Recognition Battery 
The BORB is a standardised set of psychological tests assessing visuoperceptive 
function. The elements include (1) Drawing from Memory; (2) Copying; (3) Length 
Match Task; (4) Size Match Task; (5) Orientation Match Task; (6) Position of Gap 
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Match Task; (7) Overlapping Figures; (8) Minimal Feature View Test; (9) 
Foreshortened View Task; (10) Object Decision Task; (11) Function Match Task; (12) 
Associative Match Task and (13) Picture Naming Task – short and long versions. 
Patients performed a large number of cognitive tests and other clinimetric measures and 
therefore for the purpose of this study an abbreviated set of tests was employed; tests 
were selected to cover the range of low to high level visuoperception, and included 
Length Match Task, Size Match Task and Orientation Match Task, which assess low 
level aspects of visual perception (same-different matching of elemental features such 
as orientation, length, and object size), Overlapping Figures Test, Minimal Feature 
View Test and Foreshortened View Task (higher level of visual perception assessing 
identification of overlapping images, identification of objects from minimal features and 
matching objects from usual and unusual viewpoints), Object Decision Task (test of 
stored perceptual knowledge assessing discrimination between pictures of real objects 
and non-objects made by combining parts of different real objects, Humphreys et al., 
1997)  and Associative Matching Task (semantic knowledge test where subject decides 
which of two reference pictures [e.g. a screw and a nail] is most associated with a target 
picture [a screwdriver], Humphreys et al., 1997). The BORB is a standardised set of 
neuropsychological tests to detect visual agnosia. Visual agnosia refers to impairment of 
visual object recognition, but with intact visual pathways (globe, retina, optic nerves, 
chiasm and optic tracts) and implicates involvement of cortical visual pathways, and is 
further divided into failure in interpretation of spatial and structural properties 
(apperceptive agnosia) or semantic context (associative agnosia) of visual stimuli. 
Visuoperceptive function has been explored much less in PD than other cognitive or 
high cortical modalities, in particular attention, memory and executive function and the 
BORB has not been specifically applied or validated in the PD population.   
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2.1.2  Assessment of mood, motivation and anxiety 
2.1.2.1  Hamilton Depression Rating Scale  
HDRS contains 21 items, of which 17 items are usually used in scoring. These items are 
(1) Depressed mood - feelings of sadness, hopelessness, helplessness or worthlessness, 
scored 0-4; (2) Feelings of guilt, scored 0-4; (3) Suicide - feelings, wishes, ideas or 
gestures of suicide and suicide attempts, scored 0-4, (4) Insomnia early - difficulty 
falling asleep; (5) Insomnia middle - disrupted nocturnal sleep; (6) Insomnia late - early 
morning wakening with difficulty getting back to sleep, with all insomnia items scored 
0-2, (7) Work and activities - incapacity, loss of interest, decreased productivity, scored 
0-4, (8) Psychomotor retardation - slowness of speech and thought, reduced 
concentration and decreased motor activity, scored 0-4; (9) Agitation, scored 0-4; (10) 
Psychological anxiety, scored 0-4; (11) Somatic symptoms of anxiety, particularly 
features of autonomic overactivity, scored 0-4; (12) Gastrointestinal somatic symptoms, 
scored 0-2; (13) General somatic symptoms, including heaviness in limbs, back, or 
head, diffuse backache, loss of energy and fatigability, scored 0-2; (14) Genital 
symptoms - loss of libido and menstrual disturbances; (15) Hypochondriasis - self-
absorption, preoccupation with health, complaining attitude and hypochondrial 
delusions, scored 0-4; (16) Loss of weight and (17) Lack of Insight (Hamilton, 1960). 
The HDRS has been used extensively in non-PD subjects and has demonstrated high 
sensitivity, specificity and discriminant ability for DSM-IV diagnosis of depression and 
good test-retest and inter-rater reliability (Schrag et al., 2007). Studies of the HDRS in 
PD have concentrated on discriminant validity of the scale in relation to formal DSM-
IV diagnostic criteria, to determine optimal cut-off scores with maximal sensitivity and 
specificity for diagnosis or screening of depression. There have been relatively few 
studies examining convergent validity in relation to other rating scales. The several 
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studies using ROC analysis, with DSM-IV as the diagnostic criterion have demonstrated 
good sensitivity and specificity and high AUC (Williams et al., 2012, Reijnders et al., 
2010, Weintraub et al., 2006, Narding et al., 2002). In a study where The Geriatric 
Depression Scale and HDRS was applied to PD patients there was a moderately high 
correlation between the two scales (rho = 0.54; P < 0.001) (McDonald et al., 2006). 
HDRS has also demonstrated sensitivity to change over time in PD and correlation with 
biological markers of depression in PD (Schrag et al., 2007). The scale is freely 
available to the public and has been translated into a number of different languages. The 
MDS Task Force on Rating Scales for PD recommends HDRS scale to measure of 
severity of depressive symptoms in clinical studies and as adequate screening tool for 
depression in PD. Therefore, HDRS is a well validated scale in PD and non-PD 
subjects, and has demonstrated good discriminant validity with respect to DSM criteria, 
has good convergent validity compared to other depression rating scales (for example, 
GDS) and has shown good sensitivity to change in PD.  
2.1.2.2  Hospital Anxiety Depression Scale    
The HADS consists of fourteen items, seven dealing with anxiety (HADS-Anxiety) and 
seven with depression (HADS-Depression), with each item scored from 0 to 3. Use of 
HADS in PD has been examined in some studies. For example, in a large study to 
determine the convergent validity of HADS, 342 PD patients underwent detailed 
psychological assessments, including rating scales for anxiety and depression and DSM-
IV diagnostic criteria for anxiety (Leentjens et al., 2011). HADS-D had significant 
correlation with NPI anxiety score (rho = 0.31), Hamilton Anxiety Rating Scale (HARS, 
rho = 0.32), Beck Anxiety Inventory (BAI, rho = 0.35), and HDRS total score (rho = 
0.40) (all p < 0.002). HADS-Anxiety had significant correlation with NPI anxiety (rho = 
0.19), HARS (rho = 0.25), BAI (rho = 0.36) and HDRS total score (rho = 0.27) (all p < 
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0.002). HADS-Total Score was significantly correlated with CGI (rho = 0.41), NPI 
anxiety score (rho = 0.47), HARS score (rho = 0.47), BAI (rho = 0.62) and HDRS (rho 
= 0.56) (Leentjens et al., 2011). In another study HADS-D (rho = 0.57) and HADS-A 
(rho = 0.60) had high correlation with NPI (Kulisevsky et al., 2008). In a longitudinal 
study, 67 patients were followed up for one year and score changes in the HADS-
Anxiety and HADS-Depression correlated highly with SCOPA-Psychosocial change 
(rho = 0.50 and rho =0.58 respectively) (Martinez-Martin et al., 2008).  In another study 
to assess the discriminant validity of HADS, the discrimination power of HADS-Total 
(AUC 0.75) and HADS-A (AUC 0.63) was relatively low, but statistically significant 
(Leentjens et al., 2011). Therefore, HADS total score and anxiety and depression 
subscores have demonstrated reasonable convergent validity with a wide variety of 
anxiety and depression scales in PD (although in some studies with only relatively low 
correlation coefficients) and sensitivity to change in a longitudinal study; however have 
only shown modest discriminant validity. HADS-Depression focuses on non-somatic 
features of depression, which may be advantageous in mild depression where the 
overlapping somatic symptoms of PD could lead to artificially high scores and false 
positive diagnoses. However, in moderate to severe depression somatic features have an 
important impact and contribution to severity rating. The MDS Task Force on Rating 
Scales for PD suggest HADS is moderately suitable as screening tool in PD but its role 
as a severity measure remains uncertain (Schrag et al., 2007). This study, by including 
both HDRS and HADS-Depression, therefore covered the entire range of depressive 
symptoms encountered in PD, including HDRS, which has a large focus on somatic 
symptoms and the predominantly non-somatic HADS-D. 
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2.1.2.3  Lille Apathy Rating Scale 
The LARS was designed and validated specifically for use in PD and contains 33 items, 
divided into nine domains representing (1) everyday productivity; (2) lack of interest; 
(3) lack of initiative; (4) novelty seeking; (5) motivation; (6) emotional responses; (7) 
lack of concern; (8) social life and (9) self-awareness (Sockeel et al., 2006). In addition 
four factorial scores, (1) intellectual curiosity; (2) action initiation; (3) emotion and (4) 
self-awareness, can be calculated from these nine domains. In the original study, LARS 
showed high internal consistency (Cronbach alpha coefficient between items, 0.80, and 
between subscales, 0.74), test–retest reliability (correlation coefficient = 0.95) and inter-
rater reliability (intra-class correlation = 0.98) (Sockeel et al. 2006). The scale ranges 
from −36 to +36, where higher scores represent a greater degree of apathy.  A cut-off 
score of ≥−16 was calculated to have a high degree of accuracy (accuracy 91%, 
sensitivity 89% and specificity 92%) in discriminating an expert's dichotomous 
judgement of apathy (moderately/severely apathetic versus non-apathetic/mildly 
apathetic). In a further validation study with 71 PD participants (Zahodne et al., 2009), 
the convergent validity of LARS with the Apathy Scale (AS), a self-reported 14-item 
Likert based apathy scale, was high (Intraclass Correlation Coefficient 0.75) and AS 
also had significant correlation with three of four LARS factorial subscores; intellectual 
curiosity (rho = 0.61; P < 0.001), action initiation (rho = 0.42; P < 0.001), and emotion 
(rho = 0.33; P < 0.01) and a trend to correlation with self-awareness score (rho = 0.229; 
P = 0.05) (Zahodne et al., 2009). LARS has been validated against proposed diagnostic 
criteria for apathy in neuropsychiatric disorders (Robert et al., 2009; Drijgers et al., 
2010). These proposed criteria (Robert et al., 2009) require (A) loss of or diminished 
motivation in comparison to the patient’s previous level of functioning and which is not 
consistent with age or culture, (B) presence of at least one symptom in at least two of 
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the three domains: (B1) goal-directed behaviour, (B2) goal-directed cognition and (B3) 
spontaneous emotion, and (C) symptoms which cause clinically significant impairment 
in personal, social, occupational, or other important areas of functioning and (D) 
symptoms are not exclusively explained or due to physical disabilities, to motor 
disabilities, to diminished level of consciousness or to the direct physiological effects of 
a substance. LARS had high correlation with these diagnostic criteria for apathy, 
correlation coefficient 0.72, P = 0.01 (Drijgers et al., 2010). Goal-directed behaviour 
criterion (B1) had significant correlation with intellectual curiosity (rho = 0.56), 
emotion (rho = 0.24) and action initiation (rho = 0.32) factorial scores. Goal-directed 
cognition (B2) had significant correlation with intellectual curiosity (rho = 0.62), 
emotion (rho = 0.20), action initiation (rho = 0.47) and self-awareness (rho = 0.28). 
Spontaneous emotion (B3) had significant correlation with intellectual curiosity (rho = 
0.35), emotion (rho = 0.33) and action initiation (rho = 0.20) (Drijgers et al., 2010). 
Therefore LARS has been developed and validated specifically for use in PD; the scale 
has demonstrated high internal consistency, test–retest and inter-rater reliability, high 
convergent validity with other apathy rating scales and good discriminant validity 
compared to proposed diagnostic criteria and experts’ diagnostic opinion.    
2.1.3  Sleep and fatigue scales 
2.1.3.1  Pittsburgh Sleep Quality Index 
The PSQI is a self-completed questionnaire assessing overall sleep and contains seven 
domains, each scored 0-3, and giving a total score 0-21, with higher scores indicating 
greater impairment of sleep. The seven domains are (1) sleep quality, overall subjective 
impression of quality of nocturnal sleep, (2) sleep latency, time to onset of sleep, (3) 
sleep duration, actual hours of sleep per night, as opposed to time spent in bed, (4) sleep 
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efficacy, proportion of time spent in bed actually asleep, (5) sleep disturbance, whether 
sleep is disturbed for various reasons including nocturia, breathing difficulties, 
coughing, snoring, feeling too hot or cold, dreaming or pain or any other reason, (6) 
sleep medication, how often over the previous month the subject has taken prescribed or 
over-the-counter medication for sleep and (7) daytime sleepiness (Buysee et al., 1989). 
The MDS Task Force on Rating Scales in PD commissioned a Sleep Scale Task Force 
to evaluate sleep scales in PD (Högl et al., 2010) and PSQI scale was recommended to 
screen and measure severity of overall sleep problems in PD. PSQI has been used to 
assess sleep function in PD in several studies and also in PD related complications, such 
as restless leg syndrome, mood disorders, dementia and hallucinations (Högl et al., 
2010). The scale has demonstrated high internal consistency and test-retest reliability 
(Högl et al., 2010). In a study using PSQI, ESS, Parkinson’s Disease Sleep Scale 
(PDSS) and polysomnography in PD (Uemura et al., 2009), the PSQI demonstrated 
good convergent validity. PSQI total score was significantly correlated with PDSS total 
score (rho = − 0.488, p < 0.001), the overall quality of a night's sleep in the PDSS 
significantly correlated with PSQI sleep quality subscore (rho = − 0.482, p < 0.001); the 
PDSS sleep onset and maintenance score correlated with PSQI sleep latency subscore 
(rho = − 0.361, p < 0.001); Sleep disturbances in the PSQI were correlated with the 
nocturnal restlessness (rho = − 0.276, p = 0.001), nocturnal psychosis (rho = − 0.338, p 
< 0.001), nocturia (rho = − 0.243, p = 0.004), and nocturnal motor symptoms (rho = − 
0.309, p < 0.001) in the PDSS (Uemura et al., 2009) and the PSQI daytime sleep score 
was correlated with the nocturia (rho = − 0.279, p = 0.001), sleep refreshment (rho = − 
0.272, p = 0.001), and daytime dozing (rho = − 0.349, p < 0.001) in the PDSS. In 
another study (Suzuki et al., 2012), PSQI summary index correlated significantly with 
PDSS total score (rho = 0.46), disturbed sleep (rho = 0.48), motor symptoms at night 
(rho = 0.36) and PD symptoms at night (rho = 0.34), all P < 0.001 (Suzuki et al., 2012). 
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In another study, PSQI had high correlation with SCOPA night time sleep score (rho = 
0.83, P < 0.001) (Marinus et al., 2003b). Therefore PSQI has demonstrated adequate 
scale properties (internal consistency and test-retest reliability) and convergent validity 
with a number of other validated sleep scales in several studies.  
2.1.3.2  Epworth Sleepiness Scale 
The ESS is a clinical measure of daytime somnolence and asks the subject to indicate 
how likely they are to fall asleep in eight different circumstances, (1) sitting and 
reading, (2) watching television, (3) sitting inactive in a public place, (4) as a passenger 
in a car without a break for an hour, (5) lying down to rest in the afternoon, (6) sitting 
and talking to someone, (7) sitting quietly after lunch without alcohol, and (8) in a car 
while stopped for a few minutes in traffic. Each item is scored 0-3, with maximum score 
24 and higher scores reflecting greater daytime somnolence. The MDS Sleep Scale Task 
Force (Högl et al., 2010) have recommended the ESS for evaluation of daytime 
sleepiness in PD, because the scale has good clinimetric properties (test-retest reliability 
and internal consistency), the scale has been validated for use in PD and is freely 
available in the public domain and has been translated into several languages. In studies 
in PD comparing ESS to objective measures of sleep, such as polysomnography, MSLT 
and actigraphy, there have been inconsistent results. For example, in one study (Valko 
et al., 2010), there was no correlation of ESS with any polysomnographic findings, 
including latency to stage 2 non-REM sleep and latency to REM sleep, arousal index, 
sleep efficacy and Periodic Limb Movements of Sleep index. In another study there was 
negative correlation of ESS with total sleep time (rho = –0.55; P = 0.041) but not with 
other quantitative polysomnography variables (Compta et al., 2009). However, in 
another study (Poryazova et al., 2010) there was a highly significant negative 
correlation between ESS total score and mean sleep latency (rho = -0.65, p < 0.001) on 
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MSLT, nocturnal sleep latency (rho = –0.60, p < 0.001) and apnoea/hypoxia index (rho 
= 0.392, p = 0.032) and trend to significant correlation with percentage REM sleep (rho 
= –0.345, p=0.062). Also, in a study using actigraphy (Stavitsky et al., 2010), there was 
significant correlation with total measured sleep time (rho = 0.537) and a trend for 
correlation with other measures, including actigraphic sleep efficacy (rho = 0.384) and 
sleep fragmentation (rho = 0.413).   
In a validation study comparing clinical scales, there was significant correlation of ESS 
with PDSS daytime dosing (rho = 0.403), nocturnal restless (rho = 0.286), nocturnal 
psychosis (rho = 0.309), nocturnal motor symptoms (rho = 0.365) and sleep refreshment 
(rho = 0.272, all P < 0.001) subscores (Uemura et al., 2009). In another study (Wang et 
al., 2008), there were significant correlations between EES and PDSS total score (rho = 
0.325, P < 0.01) and PDSS item 15, unexpectedly falling asleep during the day (rho = 
0.478, P < 0.01). Therefore ESS has been used extensively in PD, has acceptable scale 
properties, good convergent validity with other available sleep scales, and some 
evidence of validity compared to objective Polysomnographic and MSLT measures of 
sleep.  
2.1.3.3  SCOPA-Sleep Scale 
SCOPA-Sleep scale has sections for night time and daytime sleep. There are five 
questions for night time sleep, (1) trouble falling asleep, (2) awakening during the night, 
(3) episodes lying awake too long at night, (4) early morning waking and (5) patient’s 
impression whether they had adequate duration of sleep at night. There are six questions 
for daytime sleep, (1) falling asleep unexpectedly during the day or evening, (2) falling 
asleep while sitting peacefully, (3) while watching television or reading, (4) while 
talking to someone, (5) trouble staying awake during the day or evening, and (6) 
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experiencing falling asleep as a problem. The MDS Sleep Scale Task Force (Högl et al., 
2010) have recommended SCOPA sleep for assessment of sleep in PD. SCOPA sleep 
has demonstrated good scale properties, internal consistency and test-retest reliability 
(Marinus et al., 2003, Martinez-Martin et al., 2008). In studies to assess convergent 
validity, SCOPA-sleep night time had high correlation with PSQI (rho = 0.63, p < 0.01, 
Setthawatcharawanich et al., 2011, and rho = 0.83, p < .001, Marinus et al., 2003) and 
PDSS (rho = 0.60, Martinez-Martin et al., 2008). SCOPA- sleep daytime had high 
correlation with ESS (rho = 0.59, p < 0.01, Setthawatcharawanich et al., 2011 and rho = 
0.81, p < .001, Marinus et al., 2003). In the later study, the coefficient of variation of 
SCOPA-sleep night time and the daytime sleepiness was higher than PSQI and ESS 
respectively, indicating a better ability to detect differences between individuals 
(Marinus et al., 2003). Therefore SCOPA-sleep scale has good scale properties, high 
convergent validity with other sleep scales and high coefficient of variability.  
2.1.3.4  REM sleep behavioural disorder  
REM sleep behavioural disorder is characterised by loss of REM sleep 
electromyographic atonia, and clinically manifests as vocalisation and elaborate 
movement during dreaming. ICSD-R require that (A) the patient has a complaint of 
violent or injurious behaviour during sleep; (B) limb or body movement is associated 
with dream mentation; (C) at least one of the following occurs, (i) harmful or potentially 
harmful sleep behaviours, (ii) dreams appear to be “acted out” or (iii) sleep behaviours 
disrupt sleep continuity; (D) polysomnographic monitoring demonstrates at least one of 
the following electrophysiologic measures during REM sleep, (i) excessive 
augmentation of chin EMG tone, (ii) excessive chin or limb phasic EMG twitching, 
irrespective of chin EMG activity and one or more of the following clinical features 
during REM sleep, (a) excessive limb or body jerking, (b) complex, vigorous, or violent 
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behaviours, (c) absence of epileptic activity in association with the disorder; (E) the 
symptoms are not associated with mental disorders but may be associated with 
neurologic disorders and (F) other sleep disorders (e.g., sleep terrors or sleepwalking) 
can be present but are not the cause of the behaviour (American Academy Sleep 
Medicine, 2001). Therefore both clinical and polysomnographic features are included in 
the criteria, but ICSD-R also allows diagnosis to be made on clinical criteria only 
(termed minimal criteria), where patients fulfil parts (B) and (C) of the algorithm. 
Polysomnography was not available for this study and therefore diagnosis of RBD was 
based on ICSD-R minimal diagnostic criteria.     
2.1.3.5  Fatigue Severity Scale 
FSS is a self-completed scale with nine questions, each rated by the subject on a Likert 
scale ranging from 1 “completely disagree” to 7 “completely agree”.  The total FSS 
score is calculated by the average score of the nine items, giving a range of 1 to 7, with 
higher scores representing greater degrees of fatigue. The nine questions relate to (1) 
impact of fatigue on motivation, (2) influence of exercise on fatigue, (3) ease at which 
person becomes fatigued, (4) impact of fatigue on physical functioning, (5) how 
frequent fatigue causes problems for the patient, (6) impact of fatigue on sustained 
physical functioning, (7) how fatigue interferes with carrying out duties and 
responsibilities, (8) how disabling fatigue is in comparison to other (neurological or 
other) symptoms and (9) how fatigue interferes with work, family or social life (Krupp 
et al., 1989). The FSS has been examined in PD in several studies. For example, in a 
118 patient study, FSS demonstrated good scale properties (high reliability with alpha 
coefficient >0.90, low floor and ceiling effects, and factor and Rasch analysis supported 
unidirectionality of scale) (Hagell et al., 2006). FSS showed high convergent validity 
with 13-item Functional Assessment of Chronic Illness Therapy-Fatigue Scale (rho = 
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0.77) and Energy subscale of the Nottingham Health Profile (rho =0.62). In a second 
study, the FSS was highly correlated with Parkinson’s Fatigue Scale (rho = 0.84) and 
one question fatigue rating (rho = 0.80). MDS Task Force on Rating Scales for PD has 
given critique and recommendations on fatigue rating scales in PD (Friedman et al., 
2010). The FSS was recommended in PD, for both screening and severity rating, 
because it has been shown to have good psychometric properties (including 
discriminant validity) in non-PD and PD patients and has been used by groups other 
than the original scale developers, and demonstrated excellent convergent validity 
(Friedman et al., 2010). 
2.1.4  Quality of life 
2.1.4.1  Parkinson’s Disease Questionnaire 
PDQ-39 is a 39 item health-related quality of life questionnaire developed and validated 
in PD (Peto et al., 1995). In stage one of development, 20 patients underwent in-depth 
semi-structured interviews, where they were asked to describe which areas of their life 
were adversely affected by the disease. Researchers then formulated a 65 item pilot 
questionnaire based on their recorded responses. The pilot questionnaire was 
administered in a postal survey, and based on eigenvalues and factor loading on factor 
analysis, item number was reduced to 39 questions, forming eight discrete scales, (1) 
Mobility (10 items) - problems getting around at home or in public places; (2) Activities 
of daily living (6 items) - difficulties with personal care; (3) Emotional well-being (6 
items) - assessing aspects such as mood and expectations for the future; (4) Stigma (4 
items) - exploring social difficulties related to PD such as concealing the diagnosis from 
others or avoiding eating, drinking or other activities in public; (5) Social support (3 
items) - relationship with friends, family and carers; (6) Cognitions (4 items) - aspects 
77 
 
such as attention and memory; (7) Communication (3 items) - problems communicating 
with others and (8) Bodily discomfort (3 items). For the purposes of scoring, each scale 
is converted to a percentage (range 0-100) with higher scores representing poorer 
quality of life. PDQ-39 summary index is calculated from the mean of the eight scales. 
In this original study, Cronbach’s alpha was satisfactory for the eight scales and test-
retest correlation coefficients were all significant. Convergent validity was tested 
against the Short From (36 item) Health Survey (SF-36); PDQ-39 mobility score 
correlated with SF-36 physical functioning (rho = -0.80), PDQ-39 activities of daily 
living correlated with SF-36 limitation due to physical problems (rho = -0.36), PDQ-39 
emotion well-being correlated with SF-36 mental health score (rho = -0.71), PDQ-39 
social support correlated with SF-36 social function (rho = -0.34), and PDQ-39 bodily 
discomfort correlated with SF-36 pain (rho = -0.66) (Peto et al., 1995). The scale is 
freely available to the public and is the main health-quality of life index that has been 
used in clinical studies in PD. Therefore the PDQ-39 was specifically developed in PD 
that encompasses a wide range of symptoms that impact on quality of life, shows good 
scale properties and convergent validity with other Hr-QOL scales.  
2.1.5   Autonomic function 
2.1.5.1  Scales for Outcome in Parkinson’s disease – Autonomic Scale 
The SCOPA-AUT scale was specifically developed for use in PD (Visser et al., 2004). 
45 questions were selected following an extensive literature search and consulting 
specialists in the field. The questionnaire was applied to patients with PD and MSA, and 
subjects were asked to rate both the frequency and burden of symptoms, and items were 
selected based on high frequency, high burden, or high clinical relevance judged by 
specialists. Redundant items with high inter-item correlation were removed. The final 
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SCOPA-AUT scale consisted of 25 questions assessing gastrointestinal symptoms (7 
items), urinary symptoms (6 items), cardiovascular symptoms (3), thermoregulatory 
function (4), pupillomotor symptoms (1), and sexual function (2 items for men and 2 
items for women) giving a total of 23 items for men or women. Each question had four 
responses to rate frequency from zero “never” to three “often”, and total score ranging 
from 0-69, with higher scores representing increased autonomic dysfunction. PD 
patients had significantly higher scores on all autonomic domains compared to controls, 
suggesting good discriminant validity, except for sexual function in men and women, 
and there was also significant difference between mild, moderate and severe disease 
stages. The test-retest validity was high for scale total score and individual domain 
scores. An independent validation study (Rodriguez-Blazquez et al., 2010) assessed 
scale acceptability (completeness of data, data distribution including skewness and floor 
and ceiling effects), internal consistency, and construct validity. In terms of scale 
acceptability, computable data were obtained for 97% of the sample (however a high 
proportion of men and women reported the sexual domain as “non-applicable”), mean 
and median values were close, but floor effects (cardiovascular, thermoregulatory, 
pupillomotor and sexual domains) and ceiling effect (pupillomotor) were observed for 
parts of the scale. In terms of internal consistency, Cronbach’s alpha for domains range 
from 0.69 to 0.95. SCOPA-AUT correlation with several non-specific scales for pain, 
anxiety, depression, fatigue and quality of life was calculated but not with specific 
measures of autonomic function, in order to assess genuine convergent validity. A 
further study (Forjaz et al., 2010) using Rasch analysis has identified some scale 
weaknesses including a redundant item (incomplete bladder emptying), disordered 
thresholds of response categories and lack of empirical evidence to support scale 
subscores. However, Rasch model of the shorter 22-item scale with simplified response 
scheme revealed strengths including high internal consistency, and it is a scale which is 
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unidimensional and can be transformed into a linear metric scale. Studies have not 
shown a clear correlation between SCOPA-AUT and objective measures of autonomic 
function, for example sympathetic skin response and the R-R interval variation test 
(Papapetropoulos et al., 2006) and composite autonomic scoring scale with elements 
including presence of orthostatic hypotension (on standing for 1,3,5 minutes after 20 
minutes bed-rest), heart rate ratio during deep breathing, Valsalva ratio (maximal to 
minimal heart rate), and sweat response (Oh et al., 2007) or heart/mediastinal MIBG 
uptake ratio using cardiac SPECT (Berganzo et al., 2012). Therefore, the SCOPA-AUT 
is a comprehensive scale that rates a wide range of autonomic symptoms in PD and has 
demonstrated adequate scale properties. Correlation with objective measures of 
autonomic function has not yet been demonstrated and will require further assessment. 
Also convergent validity with other clinical scales has not been assessed.  
2.1.6  Psychosis 
2.1.6.1  Parkinson’s Psychosis Rating Scale 
The PPRS contains six items which are rated from absent, mild, moderate or severe 
(scored 1-4). The items are (a) visual hallucinations, (b) illusions and misidentification 
of persons, (c) paranoid ideation (persecutory and/or jealous type), (d) sleep 
disturbance, (e) confusion and (f) sexual pre-occupation. For each item, the rater is 
given a further explanation to assist accurate and consistent scoring. For example, 
“mild” visual hallucinations are classified as occasional, with complete or partial insight 
and non-threatening; “moderate” are frequent, with absence of full insight; patients can 
be convinced they are real and may be threatening and “severe” are persistent 
hallucinations, with no insight, associated with heightened emotional tone, agitation, 
and aggression. The scale total score ranges from 4-24, with higher scores reflecting 
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more psychotic phenomena. In a systematic review and critique of available psychosis 
scales in PD the PPRS was considered (Fernandez et al., 2008). The PPRS is short, easy 
to administer scale and does not require special training to use. The hallucinations item 
considers frequency of symptoms and retention of insight, which are important features 
of psychosis in PD. However, the PPRS does not include the full spectrum of PD 
psychotic symptoms, for example hallucinations in other modalities (auditory, olfactory, 
gustatory, or cutaneous). Also, there is only a single item for the visual hallucinations, 
illusions and delusions domains, which gives only a narrow range of potential scores, 
and limits the scales ability to measure change over time. The final three items of the 
scale; sleep disturbance, confusion and sexual preoccupation are features that are often 
associated with psychosis, rather than psychotic symptoms per se. Clinimetric testing in 
the original study showed inter-rater reliability for items and scale total was high, but 
internal consistently was variable, and poor for some items. On assessment of 
convergent validity, PPRS was correlated with Brief Psychosis Rating Scale (BPRS), 
rho = 0.92, and Nurses’ Observation Scale for Inpatient Evaluation (NOSIE) Psychotic 
dimension score (rho = 0.48) (Fernandez et al., 2008). 
2.1.6.2  University of Miami Parkinson’s Disease Hallucination Questionnaire 
The UM-PDHQ is a hallucination scale based on a structured clinical interview that was 
developed by a group of movement disorders specialists, a geriatric psychiatrist, 
neuropsychologist, nurse specialist and neuro-ophthalmologist (Papapetropoulos et al., 
2008). It contains six quantitative and fourteen qualitative questions. The six 
quantitative items rate (1) hallucination modality – visual, auditory, somatic/cutaneous, 
gustatory or olfactory, (2) frequency of episodes, (3) duration of episodes, (4) presence 
of insight, (5) variety of sensations experienced and (6) emotional distress involved. 
Total score range is 0-14, with higher scores denoting more psychotic symptoms. The 
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qualitative items ask about (1) co-existing ophthalmic problems, (2) current 
medications, (3) recent changes in treatment, (4) relationship of changes in medication 
to characteristics of hallucinations, (5) relationship to “on”-“off” motor fluctuations, if 
present, (6) description of hallucination experiences, including familiarity or non-
familiarity, (7) whether patient can do anything to make sensations disappear, (8) 
diurnal variation and relationship to lighting conditions, (9) whether hallucinations 
make noise, (10) movement of visual hallucinations, (11) hallucination size, (12) 
transparency, (13) colour and (14) onset of hallucinations. This is a relatively new 
hallucination scale in PD and has not undergone independent validation by other 
groups.   
2.1.7  Pain scale 
A specific scale to measure pain in PD was not available when this study was designed; 
however pain occurs throughout disease course (for example “frozen shoulder” if often 
a presenting of PD) and has an important impact of quality of life in PD. Consideration 
was given to the various types of pain that may be experienced by PD patients, and 
subjects were asked to rate each symptom from 0 (no pain at all) to 10 (worst possible 
pain) on a Visual Analogue Scale (VAS). The nine domains were musculoskeletal pain, 
radicular pain, restless leg pain, dystonic pain, dyskinetic pain, mouth pain, visceral 
pain, akinetic pain and headache. An overall pain score was calculated by adding the 
individual scales, with a total range 0-90.    
2.1.8  Non-motor symptom questionnaire 
The non-motor symptom questionnaire (NMSQ) was developed by a multi-disciplinary 
group of specialists as a screening tool for the range of non-motor symptoms 
encountered in PD, and consists of a binary “yes”-“no” response to thirty symptoms; 8 
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questions on gastrointestinal symptoms, 2 on urinary tract symptoms, 2 on sexual 
function, 2 on cardiovascular features, 3 for attention, apathy and memory, 2 questions 
on hallucinations and delusions, 2 questions on depression, anxiety, anhedonia, 5 
questions on sleep and fatigue, 1 question on pain, and 3 other miscellaneous items 
(Chaudhuri et al., 2006). This questionnaire was not developed as a diagnostic 
instrument or rating scale but as an initial screening tool, to allow further exploration of 
symptoms identified.              
2.1.9  Motor Scales 
2.1.9.1  Unified Parkinson’s disease Rating Scale 
The UPDRS was developed in the 1980s and has been the primary outcome measure in 
clinical studies in PD. The UPDRS contains four parts: Part I, Mentation, behaviour and 
mood; Part II, Activities of daily living; Part III, Motor examination and Part IV, 
Complications of therapy. Part I contains four items: (1) Intellectual impairment, (2) 
Thought disorder, (3) Depression and (4) Motivation and Initiative, with each item 
scored 0-4, and total score range 0-16. Part II contains 13 items: (1) Speech, (2) 
Salivation, (3) Swallowing, (4) handwriting, (5) Cutting food and handling utensils, (6) 
Dressing, (7) Hygiene, (8) Turning in bed and adjusting bed clothes, (9) Falling, (10) 
Freezing when walking, (11) Walking, (12) Tremor and (13) Sensory complaints related 
to Parkinsonism, with each item scored 0-4, and total score range 0-52. Part III contains 
27 items: (1) Speech, (2) Facial expression, (3-7) Tremor at rest, individual scores given 
for head, right and left arm, and right and left leg, (8-9) Action or postural tremor of 
hands, scored for right and left side, (10-14) Rigidity, at neck and four limbs, assessed 
on passive movement with the patient sitting in a relaxed position, (15-16) Finger taps, 
tapping thumb and index finger in rapid succession, scored for right and left side, (17-
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18) Hand movements, opening and closing hands in rapid succession, scored for right 
and left side, (19-20) Rapid alternating movements of hands, pronation and supination, 
with as large amplitude as possible, both arms simultaneously, each side scored, (21-22) 
Leg agility, tapping heel on ground in rapid succession, each side scored, (23) Arising 
from chair, (24) Posture, (25) Gait, (26) Postural stability and (27) Body bradykinesia. 
Each item is scored 0-4, giving a total score range 0-108. Part IV is divided into three 
sections: (A) Dyskinesias, with three items: (1) Duration - what proportion of the day 
dyskinesias are present, (2) Disability, (3) Painful dyskinesias (each scored 0-4) and (4) 
Presence of early morning dystonia (binary “yes”-“no” response, scored 0-1); (B) 
Clinical fluctuations, with four items: (1) Predictable “off” periods, (2) Unpredictable 
“off” periods, (3) Sudden onset “off” periods, each of these items is a binary “yes”-“no” 
response, scored 0-1, (4) percentage of waking day in “off” state, scored 0-4; (C) Other 
complications, (1) Anorexia, nausea or vomiting, (2) Disturbances of sleep such as 
insomnia or hypersomnolence and (3) Symptomatic orthostasis, each of these items 
binary “yes”-“no” response, scored 0-1.  
2.9.1.2  Movement Disorder Society-UPDRS 
The MDS-UPDRS contains four parts. Part I, Non-motor aspects of experiences of daily 
living (nM-EDL) has two sections, Part IA, Complex neuropsychiatric behaviours, 
completed by rater, and Part IB which is assessed by patient questionnaire. Part IA has 
six items (1.1) Cognitive impairment, (1.2) Hallucinations and psychosis, (1.3) 
Depressed mood, (1.4) Anxious mood, (1.5) Apathy and (1.6) Features of dopamine 
dysregulation syndrome. Part IB has items (1.7) Sleep problems, (1.8) Daytime 
sleepiness, (1.9) Pain and other sensations, (1.10) Urinary problems, (1.11) Constipation 
problems, (1.12) Light headedness on standing and (1.13) Fatigue. Each Part I item is 
scored 0-4, with total score range 0-52. Part II, Motor aspects of experiences of daily 
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living (M-EDL) has 13 items, (2.1) Speech, (2.2) Saliva and drooling, (2.3) Chewing 
and swallowing, (2.4) Eating tasks, (2.5) Dressing, (2.6) Hygiene, (2.7) Handwriting, 
(2.8) Doing hobbies and other activities, (2.9) Turning in bed, (2.10) Tremor, (2.11) 
Getting out of bed, a car or a deep chair, (2.12) Walking and balance and (2.13) 
Freezing; each item is scored 0-4, with total Part II score range 0-52. All Part II 
questions are assessed together with Part IB as a 20-item patient questionnaire. Part III, 
Motor examination, has items (3.1) Speech, (3.2) Facial expression, (3.3) Rigidity, (a) 
neck, (b) right upper extremity (RUE), (c) left upper extremity (LUE), (d) right lower 
extremity (RLE) and (e) left lower extremity (LLE), (3.4) Finger tapping, (3.5) Hand 
movements, (3.6) Pronation-supination movements of hands, (3.7) Toe tapping, (3.8) 
Leg agility, (3.9) Arising from chair, (3.10) Gait, (3.11) Freezing of gait, (3.12) Postural 
stability, (3.13) Posture, (3.14) Global spontaneity of movement (body bradykinesia), 
(3.15) Postural tremor of the hands, (3.16) Kinetic tremor of hands, (3.17) Rest tremor 
amplitude, of (a) RUE, (b) LUE, (c) RLE, (d) LLE and (e) lip/jaw, (3.18) Constancy of 
rest tremor. Each item is scored 0-4, with total Part III score range 0-132. Part IV, 
Motor complications, has items (4.1) Time spent with dyskinesias, (4.2) Functional 
impact of dyskinesias, (4.3) Time spent in “off” state, (4.4) Functional impact of 
fluctuations, (4.5) Complexity of motor fluctuations, (4.6) Painful “off”-state dystonia, 
each item scored 0-4, with total Part IV score range 0-24.  
The clinimetric properties of the MDS-UPDRS were validated in large international 
study in 39 centres (USA, 32; Canada, 2; UK 5), with 877 participating PD patients, 
from all Hoehn-Yahr stages, including drug naïve patients and those taking 
dopaminergic medication. 483 (55%) had motor fluctuations and 304 (35%) had 
dyskinesias (Goetz et al., 2008). Our site provided 45 patients’ UPDRS and MDS-
UPDRS scores for this validation study (5% of total). Internal consistency, calculated 
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using Cronbach’s alpha, was good for all parts: Part I (13 items) alpha = 0.79, Part II 
(13 items) alpha = 0.90, Part III (33 items) alpha = 0.93, Part IV (6 items) alpha = 0.79. 
Convergent validity was demonstrated, with high correlation between MDS-UPDRS 
and UPDRS total scores (rho = 0.96) and individual parts of the two scales (Part I, rho = 
0.76; Part II, rho = 0.92; Part III, rho = 0.96; Part IV [including only items covering 
motor complications on the UDPRS], rho = 0.89) (Goetz et al., 2008). MDS-UPDRS 
Part I, II and III showed extremely low floor and ceiling effects, whereas Part IV 
showed a floor effect, as expected, but there was no ceiling effect.           
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2.2  Ophthalmological Assessment 
A subgroup of patients underwent detailed ophthalmological assessment. The 
ophthalmological study received ethical approval by The Royal Free Hospital and 
Medical School Research Ethics Committee, The National Hospital for Neurology and 
Neurosurgery (NHNN) and Institute of Neurology (ION) Joint Research Ethics 
Committee. The research governance sponsor of this study was University College 
London Hospitals/University College London Joint Biomedical Research Unit, R&D 
Directorate. Ophthalmological study was done in collaboration with Mr Fion Bremner, 
Consultant Neuro-Ophthalmologist at The National Hospital for Neurology and 
Neurosurgery, Ms Clare Davey, Consultant Ophthalmologist at The Royal Free NHS 
Trust, and Mr Alexander Spratt and Mr Ameet Shah, Specialty Registrars in 
Ophthalmology. All patients provided written consent and underwent a standardised 
examination, including corrected and uncorrected visual acuity, visual field 
measurement and examination for structural optic pathology. 
2.2.1  Visual acuity  
Visual acuity was assessed using Logarithm of Minimal Angle of Resolution 
(LogMAR) chart, which differs from the standard Snellen chart in that there are an 
equal number of optotypes (letters) per line (five) and there is regular spacing between 
lines and letters (spacing between letters is equal to individual letter width and space 
between rows is equal to height of letters in the row below). The Snellen chart is 
susceptible to spatial crowding, particularly in the lower rows where there are more 
optotypes. This can lead to increased errors, particularly with ophthalmic problems such 
as strabismic amblyopia and therefore the LogMAR chart is proposed to permit more 
accurate acuity measurement. Also on the Snellen chart there is a single optotype for the 
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lowest level of acuity (6/60) whereas on the LogMAR chart, there are a consistent five 
optotypes per row, allowing more accurate assessment in patients with poorer degrees 
of visual acuity. On the LogMAR chart, there is uniform progression in optotype size 
(each row corresponds to a logarithmic progression of 0.1 LogMAR). An acuity of 6/6 
on the Snellen acuity chart corresponds to LogMAR score zero, with negative scores 
indicating better than normal visual acuity and positive score indicating power than 
normal visual acuity. Each line in the chart is scored 0.1 LogMAR and each individual 
letter is scored 0.02 LogMAR.  
2.2.2  Visual fields 
Visual field assessment was carried out using Goldmann kinetic perimetry, using 
standard calibrated equipment (Haag-Streit International), with close observation for 
correct fixation by the operator, and each eye tested individually (with the other eye 
covered) and using isopters of equal luminance during the examination and of standard 
luminance between all subjects tested at the different test sites (National Hospital for 
Neurology and Neurosurgery and Royal Free Hospital). To quantify visual fields, and 
allow statistical comparison between patients, Mean Radial Degrees (MRD) valve was 
determined for each eye, by calculating the average radial distance in degrees from the 
fixation point at 12 positions, 30 degrees apart (0-360 degrees) as per previously 
published methods (Newman et al., 2002) (Figure 2.1).   
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Figure 2.1 Goldmann Kinetic Perimetry: Example of Goldmann kinetic Perimetry from 
ophthalmology study patient, using isopters of equal luminance (4e) to calculate Mean 
Radial Degrees (MRD) field measurement from 12 positions at 30 degree intervals. 
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2.2.3  Ophthalmic examination 
Each patient underwent standard ophthalmic examination by an experienced 
ophthalmologist, and fundal photography was performed (TOPCON Corporation) and 
images printed (IMAGEnet for Windows
TM
) (Figure 2.2). Data recorded systematically 
included (1) presence or absence of corneal pathology; (2) presence or absence of lens 
pathology, including cataracts, and if present their location (nuclear, cortical or sub 
capsular) and opacity (semi-quantitative scale: mild, moderate or severe); (3) Retinal 
changes such as diabetic retinopathy (including grade), macular degeneration (including 
type) or other pathology.  
Figure 2.2 Retinal photography was performed for each patient with optic disc and 
macula views, to allow standardised retinal assessment.   
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2.3  Pathological study 
The London Multi-Centre Research Ethics Committee has approved procedures for the 
donation of brains to the Queen Square Brain Bank as well as retention of and access to 
clinical records. The Queen Square Brain Bank contains a large collection of donated 
brains, predominantly of subjects with neurodegenerative disorders, particularly 
extrapyramidal conditions (such as PD, DLB, MSA, PSP, and CBD) and other cognitive 
disorders (for example, Alzheimer’s Disease and the Fronto-Temporal Lobar 
Degenerations). Each brain is carefully examined by a neuro-pathologist and given a 
primary diagnosis and where appropriate secondary diagnoses (for example PD, with 
co-existing Alzheimer’s disease/tau pathology). The autopsy cases examined in this 
thesis have a pathological diagnosis of PD. The ante-mortem clinical records of the 
subjects are available, including in-patient notes, out-patient documentation and 
correspondence, and emergency room attendances. Demographic and clinical data has 
been systematically collected for each donor and includes age at onset of symptoms, age 
at death, disease duration, dopaminergic medication history (latency to use, duration of 
use and maximum dose of levodopa, dopamine agonists, mono-amine oxidase inhibitors 
and catechol-o-methyltransferase inhibitors), and other non-PD medication. Collation of 
clinical data from donors’ medical records was done in collaboration with Dr Sean 
O’Sullivan, Dr David Williams, Dr Luke Massey and Dr Laura Silveira-Moriyama. 
The examination of pathological material for this study was performed by Professor 
Tamas Revesz, Professor of Neuropathology and Lead of The Queen Square Brain 
Bank and Laura Parkinnen, Senior Research Fellow. Detailed analysis of LB 
distribution and density was made in different cortical and brainstem locations to 
determine whether there is an association with clinical features, such as visual 
hallucinations. Precise details of the brain locations sampled and methodology for 
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quantitative assessment of LB is given in Chapter 6, “Testing an aetiological model of 
visual hallucinations in PD”.         
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Chapter 3 
Impact of non-motor symptoms on quality of life and disability 
3.1  Introduction 
NMS have long been recognised as an important part of PD (Bulpitt et al., 1985), but 
until recently have received relatively little attention (Chaudhuri et al., 2006a, 
O’Sullivan et al., 2008). Whilst many NMS occur in elderly patients without PD, the 
mean prevalence of NMS symptoms is significantly higher than controls (Chaudhuri et 
al., 2006b). Several studies have shown that many NMS, and particularly depression 
(Gallagher & Schrag, 2008), are important determinants of health-related quality of life 
(Hr-QoL). Despite this, patients’ NMS are often under-recognised (Shulman et al., 
2002). We therefore undertook a study to (1) assess the prevalence of self-reported 
NMS in a cross-sectional sample of PD patients, (2) examine the influence of individual 
NMS on Hr-QoL and disability, (3) determine the extent to which these self-reported 
NMS are reported in the medical case notes, and (4) to determine how well the NMS 
most strongly associated with impaired Hr-QoL and disability were detected. 
3.2  Methods 
3.2.1  Assessment 
Consenting patients were assessed with the NMSQ (Martinez-Martin et al., 2007), a 
screening questionnaire which records the presence or absence of non-motor symptoms, 
and with scale for Hr-QoL (PDQ-39) and for individual NMS where validated 
clinimetric scales were available, and the UPDRS (assessed in optimal “on” state) (Fahn 
& Elton, 1987). The clinical measures used included cognitive scales, ACE (Larner, 
2007), SCOPA-COG (Marinus et al., 2003a), and FAB (Dubois et al., 2000); an apathy 
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scale, LARS (Sockeel et al., 2006); psychosis scale, PPRS (Friedberg et al., 1998); 
scales to assess mood, HDRS (Schwab et al., 1967) and HADS (Upadhyaya & Stanley, 
1993); an autonomic function scale, SCOPA-AUT (Visser et al., 2004), measures of 
nocturnal sleep and daytime hypersomnolence, PSQI (Buysee et al., 1989), ESS (Johns 
et al., 1991) and SCOPA-sleep scale (daytime and night time) (Marinus et al., 2003b); a 
fatigue scale, FSS (Krupp et al., 1989); Visual Analogue Scale of Pain (VAS); ICSD-R 
diagnostic criteria for RBD (American Academy of Sleep Medicine, 2001); 
International Restless Leg Syndrome (RLS) Study Group Criteria for the diagnosis of 
RLS (Walters et al., 2003) and the Parkinson’s Disease Questionnaire (PDQ-39) 
(Fitzpatrick et al., 1997). Except for the NMSQ which is a binary response 
questionnaire (yes/no), all remaining measures are clinimetric scales with severity 
response options or formal diagnostic criteria (RBD and RLS). DDS and ICD were 
recorded and quantified (five point scale) using the structured question in the MDS-
UPDRS, item 1.6 (Goetz et al., 2008). Percentage of daytime in the “off” state, “on” 
with dyskinesia and without dyskinesia was recorded to quantify motor complications. 
3.2.2  Symptom Documentation Rate 
Participants with the full set of clinical notes (including hand written notes, 
correspondence, requests and results of investigations) had their notes reviewed for 
documentation or action taken on non-motor and motor symptoms. The review included 
all documented patient contacts up to the neurology clinic visit at the date of completion 
of the NMSQ.  
3.2.3  Statistical Analysis 
Histograms of data were visually inspected for normality of distribution. Results were 
expressed as mean ± standard deviation or median and range. Comparison of PDQ-39 
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scores in patients with and without individual non-motor symptoms (identified on the 
NMSQ) was made using one–way analysis of variation (ANOVA) corrected for 
multiple comparisons using the Bonferroni correction. Symptom severity as assessed on 
specific scales was correlated with PDQ-39 and Schwab and England disability scores, 
using Spearman rank correlation. Stepwise multiple regression analysis was performed 
using SPSS (version 14.0). Assumption of linearity was confirmed using scatterplots. 
For collinear variables (e.g. HADS-depression scale and HDRS), clinimetric scales with 
higher Spearman regression coefficient in univariate analysis were chosen for regression 
analysis. Levodopa equivalent unit (LEU) was calculated based on theoretical 
equivalence used in previous reports (Evans et al., 2004). 
 
3.3  Results 
3.3.1  Prevalence of non-motor symptoms 
In the 89 out of 94 patients (please see demographic details, table 6.1, page 144) in 
whom full notes were available, the most commonly reported non-motor symptoms on 
the NMSQ were nocturia (62%), urgency of micturition (58%), memory difficulties 
(57%), RLS (52%), hypersalivation (48%), constipation (48%), impaired concentration 
(48%), low mood (48%), changed libido (45%) and anxiety (43%) (table 3.1). Five of 
the 10 most prevalent symptoms on the NMSQ were autonomic. Overall patients 
reported a mean of 11.0 non-motor symptoms. In addition, 15/94 (16%) had evidence of 
DDS or ICD (score ≥ 1 MDS-UPDRS item 1.6) and 55/94 (59%) had significant fatigue 
(FSS≥4), both of which are not recorded on the NMSQ.  
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Figure 3.1: The prevalence of self-reported non-motor symptoms using the Non-Motor 
Symptom Questionnaire (NMSQ) in a cross-sectional sample of Parkinson’s disease 
patients, given in order of prevalence and their documentation rate in a retrospective 
case-notes audit.   
 
3.3.2  Impact of non-motor and motor symptoms on Hr-QoL 
3.3.2.1  Patient completed and physician administered clinimetric scales 
The severity of non-motor symptoms on most individual scales correlated more strongly 
with Hr-QoL than motor function on the UPDRS (table 3.1). The following were 
strongly correlated with PDQ-39: autonomic function on the SCOPA-AUT, including 
gastrointestinal, urinary and thermoregulatory domains; mood, fatigue, night-time sleep 
and daytime somnolence, psychosis and pain. Motor function (UPDRS part III) had a 
moderate correlation with PDQ-39, which was lower than all of the above non-motor 
clinimetric variables. Anxiety, apathy and global cognitive function had a weaker 
correlation with PDQ-39 than motor function (UPDRS). Neither frontal lobe cognitive 
function nor presence and severity of DDS/ICD score were correlated with PDQ-39 
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scores. Percentage daily “off”-time and dyskinesia time also correlated with PDQ-39 
scores (table 3.1).  
 
The mean PDQ-39 score of patients with and without each non-motor symptom on 
NMSQ was compared using one-way ANOVA and corrected for multiple comparisons 
(Bonferroni-corrected significant p-value <0.0017). 18 of 30 non-motor symptoms 
reached statistical significance (table 3.2). Presence of DDS/ICD (not included in the 
NMSQ) was not found to be significantly associated with lower Hr-QOL scores 
(DDS/ICD mean PDQ-39 =30.4±17.0 versus 24.4±16.9 for non-DDS/ICD, p=0.24). 
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Table 3.1 Correlation of the health related quality of life with non-motor and motor scores 
 
Domains Clinimetric Scale Spearman’s rank correlation coefficient with PDQ-39 subscales 
Summary 
Index 
Mobility Activities 
Daily Living 
Emotion Stigma Social Cognitions Communication Bodily 
Discomfort 
Non-Motor Scores 
Autonomic 
Function 
 
SCOPA-AUT 
-Total 
0.84
 A 
0.65
 A
 0.71
 A
 0.62
 A
 0.40
 A
 0.58
 A
 0.68
 A
 0.72
 A
 0.59
 A
 
-Gastrointestinal 0.62
 A
 0.51
 A
 0.53
 A
 0.41
 A
 0.25
 C
 0.36
 B
 0.52
 A
 0.51
 A
 0.40
 A
 
-Urinary 0.71
 A
 0.61
 A
 0.60
 A
 0.55
 A
 0.28
 C
 0.45
 A
 0.60
 A
 0.62
 A
 0.47
 A
 
-Cardiovascular 0.41
 A
 0.31
 C
 0.42
 A
 0.30
 C
 0.21
 C
 0.36
 B
 0.42
 A
 0.42
 A
 0.18
 
 
-Thermoregulatory 0.57
 A
 0.34
 B
 0.46
 A
 0.48
 A
 0.41
 A
 0.42
 A
 0.41
 A
 0.38
 B
 0.56
 A
 
-Sexual 0.48
 C
 0.37
 C
 0.54
 B
 0.38
 C
 0.07 0.28 0.33
 C
 0.42
 C
 0.38
 C
 
Pain Visual analogue 
Scale 
0.56
 A
 0.40
 A
 0.36
 B
 0.47
 A
 0.35
 B
 0.39
 B
 0.40
 A
 0.36
 B
 0.68
 A
 
Sleep 
PSQI 0.55
 A
 0.44
 A
 0.37
 B
 0.46
 A
 0.26
 C
 0.43
 A
 0.39
 B
 0.33
 C
 0.64
 A
 
ESS 0.63
 A
 0.48
 A
 0.53
 A
 0.40
 A
 0.30
 C
 0.39
 B
 0.76
 A
 0.54
 A
 0.40
 B
 
SCOPA sleep (night) 0.49
 A
 0.32
 C
 0.29
 C
 0.57
 A
 0.34
 C
 0.45
 A
 0.30
 C
 0.28
 C
 0.56
 A
 
SCOPA sleep (day) 0.65
 A
 0.53
 A
 0.45
 A
 0.40
 A
 0.29
 C
 0.36
 B
 0.75
 A
 0.52
 A
 0.44
 A
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Fatigue FSS 0.74
 A
 0.69
 A
 0.58
 A
 0.56
 A
 0.36
 B
 0.43
 A
 0.58
 A
 0.51
 A
 0.50
 A
 
Apathy LARS 0.35
 B
 0.25
 C
 0.39
 B
 0.31
 C
 -0.18 0.16
 
 0.42
 A
 0.40
 A
 0.26
 C
 
Psychosis PPRS 0.55
 A
 0.39
 B
 0.47
 A
 0.39
 B
 0.26
 C
 0.34
 C
 0.62
 A
 0.53
 A
 0.25
 C
 
Mood 
HDRS 0.64
 A
 0.46
 A
 0.50
 A
 0.65
 A
 0.33
 C
 0.37
 B
 0.42
 A
 0.41
 A
 0.60
 A
 
HADS-Anxiety 0.44
 A
 0.23
 C
 0.24
 C
 0.65
 A
 0.31
 C
 0.44
 A
 0.31
 C
 0.25
 C
 0.43
 A
 
HADS-Depression 0.74
 A
 0.58
 A
 0.56
 A
 0.65
 A
 0.33
 C
 0.49
 A
 0.55
 A
 0.55
 A
 0.62
 A
 
Cognition ACE -0.22
 C
 -0.25
 C
 -0.13 -0.18 0.01 -0.01 -0.32
 C
 -0.20 -0.08 
FAB -0.15 -0.14
 
 -0.19 -0.12 0.13 0.01 -0.32
 C
 -0.15 -0.10 
SCOPA-COG -0.25
 C
 -0.21
 C
 -0.19 -0.24
 C
 0.01 -0.06 -0.35
 B
 -0.17 -0.19 
DDS/ICD Five-point scale 
(MDS-UPDRS) 
0.14 0.02 0.05 0.24
 C
 0.02 0.26
 C
 0.09 0.19 0.16 
Motor Scores 
Motor Function UPDRS (III) 0.48
 A
 0.44
 A
 0.55
 A
 0.28
 C
 0.06 0.24
 C
 0.41
 A
 0.42
 A
 0.30
 C
 
Motor 
Complications 
UPDRS (IV) 0.66
 A
 0.51
 A
 0.49
 A
 0.49
 A
 0.44
 A
 0.57
 A
 0.56
 A
 0.51
 A
 0.47
 A
 
Fluctuations 
 
% daytime “off” 0.57 A 0.47 A 0.41 A 0.41 A 0.37B 0.47 A 0.46 A 0.39 B 0.48 A 
Dyskinesia 
 
% daytime with 
dyskinesia 
0.43
 A
 0.27
 C
 0.34
 B
 0.36
 B
 0.41
 A
 0.41
 A
 0.40
 A
 0.32
 C
 0.21
 C
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Abbreviations SCOPA-AUT=Scales for outcome in Parkinson’s disease, Autonomic scale, PSQI=Pittsburgh Sleep Quality Index, ESS=Epworth 
Sleepiness Scale, FSS=Fatigue Severity Scale, LARS=Lille Apathy Rating Scale, PPRS=Parkinson Psychosis Rating Scale, HDRS=Hamilton 
Depression Rating Scale, HADS=Hospital Anxiety Depression Scale, ACE=Addenbrooke’s Cognitive Examination, FAB=Frontal Assessment 
Battery, SCOPA-COG=Scales for outcome in Parkinson’s disease, cognitive scale, ICD=Impulse Control Disorder, DDS=Dopamine 
Dysregulation Syndrome, UPDRS=Unified Parkinson’s Disease Rating Scale, Part III (motor score), Part IV (motor complications), MDS-
UPDRS=Movement Disorder Society Sponsored Revision of the UPDRS. 
Statistics High correlations (>0.50) given in bold. Statistical significance: 
A 
P<0.0001, 
B
 P<0.001 
C
 P<0.05 
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Table 3.2 Impact of individual non-motor symptoms on quality of life. One way ANOVA 
with Bonferroni correction (n=30 comparisons, significance set at P<0.0017) of mean quality 
of life scores (Parkinson Disease Questionnaire – 39 item version, summary index, PDQ-39) 
in presence or absence of symptoms on the Non-Motor Symptom Questionnaire (NMSQ). 
Significant P values are given in bold. Documentation rate of individual non-motor 
symptoms, identified in retrospective case notes audit. 
Non-motor symptom 
Mean PDQ-39-SI (±SD) 
P value 
Detection 
(%) Present Absent 
Hypersalivation 31.3 (17.3) 19.9 (14.8) 0.0012 34.9 
Loss of taste/smell 30.5 (16.2) 22.4 (16.8) 0.027 12.9 
Dysphagia 35.8 (15.9) 22.2 (16.1) 0.0017 45.0 
Nausea 29.4 (19.2) 24.3 (16.4) 0.32 44.4 
Constipation 33.0 (15.9) 18.3 (14.8) <0.0001 60.5 
Faecal incontinence 42.2 (18.9) 24.2 (16.3) 0.067 16.7 
Incomplete bowel emptying 32.4 (11.3) 21.4 (18.3) 0.0006 12.5 
Urgency 30.5 (17.3) 18.4 (14.0) 0.0004 48.1 
Nocturia 29.5 (16.4) 18.5 (15.8) 0.0022 52.7 
Pain 35.2 (16.8) 18.1 (13.1) <0.0001 57.9 
Weight change 33.9 (17.3) 23.5 (16.4) 0.038 40.0 
Memory 30.5 (16.3) 18.3 (15.4) 0.0004 74.5 
Apathy 38.4 (15.1) 18.7 (13.8) <0.0001 9.4 
Hallucinations 37.3 (16.9) 20.4 (14.4) <0.0001 82.1 
Concentration 34.7 (15.5) 17.1 (13.6) <0.0001 23.3 
Depression 32.6 (18.4) 18.9 (12.7) 0.0001 67.4 
Anxiety 32.3 (17.1) 20.4 (15.2) 0.0009 60.5 
Libido 31.2 (14.3) 20.6 (17.6) 0.0019 7.5 
Sexual difficulty 28.8 (13.6) 23.8 (18.1) 0.15 25.9 
Dizziness 33.0 (17.0) 20.4 (15.1) 0.0006 59.5 
Falling 35.3 (15.2) 21.2 (16.0) 0.0002 70.4 
Daytime somnolence 36.3 (17.3) 21.2 (15.0) 0.0004 56.0 
Insomnia 30.4 (16.1) 21.9 (16.9) 0.018 67.6 
Vivid dreaming 34.2 (17.6) 22.0 (15.6) 0.0041 42.3 
REM sleep disorder 34.4 (13.9) 21.7 (16.8) 0.0005 42.3 
Restless leg syndrome 31.9 (17.4) 19.1 (14.1) 0.0002 17.4 
Leg swelling 31.9 (17.3) 22.0 (15.9) 0.010 40.0 
Excessive sweating 33.0 (17.5) 21.6 (15.5) 0.038 23.3 
Double vision 36.6 (16.5) 20.7 (14.9) <0.0001 25.0 
Delusions 38.7 (11.1) 23.7 (16.9) 0.0019 63.6 
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3.3.2.2  Early versus later Parkinson’s disease 
In the group with ≤5 years disease duration (table 3.3), depression, autonomic function, pain 
and fatigue had the highest correlation with PDQ-39, and in the group with > 5 years disease 
duration, autonomic function, fatigue, depression and daytime hypersomnolence had highest 
correlation with PDQ-39 scores. When individual subscales on SCOPA-AUT were 
considered, differences between ≤5 years and >5 years groups are evident (most marked for 
sexual dysfunction: r=0.59, p<0.05 in early PD versus r=0.08, not significant, in later PD). In 
the group with H&Y stage ≤ 2, fatigue, autonomic function, depression, and overall sleep had 
highest correlation with PDQ-39 and in group with H&Y >2 autonomic function, daytime 
hypersomnolence, depression and psychosis had highest correlation. In both early and later 
disease (determined by either disease duration or H&Y stage) NMS had higher correlations 
with Hr-QOL scores than motor scores (UPDRS part III), overall motor complications 
(UPDRS part IV), dyskinesias and “off”-time. UPDRS part IV had highest correlation with 
Hr-QOL in H&Y>2 group (r=0.67), but this was still less than non-motor symptoms 
(depression, autonomic function and daytime somnolence, table 3.3). 
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Table 3.3 Correlation of health-related quality of life with non-motor symptom and motor 
scores in patients with disease duration ≤ and >5 years or Hoehn-Yahr stage ≤2 or >2. 
 
Domain Clinimetric Scale Correlation with PDQ-39 index 
≤5 years 
(n=45) 
> 5 years 
(n=47) 
H&Y ≤2 
(n=56) 
H&Y >2 
(n=36) 
Non-motor scales 
Depression HADS-Depression 0.81
A 
0.62
A
 0.74
A
 0.73
A
 
Autonomic (Total) SCOPA-AUT 0.79
A
 0.72
A
 0.82
A
 0.87
A
 
Pain VAS 0.66
A
 0.37
C
 0.61
A
 0.44
C
 
Depression HDRS 0.65
A
 0.49
B 
0.65
A
 0.57
 B
 
Urinary SCOPA-AUT-Urinary 0.64
A
 0.64
A
 0.73
A
 0.66
A
 
Gastrointestinal SCOPA-AUT-Gastrointestinal 0.63
A
 0.32
C 
0.60
A
 0.63
A
 
Fatigue FSS 0.60
A
 0.69
A 
0.82
A
 0.54
B
 
Sexual SCOPA-AUT-Sexual 0.59
C 
0.08 0.52
B
 0.57
C
 
Psychosis PPRS 0.49
B
 0.40
C
 0.47
B
 0.60
B
 
Thermoregulation SCOPA-AUT-Thermoregulatory 0.49
B 
0.54
A 
0.51
A
 0.67
A
 
Sleep SCOPA-day 0.47
C 
0.50
B 
0.55
A
 0.76
A
 
Sleep SCOPA-night 0.44
C
 0.45
C
 0.57
A
 0.37
C
 
Anxiety HADS-Anxiety 0.42
C
 0.39
C
 0.40
B
 0.51
C
 
Apathy LARS 0.39
C
 0.32
C
 0.43
B
 0.26 
Sleep PSQI 0.32
C
 0.45
C
 0.62
A
 0.37
C
 
Sleep ESS 0.32
C
 0.43
C
 0.56
A
 0.74
A
 
Global cognition SCOPA-COG 0.32
C
 0.21 0.20 0.14 
Cardiovascular SCOPA-AUT-Cardiovascular 0.30
C
 0.25 0.36
C
 0.39
C
 
Global cognition ACE 0.27 0.24 0.06 0.27 
Frontal cognition FAB 0.25 0.08  0.07 0.09 
Motor scales 
Motor function UPDRS part III 0.37
C
 0.35
C
 0.45
B
 0.40
C
 
Motor complication UPDRS part IV 0.49
B
 0.45
C
 0.60
A
 0.67
A
 
“off” time Percentage 0.34C 0.41C 0.56A 0.45C 
Dyskinesia Percentage 0.13 0.21 0.36
C
 0.47
C
 
 
Abbreviations: H&Y=Hoehn & Yahr, SCOPA-AUT=Scales for outcome in Parkinson’s disease, 
Autonomic scale, PSQI=Pittsburgh Sleep Quality Index, ESS=Epworth Sleepiness Scale, 
FSS=Fatigue Severity Scale, LARS=Lille Apathy Rating Scale, PPRS=Parkinson Psychosis 
Rating Scale, HDRS=Hamilton Depression Rating Scale, HADS=Hospital Anxiety Depression 
Scale, ACE=Addenbrooke’s Cognitive Examination, FAB=Frontal Assessment Battery, SCOPA-
COG=Scales for outcome in Parkinson’s disease, cognitive scale, UPDRS (III) =Unified 
Parkinson’s Disease Rating Scale, Part III (motor part). 
Spearman Rank Correlation coefficients; 
A 
P<0.0001, 
B
 P<0.001 
C
 P<0.05 
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3.3.2.3  Multiple Regression Analysis 
Using multiple regression analysis with the PDQ-39 index score as the dependent variable, 
nine scales with the strongest, unrelated univariate association with PDQ-39 index scores 
were entered (SCOPA-AUT, HADS-depression, FSS, SCOPA-daytime sleep, PPRS, pain 
VAS, PSQI, HADS-anxiety and UPDRS part III). Significant predictors of PDQ-39 scores 
were SCOPA-AUT, SCOPA sleep daytime, HADS-depression and FSS (total adjusted R
2
 
change [R
2
] 0.79, table 3.3). When individual SCOPA-subscores were entered (excluding 
sexual dysfunction due to number of missing data) together with SCOPA sleep daytime, 
HADS-depression and FSS, the results were similar with HADS depression as the main 
predictor of PDQ-39 scores, followed by the FSS, SCOPA-AUT thermoregulation, SCOPA-
AUT gastrointestinal, SCOPA-AUT cardiovascular, SCOPA-sleep day-time and SCOPA-
AUT urinary (R
2
=0.77, table 3.4). Repeating the analysis with all of the above variables did 
not change this result. The additional binary variables (RBD, RLS) that were not covered by 
clinimetric scales individually added to this model had no significant predictive effect on the 
multiple regression model. Inclusion of additional motor variables (postural instability on the 
UPDRS, UPDRS part IV, percentage “off” time, percentage time with dyskinesia) also did 
not add to the predictive effect in the regression model. In the ≤5 years disease duration 
group, using multiple regression analysis, HADS-depression, SCOPA-AUT and FSS 
(R
2
=0.81) were significant predictors of Hr-QoL. In the >5 years disease duration group 
SCOPA-AUT and FSS (R
2
=0.64) were significant predictors of Hr-QoL. In the H&Y ≤2 
group, FSS, SCOPA-AUT and PSQI (R
2
=0.76) and in the H&Y >2 group, SCOPA-AUT, 
SCOPA-sleep daytime, HADS-depression (R
2
=0.81) were significant predictors using 
multiple regression analysis. In all groups (≤5 or >5 years disease duration and H&Y stage ≤2 
or 2) addition of UPDRS part IV, percentage “off” time or percentage dyskinesia time did not 
contribute to the regression model. 
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Table 3.4 Regression analysis of clinical determinants of quality of life in Parkinson’s 
disease 
Logistic regression model Cumulative 
adjusted R
2 
Standardized 
β coefficient 
t value p value 
Clinical scale summary indices 
SCOPA-AUT 0.68 0.49 6.77 <0.001 
SCOPA sleep (daytime) 0.74 0.17 2.61 0.011 
HADS-depression 0.77 0.22 3.05 0.003 
FSS 0.79 0.18 2.69 0.009 
Including autonomic subscales 
HADS-depression 0.53 0.22 2.89 0.005 
FSS 0.64 0.17 2.22 0.029 
SCOPA-AUT thermoregulation 0.69 0.22 3.33 0.001 
SCOPA-AUT gastrointestinal 0.73 0.18 2.85 0.006 
SCOPA-AUT cardiovascular 0.75 0.15 2.77 0.007 
SCOPA sleep (daytime) 0.76 0.16 2.27 0.026 
SCOPA-AUT urinary 0.77 0.16 2.15 0.035 
Abbreviations: SCOPA=Scales for Outcome in Parkinson’s disease, SCOPA-AUT=SCOPA 
autonomic, HADS=Hospital Anxiety and Depression Scale, FSS=Fatigue Severity Scale. 
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3.3.3  Impact of non-motor and motor symptoms on disability 
3.3.3.1  Univariate analysis 
Motor function (UPDRS Part III) had the highest correlation with S&E disability scores. 
Motor fluctuations score (UPDRS Part IV) and the majority of non-motor scales also 
correlated significantly with disability, particularly autonomic symptoms, fatigue, depression, 
psychosis, pain, daytime somnolence, nocturnal insomnia, cognitive impairment and apathy 
(rho > 0.40) (table 3.5). In the ≤5 years disease duration group, motor function, depression, 
cognition, autonomic function, pain, and fatigue had highest correlation with S&E score, and 
in the >5 years disease duration group, motor function, cognition, psychosis, and apathy had 
highest correlation with S&E (rho > 0.40) (table 3.5). In the H&Y stage ≤ 2 group, fatigue, 
motor function, pain, autonomic function, insomnia, depression, motor fluctuations, apathy, 
and psychosis had highest correlation with S&E score, and in the H&Y>2 group, daytime 
somnolence, motor function, autonomic symptoms, psychosis, motor fluctuations, depression 
and apathy had highest correlation with S&E (rho > 0.40) (table 3.5). 
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Table 3.5. Correlation of Schwab & England disability score with non-motor symptom and 
motor scores in patients with disease duration ≤ and >5 years. 
Domain Clinimetric Scale Correlation with S&E 
Total 
(n=94) 
≤ 5 
years 
(n=46) 
> 5 
years 
(n=48) 
H&Y 
≤2 
(n=57) 
H&Y 
>2 
(n=37) 
Non-motor scales 
Autonomic SCOPA-Autonomic 0.58 
A 
0.48
 B
 0.39
 C
 0.58
 A
  0.57
 A
 
Pain VAS 0.49 
A
 0.47
 C
 0.28 0.60
 A
 0.33
 C
 
Sleep 
PSQI 0.41 
A
 0.36
 C
 0.10 0.52
 A
 0.10 
ESS 0.47 
A
 0.12
 
0.18 0.35
 C
 0.63
 A
 
SCOPA-sleep-night 0.27 
C
 0.32
 C
 0.06 0.37
 C
 0.11 
SCOPA-sleep-day 0.46
 A
 0.34
 C 
0.18 0.35
 C
 0.53
 B
 
Fatigue FSS 0.55
 A
 0.47
 B 
0.31
 C
 0.65
 A
 0.32 
Apathy LARS 0.41
 A
 0.37
 C
 0.46
 C
 0.42
 C
 0.42
 C
 
Psychosis PPRS 0.50
 A
 0.35
 C
 0.49
 A
 0.40
 C
 0.51
 C
 
Mood 
HDRS 0.49
 A 
0.51
 A
 0.22 0.47
 A
 0.46
 C
 
HADS-Anxiety 0.30
 C 
0.28 0.19 0.29
 C
 0.27 
HADS-Depression 0.52
 A
 0.56
 A
 0.27 0.51
 A
 0.44
 C
 
Cognition 
ACE 0.38
 A
 0.48
 B
 0.39
 C
 0.28
 C
 0.30 
FAB 0.38
 A
 0.46
 C
 0.36
 C
 0.30
 C
 0.28 
SCOPA-Cognitive 0.45
 A
 0.47
 B
 0.51
 A
 0.35
 C
 0.35
 C
 
Motor scales 
Motor function UPDRS part III 0.68
 A
 0.63
 A
 0.57
 A
 0.64
 A
 0.61
 A
 
Motor 
complication 
UPDRS part IV 0.55
 A
 0.36
 C
 0.29
 C
 0.44
 B
 0.47
 C
 
“off” time Percentage 0.52 A 0.35 C 0.29 C 0.45 A 0.31 
Dyskinesia Percentage 0.37
 A
 0.40 0.18 0.27
 C
 0.36
 C
 
Abbreviations: S&E=Schwab & England, H&Y=Hoehn-Yahr, SCOPA-AUT=Scales for outcome 
in Parkinson’s disease, VAS=Visual Analogue Scale, PSQI=Pittsburgh Sleep Quality Index, 
ESS=Epworth Sleepiness Scale, FSS=Fatigue Severity Scale, LARS=Lille Apathy Rating Scale, 
PPRS=Parkinson Psychosis Rating Scale, HDRS=Hamilton Depression Rating Scale, 
HADS=Hospital Anxiety Depression Scale, ACE=Addenbrooke’s Cognitive Examination, 
FAB=Frontal Assessment Battery, SCOPA-COG=Scales for outcome in Parkinson’s disease, 
cognitive scale, UPDRS =Unified Parkinson’s Disease Rating Scale. 
Statistical significance: 
A 
P<0.0001, 
B
 P<0.001 
C
 P<0.05 
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3.3.3.2  Multiple Regression Analysis 
Using multiple regression analysis with the S&E score as the dependent variable, nine scales 
with the strongest, unrelated univariate association with S&E scores were entered (UPDRS 
Part III, SCOPA-AUT, UPDRS Part IV, FSS, HADS-D, PPRS, pain VAS, ESS, SCOPA-
COG). Significant predictors of S&E scores were UPDRS Part III, UPDRS Part IV and 
SCOPA-COG, total adjusted R
2
=0.58, (table 3.6). A regression analysis was also performed 
with the six clinically distinct factors identified for the UPDRS Part III (axial features/gait, 
right and left limb bradykinesia, rigidity, and rest and postural tremor) (Stebbins & Goetz, 
1998). Axial bradykinesia (adjusted R
2
 0.67, beta -0.82, t-score -13.84, p < 0.001) was 
significant predictor of disability in this model. Subgroup analysis was performed based on 
disease duration and H&Y stage. For each analysis, the five variables with highest univariate 
correlation were chosen, excluding collinear variables. In the ≤5 years disease duration 
group, using multiple regression analysis, UPDRS Part III, ACE, HADS-D (R
2
=0.67) were 
significant predictors of disability and in the >5 years disease duration group UPDRS Part III, 
SCOPA-COG, and SCOPA-autonomic (R
2=0.54) were significant. In the H&Y ≤2 group, 
UPDRS Part III, FSS, Pain VAS were significant predictors of disability (R
2
=0.56) and in the 
H&Y > 2 group ESS and UPDRS Part III were significant (table 3.6).   
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Table 3.6 Regression analysis of clinical determinants of Schwab & England disability score 
in Parkinson’s disease 
Logistic regression model Cumulative 
adjusted R
2 
Standardized 
β coefficient 
t value p value 
Overall 
UPDRS Part III 0.40 -0.47 -6.18 <0.001 
UPDRS Part IV 0.52 -0.33 -4.45 <0.001 
SCOPA-COG 0.58 0.24 3.28 0.001 
Disease duration ≤ 5 years 
UPDRS Part III 0.51 -0.38 -3.26 0.002 
ACE 0.61 0.35 3.50 0.001 
HADS-depression 0.67 -0.31 -2.86 0.007 
Disease duration > 5 years 
UPDRS Part III 0.31 -0.43 -4.05 <0.001 
SCOPA-COG 0.48 0.38 3.68 0.001 
SCOPA-Autonomic 0.54 -0.25 -2.34 0.024 
H&Y ≤ 2 
UPDRS Part III 0.42 -0.49 -4.68 <0.001 
FSS 0.53 -0.29 -2.59 0.013 
Pain (VAS) 0.56 -0.20 -2.02 0.049 
H&Y > 2 
ESS 0.39 -0.45 -3.42 0.002 
UPDRS Part III 0.52 -0.40 -3.02 0.005 
Abbreviations: UPDRS =Unified Parkinson’s Disease Rating Scale, ACE=Addenbrooke’s 
Cognitive Examination, HADS=Hospital Anxiety Depression Scale, SCOPA-COG=Scales for 
outcome in Parkinson’s disease, cognitive scale, SCOPA-AUT=Scales for outcome in 
Parkinson’s disease, autonomic scale, FSS=Fatigue Severity Scale, VAS=Visual Analogue Scale, 
ESS=Epworth Sleepiness Scale. 
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3.3.4  Documentation rate of non-motor symptoms 
A mean of 4.8 non-motor symptoms were documented per patient in the clinical notes, a 
detection rate of 44% (table 3.7). Cognitive and neuropsychiatric complications of PD were 
generally well documented: hallucinations (82%), memory loss (75%), mood alteration 
(67%), delusional thought disorder (64%) and anxiety (61%) (figure 3.1 and table 3.2). The 
NMSQ is divided into nine domains and detection of symptoms in the hallucination/delusions 
(77%) and depression/anxiety (64%) domains were highest. Except for cardiovascular 
symptoms (64%), autonomic symptoms and in particular sexual function were poorly 
documented (urinary symptoms 50%, digestive 35% and sexual problems 15%). Problems in 
the domains apathy/attention/memory were documented in 40% and sleep problems in 43% 
(table 3.7).  
Table 3.7 Detection of non-motor symptoms: Number of self-reported symptoms on the non-
motor symptom questionnaire (NMSQ) by domain, and detection rate calculated from 
documentation in the clinic notes and correspondence. 
NMSQ Domain 
(items) 
Symptoms 
(total, 
N=89) 
Symptoms 
(mean per 
patient) 
Detected 
(N) 
Detected 
(mean per 
patient) 
Percentage 
(%) 
Digestive (7) 193 2.2 67 0.8 34.7 
Urinary (2) 107 1.2 54 0.6 50.5 
Apathy, Attention, 
Memory (3) 
126 1.4 51 0.6 40.5 
Hallucination/Delusion 
(2) 
39 0.4 30 0.3 76.9 
Depression/Anxiety 
(2) 
81 0.9 52 0.6 64.2 
Sexual (2) 67 0.8 10 0.1 14.9 
Cardiovascular (2) 64 0.7 41 0.5 64.1 
Sleep (5) 160 1.8 69 0.8 43.1 
Miscellaneous (5) 141 1.6 54 0.6 38.3 
TOTAL (30) 978 11.0 428 4.8 43.8 
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3.4  Discussion 
3.4.1  Quality of Life 
This study found that NMS are common (>10 per patient) and have a significant association 
with poor Hr-QoL of patients which, in patients in specialist care, exceeds the impact of 
motor dysfunction. This association was found in advanced disease where symptoms of 
autonomic dysfunction and fatigue had the strongest association with poorer Hr-QoL but also 
in early disease (<5 years disease duration), where depression, autonomic dysfunction and 
fatigue were the strongest predictors of PDQ-39 scores. 
The prevalence of overall and individual NMS in PD in this study was similarly high as in 
other studies, including autonomic symptoms (particularly nocturia and urgency), impairment 
of cognition and concentration, and psychiatric features such as depression and anxiety 
(Martinez-Martin et al., 2007, Cheon et al., 2008, Barone et al., 2009). Numerous studies 
have also assessed the clinical determinants of Hr-QoL in PD (Gallagher & Schrag, 2008), 
but most have focused on motor symptoms (disease severity and motor complications), 
disability and depression. However, these studies have been limited by the clinical scales 
used and, except for neuropsychiatric symptoms (depression, anxiety, cognition, 
hallucinations) other NMS have been included inconsistently and often without validated 
scales. The present study provides the most comprehensive and in-depth assessment of the 
range of recognised NMS in PD and their relative relationship to patients’ Hr-QoL as well as 
their recognition rate in clinical practice. 
Depression has consistently been shown to be one of the most important determinants of Hr-
QoL in PD in these studies (Gallagher & Schrag, 2008), with additional associations of Hr-
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QoL with disability, disease severity, gait, postural stability, motor complications, levodopa 
medication, cognition, fatigue, sleep, and satisfaction with explanation of diagnosis (Karlsen 
et al., 1999, Gomez-Esteban et al., 2007, Schrag et al., 2000, Global Parkinson's Disease 
Survey Steering Committee, 2002, Martinez-Martin et al., 2006). Despite the high impact of 
fatigue and autonomic dysfunction on Hr-QOL in our study, these variables have been 
infrequently included in previous Hr-QOL studies. However fatigue (Martinez-Martin et al., 
2006, Qin et al., 2009) and autonomic function (Visser et al., 2008) have been shown to 
contribute to overall Hr-QOL in some regression models. Cognitive impairment had a 
statistically significant but modest correlation of with Hr-QOL in univariate analyses (ACE, 
r=0.22 and SCOPA-COG, r=0.25). The strength of this association is of similar magnitude as 
the modest correlation in other studies in the literature (ranging from r=0.24 to 0.32 [Schrag 
et al., 2000, Visser et al., 2008, Carod-Artal et al., 2007, Slawek et al., 2005, Cubo et al., 
2002]). However, when other confounding clinical variables were considered in this and 
other studies, cognitive scores did not (Visser et al., 2008, Slawek et al., 2005, Cubo et al., 
2002, Kuopio et al., 2000) or minimally (Schrag et al., 2000) contribute to overall Hr-QOL 
prediction. Our results also confirm a moderately strong association between Hr-QOL and 
motor score (r=0.48), similar to regression coefficients reported in the literature (ranging 
from r=0.33 to 0.53 (Gomez-Esteban et al., 2007, Schrag et al., 2000, Visser et al., 2008, 
Carod-Artal et al., 2007, Slawek et al., 2005, Cubo et al., 2002). However, when other 
confounding variables are considered, UPDRS motor score has not been shown to be a major 
contributor to Hr-QOL (Slawek et al., 2005, Cubo et al., 2002, Greene & Camicioli, 2007).    
3.4.2  Disability 
As expected motor features (severity of motor symptoms and motor complications) had high 
correlation with disability score; however non-motor features also had significant association 
with disability.  This association was found in advanced disease where motor impairment, 
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cognitive impairment and autonomic dysfunction had the strongest association with increased 
disability but also in early disease (<5 years disease duration), where motor function, 
cognitive impairment and depression, were the strongest predictors. Only a few previous 
studies have examined the influence of motor and non-motor symptoms on disability in PD 
and compared to our study, these have been more limited in terms of the number of predictive 
measures included. For example, one study assessed the influence of motor features 
(UPDRS), cognitive function (MMSE and a battery of neuropsychological tests to measure 
attention, psychomotor speed, memory, executive function and visuospatial function) and 
mood (HADS) on three disability measures (S&E, AMC [American Medical Center] -Linear 
Disability Score [ALDS] and Functional Independence Measure [FIM]) (Muslimovic et al., 
2008). The motor features, axial impairment, bradykinesia and hypomimia contributed to 
S&E score in the regression analysis (35% of variance); axial impairment and medical 
comorbidity contributed to ALDS score (37% of variance) and axial impairment, 
comorbidity, hypomimia, and executive function (semantic verbal fluency) contributed to 
FIM score (45% variance). In each case axial UPDRS score was the strongest predictor. A 
longitudinal study examined determinants of progression of disability (Post et al., 2011). Age 
at onset and motor subscore were significant predictors of progression of S&E score and age 
at onset, motor subscore and comorbidities were significant predictors of ALDS. Our results 
are consistent with these findings, with motor severity and motor complications significant 
predictors in the regression model, and on separate analysis axial symptoms having a large 
influence on disability. However, the inclusion of other non-motor variables in this study 
demonstrated the impact of non-motor features, including cognitive impairment (overall 
regression model), depression (<5 years disease duration), autonomic symptoms (>5 years 
duration), fatigue and pain (H&Y stage ≤ 2) and daytime somnolence (H&Y stage >2) on 
disability in PD.  
113 
 
3.4.3  Documentation of non-motor symptoms  
Whilst some of the NMS were well documented, others were poorly documented in clinic 
notes, particularly seemingly PD-unrelated ones, such as apathy, or potentially embarrassing 
ones, such as faecal incontinence, which patients may be unlikely to report spontaneously and 
may not be routinely enquired about. Depression, which has high impact on Hr-QoL in the 
multivariate analysis, and other neuropsychiatric complications (such as hallucinations and 
delusions) were generally well detected although documentation rate was less than 100%. A 
low detection rate of NMS has been reported in previous studies (Shulman et al., 2002, 
Sullivan et al., 2007). In one study (Sullivan et al., 2007) depression, anxiety and constipation 
were addressed and treated in only 50% of patients, with even lower detection rates for other 
NMS such as fatigue (6%), memory (9%), somnolence (16%), insomnia (30%), incontinence 
(35%) and pain (35%). Another study (Shulman et al., 2002) found a lower diagnostic 
sensitivity for fatigue (25%), depression (35%), anxiety (42%) and sleep disturbance (60%) 
by physicians’ interview compared to patients’ response using a screening questionnaire. 
However patients’ responses were less specific with a higher rate of false positive responses, 
highlighting that self-reported symptom questionnaires are not diagnostic tools and require 
clinical validation in the consultation. Thus, the higher reports of self-reported symptoms 
than documented NMS may also partly result from false positive responses. Another 
explanation for low detection rates of NMS may be low patient awareness of NMS associated 
with PD, which was examined in one study (Cheon et al., 2008). Patients recognised on 
average only 5.2±6.8 NMS (of 30 symptoms on the NMSQ) as being related to PD, although 
this was higher (7.7±6.5) for carers and relatives. This may be analogous to the often seen 
unawareness of dyskinesias by patients. NMS which patients were least aware of being part 
of PD included delusions, faecal incontinence, RBD, weight change, hallucinations, nausea, 
unexplained pain, interest in sexual activity, sexual difficulty and  incomplete bowel 
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emptying. This unawareness is likely to contribute to the low rate of documentation of at least 
some of the symptoms in this study, and highlights the importance of patient education and 
vigilance for NMS that patients may not be aware as symptoms of PD. Further explanations 
for under-recognition may be relatively low symptom severity, embarrassment, expectation 
that these cannot be dealt with and insufficient time for consultations. 
3.4.4  Methodological considerations  
There are some methodological considerations in this study. (1) Given that this study required 
completion of a large number of physician-assessments and self-completed questionnaires, it 
may not be fully representative, and patients with cognitive impairment and apathy may be 
under-represented. Cognitive symptoms could have a higher impact on Hr-QoL than detected 
by this analysis. However, we endeavoured to include patients in all stages of PD, from early 
untreated to advanced disease, which is reflected in the motor and cognitive scores of our 
patients. This included patients with a range of mild and sub-clinical cognitive impairment; 
(2) DDS/ICD and FAB scores correlated poorly with Hr-QoL. However, the lack of insight 
found in some these patients may obscure declines in Hr-QOL despite possible severe 
consequences on the social, familial and personal life of patients. In addition, consequences 
associated to these abnormalities are not represented in the PDQ39 questionnaire and their 
impact may be underrepresented; (3) Patients were seen in specialty movement disorder 
clinics and thus optimization of dopaminergic therapy may be better than for primary 
neurologists or patients in the community and therefore it is possible that NMS might be 
proportionately more troublesome in this study. However, this study included a high 
proportion of patients with marked motor symptoms despite maximal possible drug therapy, 
and mean UPDRS motor score in optimal state was 30, reflecting moderate to advanced 
disease. (4) Motor scores assessed in the “on” state may underestimate the impact of motor 
impairment on Hr-QoL as they are likely to have less variability between subjects than in the 
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“off” state, which could explain the lower correlation of motor function and Hr-QoL found in 
this study. However, patients were assessed on maximal motor and non-motor therapies as 
encountered in a naturalistic setting. Therefore our conclusions apply to patients as seen in 
clinical practice and highlight a possible inattention of treating physicians to non-motor 
features (44% from our data), disproportionate emphasis on motor symptoms or 
unavailability of treatment options for NMS. (5) Part of this study was based on a patient-
reported measure with single questions without diagnostic clarification (NMSQ). It is 
therefore possible that some symptoms were misinterpreted (e.g. RLS may represent motor 
impatience, akathisia or non-specific sensory symptoms than classical RLS). 
3.4.5  Conclusions  
The results indicate that NMS are frequently under-recognised despite their importance for 
patients’ subjective Hr-QoL and disability. In optimally treated patients from a motor point of 
view, particularly autonomic features, fatigue and daytime somnolence are correlated with 
poor Hr-QoL, in addition to the now well-recognised impact of depression. The detection of 
NMS has important consequences for the management of patients, as treatment options are 
available for many (Chaudhuri & Schapira, 2009), with potential for improvement of Hr-
QoL. Clinicians should therefore try to elicit NMS more systematically, e.g. by the use of 
screening instruments. This may be particularly relevant for embarrassing or seemingly 
unrelated symptoms and for features of the disease that are not commonly included in PD 
evaluations, such as autonomic function and fatigue.  
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Chapter 4 
Non-motor symptoms as presenting complaints in Parkinson’s disease  
4.1  Introduction 
NMS are increasingly recognized as a significant cause of morbidity in later stages of PD. 
Prodromal NMS are also a well-recognized component of the clinical picture in some patients 
but the prevalence of NMS as presenting complaints, and their impact on clinical 
management, in pathologically-proven cases of PD is unknown. PD cannot be diagnosed until 
motor symptoms appear but many patients will in hindsight recall a prodromal phase 
including NMS (Wilson et al., 1954). It is also reported that more non-specific complaints are 
reported by PD patients to their general practitioners in the 5 years leading up to diagnosis 
than are reported by age matched controls (Gonera et al., 1997). The aims of this study were 
to review the prevalence of NMS as presenting complaints in pathologically-proven cases of 
PD. 
4.2  Methods 
4.2.1  Patients 
A retrospective review of cases of pathologically-proven PD archived at the Queen Square 
Brain Bank for Neurological Diseases was made. Donors were from the UK and died 
between 1988 and 2005. Of the 543 cases identified 110 were excluded because of 
inadequate clinical detail of the presenting features. The London Multi-Centre Research 
Ethics Committee has approved procedures for the donation of brains to the Queen Square 
Brain Bank as well as retention of and access to clinical records. 
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4.2.2  Data Collection 
A systematic chart review was performed paying particular attention to the case notes of the 
family doctor in the 3 years before the documentation of the first motor symptom definitively 
linked to progressive Parkinsonism. First and subsequent correspondence between the 
medical specialist and family doctor were also scrutinized. Hospital inpatient notes, inpatient 
consultations, and emergency room admission notes were also reviewed. The initial 
presenting complaint prompting patients to attend medical services was noted, and early 
diagnoses made were documented. The included symptoms or doctors' diagnoses were those 
considered retrospectively to be associated with PD. That is, they did not resolve or they were 
related to the eventual motor problems, for example; frozen shoulder or sensory disturbances 
with the later development of bradykinesia, tremor, or rigidity on that same side; depression 
that did not improve; urinary symptoms with subsequent autonomic dysfunction; new onset 
low back pain; personality or cognitive changes. Patients were compared according to two 
groups; those presenting with exclusively non-motor and those presenting with motor 
symptoms. In patients with more than one presenting complaint documented, if motor 
symptoms were present in addition to NMS as first complaints, these patients were included 
in the “motor symptoms” group for analysis. The latency from presenting complaint to final 
clinical diagnosis was reviewed. Other clinical features were recorded as present or absent 
early in the disease (within 2 years of first symptom onset) and at any time during the disease. 
These features included: age of onset (age at the time of the first reported symptom 
considered to be attributable to disease), disease duration (time from onset until death), falls, 
bradykinesia, cognitive dysfunction (reported by the family, patient, or physician, and not 
attributed to affective disorder), symmetry of disease at onset, tremor, rigidity, postural 
reflexes (reported by the physician), response to L-dopa (graded by patient or clinician from 
1 to 4, 1 = nil or slight, 2 = moderate, 3 = good, or 4 = excellent), and autonomic dysfunction. 
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Abnormal autonomic function was recorded according to test results or reports of any two of 
these symptoms: urinary urgency, frequency, and nocturia without hesitancy; chronic 
constipation; postural hypotension; sweating abnormalities; erectile dysfunction. The 
presence and time of onset of hallucinations and dyskinesias were noted. Sleep disturbances 
were not included in the analysis. We recorded symptoms as absent if not reported and 
clinical signs as missing if they were not specifically mentioned in the notes. Where reports 
of clinical features conflicted, the findings of the neurologist were used. Complete drug 
history was obtained, including latency from symptom onset to initiation, and time from 
initiation to maximum dose of L-dopa. 
4.2.3  Statistics 
Comparison between groups was performed using the parametric (Student's t test) or non-
parametric (Mann-Whitney U) tests as appropriate. Statistical analysis of difference in the 
frequency of categorical variables was performed using the chi square (χ2) test or Fisher 
Exact Tests as appropriate. Statistical analyses of data were performed with SPSS version 
12.0 (SPSS, Chicago, IL). 
4.3  Results 
From the 433 cases with detailed histories of early symptoms, 91 (21%) had exclusively 
NMS at presentation to their general practitioner. Of the NMS, pain was the most frequent, 
seen in 48 (53%) of these cases, urinary symptoms were present in 15 (16.5%), depression or 
anxiety in 11 (12.1%). Other NMS included non-specific cognitive impairment without 
functional limitation or dementia (5.5%), lethargy (4.4%), sensory disturbances, and visual 
impairment (Table 4.1). 
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Table 4.1 Patient characteristics and presenting symptoms. 
 Total cases  
(N = 433) 
Cases with 
“motor 
symptoms” at 
presentation 
(N = 342) 
Cases 
without 
“motor 
symptoms” at 
presentation 
(N = 91) 
P value 
Male: Female (%) 274:159 
(63:37%) 
215:127 
(63:37%) 
59:32 
(65:35%) 
NS
A
 
Number of patients with a 
documented family history 
of PD (%) 
31 (7%) 28 (8.2%) 3 (3.3%) 0.08
A
 
Age of PD onset (mean ± 
SD) 
60.9 ± 10.4 
years 
60.6 ± 10.6 
years 
61.9 ± 9.5 
years 
NS
B
 
Interval between symptom 
onset and diagnosis of PD 
(median, interquartile range 
[years]) 
1.1 (0.9–2.4) 1.0 (0.8–2.2) 1.6 (1.0–3.0) 0.001C 
Duration of PD before 
death (mean ± SD [years]) 
14.9 ± 6.9 15.3 ± 7.0 13.4 ± 6.6 0.016
B
 
Age of death (mean ± SD) 75.8 ± 7.4 75.9 ± 7.6 75.3 ± 6.6 NS
B
 
First symptoms including 
tremor 
196 (45.3%) 196 (57.3%) 0 N/A 
First symptoms including 
bradykinesia 
136 (31.4%) 136 (39.8%) 0 N/A 
First symptoms including 
rigidity 
44 (10.2%) 44 (12.9%) 0 N/A 
First symptoms including 
unspecified gait disturbance 
51 (11.8%) 51 (14.9%) 0 N/A 
First symptoms including 
pain 
65 (15%) 17 (5%) 48 (52.7%) N/A 
First symptoms including 
urinary dysfunction 
17 (3.9%) 2 (0.6%) 15 (16.5%) N/A 
First symptoms including 
depression or anxiety 
11 (2.5%) 0 11 (12.1%) N/A 
Other symptoms 59 (13.6%) 34 (9.9%) 25 (27.5%) N/A 
Statistical analysis A= Chi square test, B= students t-test, C= Mann-Whitney U 
 
Presenting with NMS is associated with a delayed diagnosis of PD, with a median interval of 
1.6 years between first symptom and diagnosis of PD, compared with 1.0 years in those 
presenting with motor symptoms (Mann-Whitney U, P = 0.001). PD was the initial diagnosis 
made in only 15 (16.5%) of patients presenting with NMS, compared to 230 (67.3%) for 
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patients in the motor group (χ2, P < 0.0001). The non-motor cases were more likely to be 
diagnosed with osteoarthritis, degenerative spinal disease, frozen shoulder, depression, or 
anxiety. (Table 4.2) Correspondingly, patients presenting with NMS were significantly less 
likely to be initially referred to a neurologist by their general practitioner than the motor 
group (5.5% vs. 44.2%, χ2P < 0.0001). Patients in the non-motor group were more likely to 
be referred to orthopaedic and rheumatological services (29.7%), urological services (15.4%), 
general physicians (13.2%), and psychiatrists (11%) than a neurologist. In contrast, 26% of 
patients from the motor group were referred to general physicians and only 4.3% to 
orthopaedic or rheumatological services. A high proportion of patients presenting with NMS 
underwent surgical interventions prior to the diagnosis of PD, including steroid injections in 9 
of 10 patients diagnosed with frozen shoulders, and five out of 12 patients diagnosed with 
degenerative spinal disease. 
 
Table 4.2 Initial diagnoses following symptom onset 
 Total cases  
(N = 433) 
Cases with “motor 
symptoms” at 
presentation (N = 
342) 
Cases 
without 
“motor 
symptoms” 
at 
presentation 
(N = 91) 
P value 
(Chi 
Square) 
Parkinson’s disease 245 (56.6%) 230 (67.3%) 15 (16.5%) <0.0001 
Osteoarthritis/degenerative 
vertebral disease 
21 (4.8%) 9 (2.6%) 12 (13.2%) <0.0001 
Depression, anxiety or 
psychogenic causes 
17 (3.9%) 7 (2%) 10 (11%) 0.0003 
Frozen shoulder 14 (3.2%) 3 (0.7%) 11 (12.1%) <0.0001 
Stroke 9 (2.1%) 7 (2%) 2 (2.2%) NS 
Essential tremor 8 (1.8%) 8 (2.3%) 0 (0%) NS 
Other diagnoses 57 (13.2%) 23 (6.7%) 34 (37.4%)   
Unknown 62 (14.3%) 55 (16.1%) 7 (7.7%) NS 
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A small percentage of patients from the non-motor group (4.4%) had no bradykinesia, 
rigidity, or tremor documented 2 years after symptom onset. After the same interval, only two 
of the 342 patients (0.6%) had none of the “classical parkinsonian triad” documented, both 
patients having presented with unspecified gait disturbances or writing difficulties (P = 0.02, 
χ2 analysis) (Table 4.3). Autonomic dysfunction was the only symptom that was more 
common in the non-motor group (P = 0.025, χ2 analysis). Tremor was more frequently 
documented throughout the disease in the motor group (P = 0.04, χ2 analysis). There were no 
other differences in the frequency of clinical features between the groups. Hallucinations 
were documented in 168 (52.2%) of the motor group and 46 (53.5%) of the non-motor group 
during their disease history. There was no difference in the mean latency from first symptom 
onset to the development of hallucinations between groups (motor group 131 ± 75 months, 
nonmotor 115 ± 81 months). Drug-induced dyskinesias were documented in 158 (53%) of the 
motor group, and 41 (50%) in the nonmotor group during the disease history. The mean 
latency to onset of dyskinesias from first symptom onset was similar in both groups (motor 
group 101 ± 52 months, nonmotor group 93 ± 45). 
Table 4.3 Symptoms documented at 2 years from first symptom 
 Total cases  
(N = 433) 
Cases with  
“motor symptoms” 
at presentation 
Cases without 
“motor symptoms” 
at presentation 
P 
value* 
Bradykinesia 354 (85.3%) 278 (85%) 76 (86.4%) NS 
Tremor 308 (73.9%) 251 (76.3%) 57 (64.8%) 0.04 
Extra-axial rigidity 321 (78.3%) 254 (78.2%) 67 (78.8%) NS 
Postural instability 36 (9%) 25 (7.8%) 11 (13.9%) NS 
Falls 23 (5.5%) 17 (5.2%) 6 (6.7%) NS 
Cognitive impairment 42 (10%) 29 (8.8%) 13 (14.6%) NS 
Autonomic 
dysfunction 
29 (7%) 15 (4.6%) 14 (16.1%) 0.001 
Depression 97 (24.7%) 71 (22.9%) 26 (31.3%) NS 
Dysarthria 50 (12.3%) 39 (12.1%) 11 (13.4%) NS 
Hallucinations 12 (5.9%) 8 (5.0%) 4 (8.9%) NS 
Dyskinesia 7 (3.6%) 6 (3.8%) 1 (2.9%) NS 
*Chi Square test, NS= non-significant 
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The final clinical diagnosis before death was PD in 81 of 91 (89%) patients initially 
presenting with NMS, compared with 316 of 342 (92.4%) patients presenting with motor 
symptoms (P > 0.05). There were no significant differences in the latency to initiation of L-
dopa, the maximum doses prescribed, or the response to this medication between these 
groups (Table 4.4). Similarly, no differences were seen between groups regarding the 
prescription of dopamine agonists (DA). DA were used in 52% of patients presenting with 
motor symptoms, compared to 46% of the patients presenting with NMS, (P = 0.5). Non-
ergot agonists were prescribed in ∼80% of these cases in both patient groups. Antidepressant 
medication prescription rates throughout the disease course were also similar between patient 
groups, at 29.2% of patients presenting with motor symptoms, compared to 29.7% of the 
patients presenting with NMS. 
It is thought that by the time patients fulfil diagnostic criteria for the diagnosis of PD, there 
may be degeneration of ∼50% of neurons in the substantia nigra (Greffard et al., 2006, 
Fearnley & Lees, 1991). The duration of the premotor phase following the onset of nigral loss 
is uncertain, but pathological and radiological estimates have suggested between 5 and 7 
years (Fearnley & Lees, 1991, Morrish et al., 1998) 
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Table 4.4 History of L-dopa use and response 
 Total 
cases 
Cases with 
“motor 
symptoms” at 
presentation 
Cases 
without 
“motor 
symptoms” 
at 
presentation 
P 
value* 
Latency from first symptom to L-dopa 
commencement (mean ± SD) 
2.9 ± 2.8 
years 
2.9 ± 2.9 2.9 ± 2.2 NS 
Maximum L-dopa dose (mg/day)  
(mean ± SD) 
923 ± 499 947 ± 502 828 ± 478 NS 
Response to L-dopa (%) 395 (96%) 299 (94.9%) 79 (98.8%) NS 
Grade of response to L-dopa  
(QSBB scale) (mean ± SD) 
3.2 ± 0.9 3.2 ± 0.9 3.3 ± 0.9 NS 
QSBB = Queen Square Brain Bank, *Student’s t-test, NS = non-significant 
 
4.4  Discussion  
In this study 21% of people who went on to develop motor features of PD, described their 
initial symptoms in exclusively non-motor terms, and pain was seen as a presenting symptom 
in 15%. We acknowledge the retrospective nature of the study is a limiting factor and the 
recording and interpretation of non-specific non-motor symptoms in general practice may 
vary. General practitioners in the United Kingdom are however required to make a written 
entry of all symptom complaints for every consultation. We accept nonetheless that some 
physicians may be more aware and astute in suspecting early Parkinsonism when a non-
motor presentation occurs. Hyposmia is rarely spontaneously reported by patients with PD 
and REM sleep disorder may be dismissed. Once the diagnosis of PD has been firmly 
established however direct enquiry about deterioration of olfaction frequently results in a 
positive response We also acknowledge that among the high percentage of pain as a 
presenting symptom, some could be pain related to bradykinesia in akinesia dominant PD, 
which would be more likely to be mechanical pain related to a rigid arm rather than the 
typical pain of PD. Nevertheless, we feel that this study is relevant as it is the first to assess 
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the prevalence and clinical characteristics of a subgroup of patients with pathologically 
proven PD who present with NMS. 
 
Autonomic dysfunction has been described in up to 50% of patients with diagnosed PD 
(Magerkurth et al., 2005), and one study on constipation has been associated with an almost 
threefold increased risk of a subsequent diagnosis of PD after 12-year follow-up (Abbot et al., 
2001). In our cohort, new urinary symptoms were found to be a presenting complaint in 3.9% 
of patients with PD. Autonomic dysfunction was found to be the only NMS that remained 
more prevalent throughout the course of the PD in the group of patients presenting initially 
with NMS, compared to those presenting with motor-related complaints. Shorter disease 
duration is found in patients presenting with NMS (P = 0.0016, t-test). Whether this is due to 
more frequent and severe autonomic dysfunction in this group is unclear, as in the majority of 
our cases formal autonomic function tests were not performed, and the specific cause of death 
is not documented. 
Depression or anxiety was shown to be a presenting complaint in 2.5% of our PD cases, with 
∼25% developing these symptoms within two years of disease onset. These findings are in 
keeping with previous research showing that depression affects between 30 and 50% of 
people with PD (Slaughter et al., 2001, Dooneief et al., 1992). Studies have suggested that 
neuropsychiatric conditions may also be “preclinical” symptoms of PD, with strong 
associations between premorbid depression and subsequent development of PD (Schuurman 
et al., 2002, Ishihara & Brayne, 2006, Shiba et al., 2000). Similarly, anxiety has been 
associated with subsequent diagnoses of PD (Shiba et al., 2000, Weisskopf et al., 2003) 
although the evidence is not as strong as for depression (Ishihara & Brayne, 2006). 
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Hyposmia has been associated with PD for over 30 years, and has been widely studied with 
clinical and pathological evidence of olfactory dysfunction in a majority of patients (Ansari 
& Johnson, 1975). The presence of idiopathic hyposmia is thought to predict the development 
of clinical PD in around 10% of patients at 2-year follow-up (Ponsen et al., 2004). Sleep 
disturbance, including RBD precede the development of the classical parkinsonian symptoms 
in up to 38% of cases, with a latency of over 10 years between RBD onset and clinical 
Parkinsonism (Schenck et al., 1996, Iranzo et al., 2006). Excessive day-time sleepiness has 
also been shown to precede the diagnosis of PD, with a threefold increased risk demonstrated 
in one longitudinal study (Abbott et al., 2005). Unfortunately there was almost no 
documentation of the presence or absence of olfactory or sleep disturbances in patients we 
studied, possibly due to a lack of awareness of the clinical importance of these features 
during the period in which this cohort was treated. 
Non-motor presentations of PD were frequently misdiagnosed initially by primary carers, 
leading to a high proportion of potentially inappropriate specialist referrals and treatments, 
including steroid injections for frozen shoulders and surgical interventions for degenerative 
spinal disease or carpal tunnel syndromes. Clearly, such interventions may have a deleterious 
effect on patients' quality of life, in addition to potentially increasing costs of health care. An 
increased latency between symptom onset and final diagnosis of PD was made in these 
patients. However, despite these early diagnostic difficulties, it has been shown that, after the 
first 2 years from symptom onset, these groups have similar symptoms and signs, and the rate 
of correct final clinical diagnoses did not differ. A good response to L-dopa therapy was seen 
in both subgroups, despite suggestions that NMS tend to respond less well than motor 
symptoms to dopaminergic treatments (Dhawan et al., 2006). However, the response rating to 
L-dopa is an overall clinical impression, and does not account for individual symptoms that 
may not be deemed significant by the treating clinicians. Furthermore the limitations of the 
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retrospective nature the data, and the selection bias that is expected in a brain bank post-
mortem series, may account for the differences with previous studies (Maraganore et al., 
1999). The large number of patients and the inclusion of patients that otherwise might not 
have been included in a prospective clinical study are relative strengths of this study. 
Despite the increasing literature demonstrating that NMS are frequent and disabling features 
of more advanced PD (Witjas et al., 2002), they are still likely to be under-recognized by 
neurologists (Shulman et al., 2002). Our findings suggest that NMS may be significant 
features in earlier PD stages and that an increased awareness of these problems as 
manifestations of PD is also required at a primary care level. To minimize misdiagnoses and 
potentially harmful and inappropriate interventions in patients presenting without the typical 
motor symptoms, a clearer message about NMS of early PD in medical education is required. 
This may be facilitated by the development of clinical tools such as the validated Non Motor 
Questionnaire to aid clinicians in identifying, and managing, NMS in patients at earlier stages 
of PD (Chaudhuri et al., 2006). 
 
 
 
 
 
 
 
 
 
 
127 
 
Chapter 5 
 
Assessment of non-motor symptoms in PD, including validation of the  MDS-UPDRS 
Part I 
 
 
 
5.1  Introduction 
The UPDRS has been the main outcome measure in clinical trials in PD and a revision 
developed by the Movement Disorder Society (MDS-UPDRS) has recently been published 
(Goetz et al., 2008). Particular emphasis was placed on improving scale properties and 
representing the breadth of manifestations, including NMS of the disease. However, the 
convergent validity of the scale in comparison to validated scales for individual non-motor 
aspects of PD has not been demonstrated. We here present a validation of MDS-UPDRS Part 
I (nM-EDL).  
 
5.2  Methods 
5.2.1  Patients and assessments 
Consenting patients were assessed with the MDS-UPDRS part I (Goetz et al., 2008), original 
UPDRS (Fahn et al., 1987), ACE (Larner, 2007), SCOPA-COG (Marinus et al., 2003), FAB 
(Dubois et al., 2000), PPRS (Friedberg et al., 1998), HDRS (Schwab et al., 1967), HADS-
Anxiety and HADS-Depression (Upadhyaya & Stanley, 1993), LARS (Sockeel et al., 2006), 
PSQI (Buysse et al., 1989), ESS (John, 1991), SCOPA-sleep scale (daytime and night time) 
(Marinus et al., 2003), Visual Analogue Scale (VAS) of Pain, SCOPA-AUT (Visser et al., 
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2004), and FSS (Krupp et al., 1989). 84% of questionnaires were completed by patients alone 
and 16% by both patients and their carers. 
 
5.2.2  Statistical analysis 
Statistical analysis was performed using SPSS version 17.0 (SPSS, Inc., Chicago, IL). 
Variables were expressed as mean and standard deviation (SD). In order to compare the scale 
scores in a common framework, standardized z-scores were calculated for MDS-UPDRS Part 
I and the non-motor scales from the raw scores. Cognitive impairment score was derived 
from ACE, SCOPA-COG and FAB; hallucinations and psychosis from PPRS; depressed 
mood from HDRS and HADS-D; anxious mood from HADS-A; apathy from LARS; sleep 
problems from PSQI and SCOPA-sleep-night; daytime sleepiness from ESS and SCOPA-
sleep-daytime; pain and other sensations from VAS; urinary problems from SCOPA-AUT 
urinary; constipation problems from SCOPA-AUT gastrointestinal; light headedness on 
standing from SCOPA-AUT cardiovascular and fatigue from FSS. This study does not 
include a clinimetric assessment for dopamine dysregulation or impulse control disorders as 
no scale was available at the time of the study onset. Where there was more than one scale 
representing a non-motor symptom, a mean z-score was calculated from the individual z-
scores (eg, cognition z-score = [ACE z-score + SCOPA-COG z-score + FAB z-score]/3). In 
addition composite z-scores were calculated for non-motor symptoms overall and the two 
non-motor sub-scores (depression/anxiety/apathy and other non-motor symptoms) identified 
in the MDS-UPDRS exploratory factor analysis (Goetz et al., 2008). Internal consistency was 
measured using Cronbach’s alpha, for the MDS-UPDRS part I total score and the two factor 
sub-scores. Internal consistency, homogeneity of items in relation to the construct, was 
expected to be higher than 0.70. Floor and ceiling effects were assessed by calculating 
number of lowest and highest possible responses and acceptable values were expected to be 
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less than 3%. To assess concurrent validity, the MDS-UPDRS Part I was correlated with the 
original UPDRS Part I. Convergent validity was assessed by correlating standardized z-scores 
of MDS-UPDRS Part I, its two sub-scores previously derived from the original factor 
analysis of the MDS-UPDRS, and individual item scores with standardized scores of 
validated scales for each non-motor component. Correlation coefficients were calculated 
using Spearman rank analysis. The magnitude of correlation coefficients for MDS-UPDRS 
total score, factor sub-scores and individual items was expected to be at least moderate (r > 
0.40) in order to demonstrate acceptable convergent validity.   
 
5.3  Results 
5.3.1  Clinimetric properties of MDS-UPDRS 
All Hoehn and Yahr stages were represented with the majority (90%) being stages II and III. 
On cognitive assessment, 5/94 (5%) had evidence of mild dementia on the MMSE (24/30 or 
less) and none had MMSE <20. The internal consistency of MDS-UPDRS Part I total score 
(Cronbach’s alpha) was 0.85, for the depression/anxiety/apathy factor score was 0.69 and 
other non-motor factor score was 0.82. MDS-UPDRS Part I had high concurrent validity with 
the original UPDRS part I (correlation, r = 0.81, p<0.001). Floor and ceiling effects were 
small (2% floor and 0% ceiling effect). In a sub-analysis that examined only the 54 subjects 
not included in the original MDS-UPDRS validation program, the analysis was repeated with 
similar results (correlation with original UPDRS, r=0.84, p<0.001). 
 
  
130 
 
5.3.2 Correlation of MDS-UPDRS items with validated non-motor clinimetric 
scales 
The standardized z-score of MDS-UPDRS Part I had a high correlation with the composite z-
score of non-motor scales (r = 0.89, p < 0.0001, figure 5.1). The two MDS-UPDRS part I 
standardized factor scores had high correlations with composite z-scores of corresponding 
non-motor features (depression, anxiety, apathy factor score, r = 0.72, p < 0.0001 and other 
non-motor features factor score, r = 0.87, p < 0.0001, figure 1). Amongst individual MDS-
UPDRS items, scales for hallucinations and psychosis (PPRS), sleep problems (PSQI, 
SCOPA-sleep night-time and daytime), cardiovascular and gastro-intestinal autonomic 
symptoms (SCOPA-AUT), fatigue (FSS), pain and other sensations (VAS) and apathy 
(LARS) had high and significant correlations (r ≥ 0.60) with the MDS-UPDRS items, and 
scales for depression (HDRS and HADS-D), anxiety (HADS-A), daytime sleepiness (ESS), 
and urinary autonomic symptoms (SCOPA-AUT-urinary) had moderate and significant 
correlations with corresponding scales (r = 0.40 to 0.60), The only MDS-UPDRS item with 
weak correlation with more detailed scales was Cognitive Impairment where r values for all 
three cognitive scales (ACE, SCOPA-COG and FAB) fell below 0.40 (Table 5.1). 
 
 
 
 
  
131 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1 Validation of MDS-UPDRS Part I. Scatterplots and Spearman rank correlation coefficients 
for (a) standardized z-score of total MDS-UPDRS Part I (non-motor experiences of daily living) versus 
composite z-score of non-motor scales, (b) standardized z-score of MDS-UPDRS depression, anxiety 
and apathy factor score versus composite z-score of depression, anxiety and apathy scales and (c) 
standardized z-score of MDS-UPDRS other non-motor functions factor score versus composite z-score 
of other non-motor scales.  
A B 
C 
r = 0.89 
p < 0.0001 
r = 0.72 
p < 0.0001 
r = 0.87 
p < 0.0001 
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Table 5.1 MDS-UPDRS item correlations with individual corresponding clinical scales and 
with composite scores of corresponding scales (z-scores) 
MDS-UPDRS 
item 
Non-motor 
symptoms 
Clinical scale Mean  
(± standard 
deviation) 
Correlation of 
MDS-UPDRS 
items with 
corresponding 
clinical scale 
Correlation of 
MDS-UPDRS 
items with 
composite of 
corresponding 
scales 
1.1 
Cognitive 
impairment 
ACE 89.0 ± 10.3 0.32
B
 
0.29
B
 SCOPA-COG 24.9 ± 7.0 0.26
C
 
FAB 15.1 ± 2.8 0.33
B
 
1.2 
Hallucinations 
and psychosis 
PPRS 7.6 ± 2.3 0.86
A 
0.86
A
 
1.3 
Depressed 
mood 
HDRS 4.1 ± 4.1 0.56
A
 
0.53
A
 
HADS-D 5.8 ± 3.6 0.41
A
 
1.4 Anxious 
mood 
HADS-A 6.0 ± 4.1 0.53
A
 0.53
A
 
1.5 Apathy LARS -23.4 ± 8.4 0.67
A
 0.67
A
 
1.7 
Sleep 
problems 
PSQI 6.9 ± 4.2 0.70
A
 
0.80
A
 
SCOPA-night 5.1 ± 4.1 0.78
A
 
1.8 
Daytime 
sleepiness 
ESS 8.9 ± 5.2 0.56
A
 
0.60
A
 
SCOPA-day 5.4 ± 4.3 0.62
A
 
1.9 Pain and other 
sensations 
VAS 17.4 ± 16.9 0.64
A
 0.64
A
 
1.10 Urinary 
problems 
SCOPA-AUT-
urinary 
5.8 ± 3.7 0.55
A
 0.55
A
 
1.11 Constipation 
problems 
SCOPA-AUT-
gastrointestinal 
3.9 ± 3.0 0.68
A
 0.68
A
 
1.12 Light 
headedness on 
standing  
SCOPA-AUT-
cardiovascular 1.0 ± 1.4 0.84
A
 0.84
A
 
1.13 Fatigue FSS 4.2 ± 1.7 0.61
A
 0.61
A
 
Abbreviations, MDS-UPDRS - Movement Disorder Society sponsored revision of the 
Unified Parkinson’s Disease Rating Scale (UPDRS), ACE – Addenbrooke’s Cognitive 
Examination, SCOPA-COG - Scales for Outcome in Parkinson’s disease (SCOPA), 
cognitive scale, FAB - Frontal Assessment Battery, PPRS – Parkinson Psychosis Rating 
Scale, HDRS – Hamilton Depression Rating Scale, HADS-D – Hospital Anxiety Depression 
Scale (HADS), depression score, HADS-A – HADS anxiety score, LARS – Lille Apathy 
Rating Scale, PSQI – Pittsburgh Sleep Quality Index, ESS – Epworth Sleepiness Scale, VAS 
– Visual Analogue Scale, SCOPA-AUT – SCOPA autonomic scale, FSS – Fatigue Severity 
Scale. Statistical Analysis, Spearman rank correlations with significance levels A, p<0.001, 
B, p<0.01, C, p=0.01. All MDS-UPDRS Part I items represented except dopamine 
dysregulation syndrome (item 1.6) 
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5.4  Discussion 
Our data demonstrate that the MDS-UPDRS Part I total score has a strong and highly 
significant relationship with a composite score of non-motor aspects of PD, based on 
validated scales of individual non-motor symptoms. This observation suggests that the MDS-
UPDRS Part I, with an application time of only 10 minutes, appropriately reflects the burden 
of NMS in PD patients and is indicative of performance on extensive battery of established 
scales with an application time over 2 hours. We have also demonstrated statistically 
significant correlations of individual MDS-UPDRS Part I items with corresponding clinical 
scales with moderate to high correlation for the majority of items despite their brevity. Only 
the MDS-UPDRS cognition item had weak correlation with the three corresponding cognitive 
scales. This problem is likely due to heterogeneity in cognitive profiles in PD including 
dysexecutive but also amnestic, visuoperceptive, visuospatial and global cognitive 
impairment; behaviours difficult to correlate with a single screening question. The MDS-
UPDRS depression item was more highly associated with the HDRS than with the HADS-D. 
This discrepancy may be due to the differing content of these scales with greater in-depth 
assessment of depressive symptoms on the HDRS. Our analysis also confirmed the 
clinimetric properties of the scale in a new patient population. The MDS-UPDRS has 
undergone initial validation (Goetz et al., 2008) and has demonstrated high internal 
consistency, concurrent validity and internal validity. Our analysis of the non-motor part of 
the scale in another population has confirmed this initial validation. The internal consistency 
of the MDS-UPDRS Part I score was high for the total score and the first factor score with 
slightly lower consistency for the second factor measuring mood. This lower internal 
consistency is likely to reflect the low number of items (n=3) in this subscale rather than low 
correlation between items. 
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This study has some methodological considerations: (1) Scales at study onset were chosen to 
reflect the broad spectrum of non-motor features and have been at least partially validated in 
PD but many require further assessment. (2) Composite Z-scores are derived from a battery 
of individual scales and while most of the individual components of the composite may be 
validated measures in PD, the validity of the composite measure has never been established. 
(3) This study does not include an assessment for dopamine dysregulation or impulse control 
disorders as no scale was available at study onset. (4) The majority of patients in this study 
were Hoehn-Yahr stages II and III, with early and advanced stages under-represented. 
However studies suggest that clinic populations regardless of time frame are almost fully 
composed of patients in Hoehn-Yahr stages II and III (Sato et al., 2006). (5) MDS-UPDRS 
item 1.11 (constipation problems) was compared to SCOPA-AUT gastrointestinal score, 
which encompassed other aspects including swallowing, hypersalivation, early satiety and 
faecal incontinence. (6) Given the relatively small sample size and the distribution of patients 
by Hoehn and Yahr stages, these findings will require confirmation by future studies.   
   
Overall our preliminary data demonstrate that the MDS-UPDRS Part I total score has a strong 
convergent validity with a composite score of scales for the non-motor aspects of PD and that 
the majority of MDS-UPDRS Part I items have at least moderate correlation with 
representative non-motor scales. Further studies to confirm the validity of the MDS-UPDRS 
in larger samples, including greater numbers of patients in higher Hoehn and Yahr stages, are 
required.  
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Chapter 6 
Testing an aetiological model of visual hallucinations in Parkinson’s disease 
 
 
6.1  Introduction 
6.1.1  Epidemiology of visual hallucinations in Parkinson’s disease 
Visual hallucinations (VH) are common in Parkinson’s disease (PD) with estimates ranging 
from 16 to 75 percent (Goetz et al., 2009). The occurrence of VH may predict progression to 
more severe forms of psychosis, increased risk of nursing home placement and development 
of dementia (Fenelon and Alves, 2010). Previously reported risk factors include older age, 
longer disease duration, greater disease severity (Papapetropoulos et al., 2005, Fenelon and 
Alves, 2010), cognitive impairment (Papapetropoulos et al., 2005, Merims et al., 2004), 
particularly frontal lobe (Ozer et al., 2007, Grossi et al., 2005) and visuoperceptive function 
(Meppelink et al., 2008, Ramirez-Ruiz et al., 2006, Barnes et al., 2003). The role of 
dopaminergic medication and other PD treatments in the development of VH is unclear 
(Aarsland et al., 1999, Fenelon et al., 2000, Fenelon and Alves, 2010, Merims et al., 2004). 
Some studies have shown an association of VH with co-existing psychiatric disorders, 
including depression (Sanchez-Ramos et al., 1996, Holroyd et al., 2001, Marsh et al., 2004) 
and apathy (Mosimann et al. 2006), but when other factors are considered, co-existing 
psychiatric comorbidity appears less important (Fenelon et al., 2000). Autonomic dysfunction 
such as fall in systolic blood pressure and cardiac sympathetic denervation has also been 
associated with the presence of VH in PD (Kitayama et al., 2008, Oka et al., 2007, Williams 
and Lees, 2005). In addition, excessive daytime somnolence, sudden onset REM periods and 
intrusion of episodes of REM sleep during wakefulness have been shown to be associated 
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with VH in PD (Nomura et al., 2003, Diederich et al., 2005, Whitehead et al., 2008, Goetz et 
al., 2009).  
 
6.1.2  Pathogenesis of visual hallucinations in PD 
LB in PD are found in the substantia nigra in association with nigral cell loss but are also 
found in widespread extra-nigral cortical locations (Braak et al.,2003).  A higher LB burden 
in the temporal lobe and amygdala (Harding et al., 2002a, Harding et al., 2002b, Kalaitzakis 
et al., 2009, Papapetropoulos et al., 2006b), and in the frontal and parietal cortices 
(Papapetropoulos et al., 2006b) has been associated with VH in PD in pathological studies. In 
addition several milestones of advanced disease, including dementia and the development of 
VH, have been associated with higher cortical LB scores (Kempster et al., 2010). Functional 
imaging studies also suggest involvement of these regions in PD patients with VH 
(Meppelink et al., 2009, Boecker et al., 2007, Oishi et al., 2005, Ramirez-Ruiz et al., 2007, 
Nagano-Saito et al, 2004). These areas are also thought to play an important role in 
visuoperception. The dual stream hypothesis of visual processing proposes a dorsal stream 
from the occipital to the parietal lobe specialized for spatial location and a ventral stream 
involving the temporal lobes and limbic structures for object recognition (Mishkin & 
Ungerleider, 1982), with white matter tracts projecting to the medial and lateral temporal 
cortices including the amydgala and parahippocampal gyrus (Catani et al., 2003). As a 
mechanism for the pathophysiology of VH in PD, it has been suggested that impaired object 
identification through pathology in temporal lobe and limbic structures can lead to 
disinhibition of internally generated imagery (Diederich et al., 2005, Goetz et al., 2009). 
Thus, there is evidence to suggest that hallucinations in other conditions as well as in PD are 
associated with impaired discrimination of external perceptions from internally generated 
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information, referred to as Reality Monitoring, and the medial temporal and frontal lobes 
have been implicated in this process (Henkel et al., 1998, Barnes et al., 2003).  
 
6.1.3  Integrated hypothesis for VH in PD 
Taking together the results from clinical, neuropsychological, imaging and pathological 
studies, a model of imbalance of external and internal inputs and impaired Reality Monitoring 
(Diederich et al., 2005, Diederich et al., 2009, Goetz et al., 2009) leading to the development 
of VH has therefore been suggested, including (a) impaired visual input and central visual 
processing, (b) impaired brainstem regulation of the sleep-wake cycle with fluctuating 
vigilance, intrusion of REM dream imagery into wakefulness and emergence of internally 
generated imagery, (c) cognitive dysfunction including areas implicated in discriminating 
internal and external generated information (reality monitoring), and (d) influence of 
dopaminergic drugs on mesolimbic and visual processing pathways (Goetz et al., 2009).  
 
This study was undertaken to examine the in vivo and pathological validity of this proposed 
hypothesis, taking into account all clinical and pathological features that have been proposed 
to contribute to VH in PD. The aim was therefore (a) to determine the demographic and 
clinical variables associated with VH in PD including age, disease duration, dopaminergic 
medication, sleep disorders (daytime somnolence, nocturnal insomnia and RBD), current 
psychopathology (depression, anxiety and apathy), and presence of executive and global 
cognitive dysfunction, (b) to determine the relative importance of cortical visual processing 
and presence of ophthalmic pathology in the aetiology of VH in PD, (c) to validate an 
integrated model of VH in PD including abnormal visual processing, RBD and brainstem 
dysfunction, dysexecutive cognitive impairment and dopaminergic medication, (d) to 
determine the distribution of LB and Lewy neurite (LN) load as a marker of disease 
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involvement at different cortical regions involved in visual processing (temporal lobes and 
limbic structures including the amygdalae) and regions implicated in reality discrimination 
(medial temporal and frontal lobes). 
 
6.2  Methods 
6.2.1  Clinical study participants 
Consecutive patients who fulfilled UK Brain Bank criteria for PD (Gibb and Lees, 1989) 
were recruited from PD outpatient clinics. Subjects underwent a face-to-face interview, 
comprising clinical examination and physician-administered questionnaires in clinic, and 
were given further questionnaires to complete at home. A subgroup of patients, who 
consented to an additional appointment, also had a full ophthalmological assessment. VH 
were defined as persistent formed visual hallucinations and illusions. Patients with brief 
episodes of hallucinations related to sepsis or alteration of medication were excluded. 
 
6.2.2  Measures 
(a) Unified Parkinson’s Disease Rating Scale (UPDRS) (Fahn et al., 1987), (b) non-motor 
scales and assessments including SCOPA-Sleep scale (Marinus et al., 2003a), ICSD-R 
minimal diagnostic criteria for RBD (American Academy of Sleep Medicine, 2001), LARS 
(Sockeel et al., 2006), HDRS (Schwab et al., 1967), FAB (Dubois et al., 2000), SCOPA-
COG) (Marinus et al., 2003b), SCOPA-AUT (Visser et al., 2004), UM-PDHQ 
(Papapetropoulos 2008), (c) (in a subgroup) ophthalmological measures including LogMAR 
visual acuity testing (Sprague et al., 1989) (LogMAR of zero is equivalent to normal visual 
acuity [6/6] on Snellen chart, with negative scores representing better than normal acuity and 
positive scores poorer acuity), Goldmann kinetic perimetry (Niederhauser and Mojon, 2002), 
mean peripheral field diameter expressed as mean radial degrees (MRD), retinal 
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photography, descriptive assessment of cataract presence, location (nuclear, cortical, 
subcapsular) and degree of opacity, (d) (in a subgroup) tests for visual agnosia, the BORB 
(Riddoch and Humphreys, 1993) including low level aspects of visual perception (same-
different matching of elemental features such as orientation, length, and object size), higher 
visual perception (identification of overlapping images, matching objects from usual and 
unusual viewpoints and identification of objects from minimal features) and stored perceptual 
knowledge (object decision tasks; discrimination between pictures of real objects and non-
objects made by combining parts of different real objects, Humphreys et al., 1997) and 
semantic knowledge testing (associative matching; deciding which of two reference pictures 
[e.g. a screw and a nail] is most associated with a target picture [a screwdriver], Humphreys 
et al., 1997). Ethical approval for the clinical studies was obtained from the local research 
ethics committees.  
 
6.2.3  Pathological Study 
In a separate study, histological specimens were obtained from cases of pathologically-
proven PD archived at the Queen Square Brain Bank for Neurological Diseases. A 
retrospective case notes review was made for reporting of persistent formed visual 
hallucinations. Demographic and disease characteristics including age, sex, disease duration, 
dopaminergic medication and documented presence of cognitive impairment were recorded. 
An approximation of the cumulative life-time L-dopa amount was made based on the 
information available in the patient records. 
 
6.2.4  Neuropathological assessment  
After fixation in 10% buffered formalin, the brains were examined by a neuropathologist and 
sampled in accordance with the standardised protocols of the Queen Square Brain Bank. In 
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compliance with established criteria for the neuropathological diagnosis of PD (Ince et al., 
2008), brain samples from selected regions were embedded in paraffin. Eight µm-thick tissue 
sections were cut, deparaffinised and rehydrated, followed by pre-treatment with formic acid 
and pressure-cooking in citrate buffer at pH 6.0. Following epitope unmasking, monoclonal 
antibody to alpha-synuclein (αS) (clone KM51, dilution 1:1000; Novocastra; Newcastle upon 
Tyne, UK) was applied and incubated overnight at +4
o
C. For detection, Histostain SP kit 
(Zymed, San Francisco, CA) was used with Romulin AEC chromogen (Biocare Medical, 
Walnut Creek, CA). Semiquantitative assessment of αS-immunoreactive (IR) LB-type 
pathology was carried out in five cortical regions, frontal (middle frontal gyrus, Brodmann’s 
area [BA] 8/9), temporal (middle temporal gyrus, BA 21), parietal (inferior parietal lobule 
BA 40), entorhinal (parahippocampal gyrus, BA 28) and cingulate (anterior cingulate, BA 
24) cortices as recommended by the consensus diagnostic criteria for DLB, (McKeith et al., 
2005) and rated as follows: 1 = mild (sparse LBs at x100 magnification); 2 = moderate (1 to 3 
LBs at x100 magnification); 3 = severe (≥ 4 LBs at x200 magnification); 4 = very severe 
(numerous LBs and LNs at x200 magnification). In addition, all LBs were systematically 
counted within the same five cortical areas of interest and these counts were adjusted to the 
surface area (LB/mm
2
) using Image-Pro Plus software package (MediaCybernetics, UK). The 
“total cortical LB density” was determined as the sum of counts in the five cortical areas 
divided by a sum of respective surface areas. In addition, in the amygdala, the number of αS-
IR LBs per x200 microscopic field (field diameter 1mm) was determined in the region with 
the greatest LB density. In the brainstem, αS-immunopositive LBs were counted unilaterally 
within entire nuclei and assessed following an arbitrary grading system: in SN, + ≤ 25 LBs; 
++ 25-50 LBs; +++ ≥ 50 LBs, in LC and DMV, + = 1-9 LBs; ++ = 10-19 LBs, +++ = >20 
LBs. The αS-IR LNs in each region were rated semi-quantitatively as: 0=absent, 1= sparse; 
2= moderate; and 3= frequent. Finally, each case was also classified according to Braak PD 
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stage (ranging from 0 to 6) depending on the topographic distribution of αS-IR inclusions 
(Braak et al., 2002).  All pathological analyses were done blinded to the clinical data.  
 
6.2.5  Statistical Analysis 
Data were entered into the statistical programme SPSS version 17.0 (SPSS, Inc., Chicago, IL) 
and inspected for normality of distribution. As the data were mostly not normally distributed, 
we used non-parametric tests for analysis. For comparison of VH and non-VH groups, data 
was expressed as median and inter-quartile range and non-parametric (Mann-Whitney U) 
analysis was performed. Categorical data was analysed using Chi-Square or Fisher exact test. 
The univariate analysis was used to select variables for inclusion in the multivariate 
regression analysis. A binary logistic regression analysis was performed to assess the effect 
of different clinimetric variables (treatment duration, UPDRS part III, UPDRS part IV, RBD, 
SCOPA-sleep daytime, HDRS, SCOPA-AUT, FAB, SCOPA-COG-executive score, BORB 
object decision, minimal feature match, association match and overlapping images) on the 
main dichotomous outcome measure (presence or absence of visual hallucinations).  
 
6.3  Results 
6.3.1  Clinical study 
94 patients participated in the study, of whom five (5%) had evidence of global dementia 
(Mini-mental State Examination, MMSE≤24). No patient fulfilled clinical criteria for DLB 
(McKeith et al., 2005), with onset of dementia before or within one year of onset of 
parkinsonism. Thirty patients had experienced visual hallucinations and/or illusions (referred 
to as VH henceforth). Three of five patients with dementia had VH whereas the remainder 
with VH were non-demented (MMSE>24). The type of visual experiences reported by 
patients were (a) illusions of presence (N=18), (b) illusions of passage (N=26), (c) visual 
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illusions (N=27) and (d) formed visual hallucinations (N=22). 6 patients also reported 
acoustic, 5 tactile and 3 olfactory hallucinations. 27 of 30 patients with VH completed the 
UM-PDHQ hallucinations questionnaire. 14/27 (52%) had very frequent hallucinations (≥ 
once per day). In terms of VH content, 19/27 (70%) reported seeing animals, 18/27 (67%) 
saw people, 15/27 (56%) whole faces, 13/27 (48%) insects or reptiles, 13/27 (48%) objects 
and 6/27 (22%) fragmented faces. In only one patient were VH not formed or difficult to 
describe. In 23/27 (85%) the visual experience was familiar. Images were solid (rather than 
transparent) in 24/27 (89%), moving in 15/27 (56%), coloured in 15/27 (56%) and made a 
sound in 3/27 (11%). 
 
After adjustment for multiple comparisons (N=29 comparisons, Bonferroni correction, 
significance p<0.0017) disease duration, treatment duration, dopaminergic medication dose 
(Levodopa Equivalent Units, LEU), motor function (UPDRS) and motor complications 
(UPDRS total part IV and percentage daily “off” time) were significantly associated with VH 
in PD (table 6.1). A higher proportion of patients with VH were taking levodopa (87% versus 
58%, p<0.009) but this was not significant for multiple corrections and there was no 
association with other medication (ergot or non-ergot dopamine agonists, amantadine, 
catechol-O-methyl transferase inhibitors, monoamine oxidase-B inhibitors, anticholinergics, 
cholinesterase inhibitors or atypical antipsychotics). Significant associations with non-motor 
aspects of PD, after correction for multiple comparisons, included excessive daytime 
somnolence (SCOPA-sleep-daytime) and RBD, depression (HDRS) and overall autonomic 
dysfunction (SCOPA-AUT) (table 6.1) and gastro-intestinal, urinary and cardiovascular 
subscales (all p≤0.0001). In addition, VH were associated with global cognitive impairment 
scores (SCOPA-COG total) but in particular frontal cortical dysfunction (FAB total score, 
FAB motor series and inhibitory control subscores, and SCOPA-COG executive subscore, 
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table 6.1). 81 of 94 (86%) patients were assessed using the BORB. Several tests of 
visuoperceptive cortical function including BORB object decision, overlapping images, 
minimal feature match and association match were associated with VH. In contrast, there was 
no clear association of VH with lower-level visuoperceptual tasks on the BORB and 
visuospatial tasks on the SCOPA-COG. 
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Table 6.1 Clinical findings of PD patients with and without visual hallucinations.  
 VH (n=30) Non-VH (n=64) p-value 
(Mann-
Whitney U 
or chi 
square test) 
Median (interquartile 
range) or n (%) 
Median 
(interquartile range) 
or n (%) 
Demographics 
Age (years) 71.0 (65.5, 74.3) 66.5 (59.0, 74.0) 0.018 
Sex (male) 24/30 (80%) 41/64 (64%) 0.15 
Disease duration (years) 11.2 (5.3, 15.8) 3.4 (1.8, 7.7) 0.0001 
Treatment duration (years) 10.5 (4.8, 15.4) 2.8 (0.2, 7.0) <0.0001 
LEU (mg) 750 (400, 1026) 300 (100, 739) 0.0012 
UPDRS part III 38.0 (28.5, 48.0) 26.0 (17, 33.8) <0.0001 
UPDRS part IV 6.0 (3.0, 8.0) 1.0 (0.0, 4.0) <0.0001 
“off” (% of waking day)  18.0 (6.8, 31.3) 0.0 (0.0, 6.8) <0.0001 
Dyskinesia (%) 0.0 (0.0, 31.8) 0.0 (0.0, 3.0) 0.045 
Non-motor Scales 
REM sleep disorder 16/30 (53%) 11/64 (17%) 0.0005 
SCOPA-sleep-night 6.0 (3.0, 11.0) 3.0 (1.0, 7.0) 0.012 
SCOPA-sleep-day 7.5 (4.0, 12.3) 3.0 (2.0, 6.0) <0.0001 
LARS-total -21 (-27, -16.5) -26.5 (-31.0, -22.0) 0.0096 
HDRS 5.0 (2.0, 8.0) 2.0 (0, 5.0) 0.0002 
SCOPA-AUT total 21.5 (16.8, 26.3) 11.0 (8.0, 17.0) <0.0001 
Cognition 
FAB total 14.0 (12.0, 16.0) 17.0 (15.0, 17.0) <0.0001 
SCOPA-COG total 22.0 (17.8, 25.5) 26.0 (23.0, 31.8) 0.0004 
SCOPA-COG memory 7.5 (5.0, 9.3) 9.0 (7.0, 12.8) 0.017 
SCOPA-COG attention 4.0 (3.0, 4.0) 4.0 (4.0, 4.0) 0.026 
SCOPA-COG executive 7.0 (5.5, 9.0) 9.5 (8.3, 11.0) <0.0001 
SCOPA-COG visuospatial 3.0 (2.0, 5.0) 4.0 (3.0, 5.0) 0.13 
Visuoperceptive function 
BORB size match 26.0 (23.5, 27.0) 27.0 (26.0, 28.0) 0.048 
BORB length match 25.0 (23.0, 27.0) 26.0 (25.0, 27.0) 0.12 
BORB orientation match 25.0 (23.0, 25.5) 26.0 (25.0, 27.0) 0.0064 
BORB foreshortened 24.0 (22.0, 25.0) 24.0 (24.0, 25.0) 0.045 
BORB minimal feature 24.0 (23.0, 25.0) 25.0 (25.0, 25.0) 0.0006 
BORB overlapping 36.0 (32.0, 39.0) 40.0 (38.3, 40.0) <0.0001 
BORB association match 28.0 (26.0, 30.0) 30.0 (29.0, 30.0) 0.0002 
BORB object decision 23.0 (21.5, 24.5) 26.0 (25.0, 28.0) <0.0001 
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Abbreviations: VH – Visual Hallucinations, LEU – Levodopa Equivalent Units, UPDRS – 
Unified Parkinson’s Disease Rating Scale, SCOPA – Scales for Outcome in Parkinson 
Disease, LARS – Lille Apathy Rating Scale, HDRS – Hamilton Depression Rating Scale, 
FAB – Frontal Assessment Battery, SCOPA-COG – SCOPA cognitive scale, BORB – 
Birmingham Object Recognition Battery. Variables that reach statistical significance when 
corrected for multiple comparisons (Bonferroni correction, n=29, p<0.0017) are given in 
bold. BORB scores based on subgroup, 81 of 94 (86%) patients. 
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6.3.2  Ophthalmological Assessments 
Fifty out of 94 (53%) of participants underwent full ophthalmological assessment including 
23 of the 30 (77%) of participants with visual hallucinations. There were no differences in 
disease duration, LEU, MMSE and UPDRS between participants and non-participants in 
ophthalmological substudy; however patients undergoing ophthalmological assessments were 
older (p=0.01). The ophthalmological and visuoperceptive variables were compared between 
patients with VH and those without. There were no differences in the ophthalmological 
parameters tested between the VH and non-VH group (table 2). However, in this smaller 
subgroup several of the visuoperceptive variables (minimal feature match, overlapping 
images, object decision, association match, size match and orientation match) were still more 
impaired (p<0.05) in the group of patients with hallucinations, with minimal feature match 
and overlapping images scales meeting significance for multiple comparisons (Bonferroni 
correction, 21 comparisons, p<0.0024, table 6.2). 
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Table 6.2 Ophthalmological findings and visuoperceptive measures in Parkinson’s disease 
patients with or without visual hallucinations. 
 VH (n=23) Non-VH (n=27) 
p value (Mann-
Whitney U or 
chi square) 
Median 
(interquartile range) 
or n (%) 
Median (interquartile 
range) or n (%) 
Ophthalmology findings 
VA right uncorrected 0.27 (0.14, 0.55) 0.28 (0.10, 0.46) 0.69 
VA left uncorrected 0.25 (0.12, 0.48) 0.20 (0.10, 0.40) 0.61 
VA right corrected 0.16 (0.04, 0.30) 0.14 (0.02, 0.22) 0.46 
VA left corrected 0.20 (0.06, 0.30) 0.08 (0.0, 0.20) 0.076 
Fields right (MRD) 46.8 (41.7, 48.9) 46.3 (37.9, 49.7) 0.80 
Fields left (MRD) 45.5 (39.5, 49.3) 46.9 (40.5, 50.5) 0.44 
Cataract right 14/23 (61%) 14/27 (52%) 0.58 
Cataract left 14/23 (61%) 14/27 (52%) 0.58 
Macular degeneration R 1/22 (5%) 5/27 (19%) 0.20 
Macular degeneration L 1/22 (5%) 5/27 (19%) 0.20 
Corneal pathology R 1/23 (4%) 1/27 (4%) 1.00 
Corneal pathology L 1/23 (4%) 0/27 (0%) 0.46 
Optic pathology (any) 17/23 (74%) 17/27 (63%) 0.55 
Visuoperceptual function* 
BORB object decision 23.0 (21.0, 25.0) 26.0 (23.0, 27.0) 0.0026 
BORB length match 25.0 (23.0, 27.0) 26.0 (25.0, 27.0) 0.072 
BORB foreshortened 24.0 (22.0, 25.0) 24.0 (24.0, 25.0) 0.23 
BORB minimal feature 24.0 (23.0, 25.0) 25.0 (25.0, 25.0) 0.0011 
BORB association 28.0 (26.0, 30.0) 30.0 (28.0, 30.0) 0.008 
BORB size match 26.0 (23.0, 27.0) 27.0 (26.0, 28.0) 0.026 
BORB orientation 25.0 (23.0, 25.0) 26.0 (25.0, 27.0) 0.022 
BORB overlapping 36.0 (33.0, 39.0) 40.0 (38.0, 40.0) 0.0014 
Abbreviations, VA = Visual Acuity (Logarithm of Mean Angular of Resolution [logMAR]), 
MRD = Mean Radial Degrees, BORB = Birmingham Object Recognition Battery. Bonferroni 
correction for multiple comparisons, significance set at p< 0.0024  
*only includes those patients who had ophthalmological assessments 
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6.3.3 Multivariate Analysis of clinical, cognitive and ophthalmological variables 
and visual hallucinations 
All variables that were associated with VH in the univariate analyses (excluding collinear 
variables where scale with highest statistical significance was chosen) were added to the 
regression analysis (treatment duration, UPDRS part III, UPDRS part IV, RBD, SCOPA-
sleep daytime, HDRS, SCOPA-AUT, FAB, SCOPA-COG-executive score, BORB object 
decision, minimal feature match, association match and overlapping images). The four 
independent determinants of VH in PD were RBD (p=0.026), SCOPA-AUT (p=0.004), 
SCOPA-COG executive (p=0.020) and BORB object decision (p=0.031) (table 6.3), and 
overall predicted 67% of the variability in the regression model.  
 
 
Table 6.3 Factors associated with visual hallucinations in a multiple regression analysis 
 Odds ratio 95% CI P value 
RBD 6.18 1.24-30.78 0.026 
SCOPA-AUT 1.16 1.05-1.28 0.004 
SCOPA-COG-
Executive 
0.63 0.43-0.93 0.020 
BORB-object 
decision 
0.66 0.46-0.96 0.031 
Abbreviations CI – Confidence Interval, RBD - REM sleep behavioural disorder, SCOPA - 
Scales for Outcome in Parkinson Disease, SCOPA-AUT - autonomic scale, SCOPA-COG – 
cognitive scale, BORB – Birmingham Object Recognition Battery. 
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6.3.4  Clinico-pathological analysis of visual hallucinations 
Post-mortem analysis was performed in 91 subjects. Amygdala analysis was performed in a 
subset of 68 patients (43 with and 25 without hallucinations) where pathological samples 
were adequate. On retrospective case notes examination, persistent formed VH were found in 
57/91 (63%). The VH and non-VH did not differ in terms of demographic characteristics, 
including age and disease duration (table 4) however VH patients were significantly more 
likely to be cognitively impaired (p=0.004).  Patients with VH had significantly higher LB 
densities particularly in the middle frontal gyrus and transentorhinal cortices with higher 
counts also in the total, middle temporal gyrus and anterior cingulate cortices but not inferior 
parietal cortex (table 4). Semi-quantitative LN density scores did not differ in any of the 
cortical locations sampled, although there was a trend for higher LN density in the temporal 
cortex (p=0.056). There was no significant difference in semi-quantitative LN or LB scores in 
the brainstem nuclei assessed (substantia nigra, locus coeruleus and dorsal motor nucleus of 
vagus).  In the VH group, the majority were Braak stage 6 (72%) whereas in non-VH group 
the majority were Braak stage ≤5 (65%), p=0.002. In the subgroup with amygdala analysis, 
there was no difference in amygdala LB density between the VH (N=43) and non-VH (N=25) 
groups (p=0.69); however there was significantly higher total cortical (p=0.027) and 
particularly middle frontal gyrus LB density (p=0.006) in association with VH in this 
subgroup. 
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Table 6.4 Difference in clinical and pathological features of patients with and without visual 
hallucinations in the pathological study  
 VH (N=57) Non-VH (N=34) 
P value 
(Mann-
Whitney U or 
Chi square) 
Median 
(interquartile 
range) or number 
(%) 
Median 
(interquartile 
range) or number 
(%) 
Medication use and cognitive impairment 
Cumulative levodopa dose 
(x10
6
 mg) 
2.5 (1.1-5.3) 2.5 (0.8-5.3) 0.71 
Maximum levodopa dose 
(mg) 
700 (500-1050) 750 (500-1000) 0.95 
Ergot agonist use  18/57 (32%) 13/34 (38%) 0.52 
Non-ergot agonist use 32/57 (56%) 18/34 (53%) 0.77 
Apomorphine use 16/57 (28%) 6/34 (18%) 0.26 
COMT inhibitor use 9/57 (16%) 6/34 (18%) 0.82 
Selegiline use 31/57 (54%) 21/34 (62%) 0.49 
Amantadine use 12/57 (21%) 7/34 (21%) 0.96 
Anti-cholinergic use 29/57 (51%) 16/34 (47%) 0.73 
†Cognitive impairment 45/52 (87%) 16/32 (50%) 0.0004 
Pathological data – Lewy body density 
Parietal cortex (LB/mm
2
) 0.00 (0.00-0.06) 0.00 (0.00-0.00) 0.22 
Frontal cortex (LB/mm
2
) 0.08 (0.00-0.43) 0.00 (0.00-0.07) 0.002 
Temporal cortex (LB/mm
2
) 0.15 (0.04-0.43) 0.06 (0.00-0.22) 0.033 
Cingulate cortex (LB/mm
2
) 0.82 (0.23-2.02) 0.38 (0.07-0.98) 0.020 
Entorhinal cortex (LB/mm
2
) 0.85 (0.28-2.74) 0.27 (0.06-1.00) 0.005 
Total cortex (LB/mm
2
) 0.40 (0.16-0.86) 0.17 (0.03-0.43) 0.004 
Abbreviations VH = visual hallucinations, LB = Lewy body, COMT = catechol-O-methyl 
transferase. †Smaller sample (N=84, 92%) in whom reliable impression of cognitive status 
could be made on retrospective case notes review. 
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6.4  Discussion 
This study supports an integrative model of pathogenesis of VH in PD, examining the diverse 
abnormalities reported in clinical, neurophysiological and imaging studies of VH in PD. In 
keeping with previous work, we found that VH in our PD population were associated with 
older age and longer disease duration (Fenelon and Alves, 2010, Papapetropoulos et al., 2005, 
Sanchez-Ramos et al., 1996) and greater disease severity (Holroyd et al., 2001, 
Papapetropoulos et al., 2005). Using a comprehensive assessment of the clinical, 
demographic, ophthalmological and pathological correlates of VH in PD, the combined data 
support a model of impaired visual processing, sleep-wake dysregulation and brainstem 
dysfunction and cognitive impairment. 
 
6.4.1  Visual pathways 
Examining different aspects of the visual pathways, we did not find evidence to support 
ophthalmic factors such as impaired visual acuity, reduced visual fields, cataracts, macular 
degeneration, and corneal or other optic pathology contributing to VH in PD overall. This is 
in contrast to previous studies of VH associated with poor visual acuity (Matsui et al., 2006, 
Holroyd et al., 2001) and ocular pathology (Fenelon et al., 2003). We did not examine subtle 
retinal abnormalities using contrast sensitivity or colour discrimination, which has been 
shown in previous studies to be more prevalent in patients with VH than without (Diederich 
et al., 1998), but visual acuity, visual fields and standard optic examinations did not show any 
differences in this study. Visuospatial tasks which are processed through the parietal lobes 
(Parks et al., 2010) and lower level visuoperceptive tasks related to posterior temporal lobe 
areas (Bright et al., 2005) did also not differ between patients with and without VH in PD. 
However, several higher level visuoperceptive tasks, which implicate the anteromedial 
temporal cortex, including the entorhinal cortex (Bright et al., 2005), were significantly 
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different even when corrected for multiple comparisons. This is consistent with 
neuropsychological studies demonstrating impaired visuoperceptive function in PD patients 
with VH (Meppelink et al., 2008, Ramirez-Ruiz et al., 2006, Barnes et al., 2003) and 
functional imaging studies demonstrating involvement of extrastriate visual processing 
pathways (Meppelink et al., 2009, Boecker et al., 2007, Oishi et al., 2005, Ramirez-Ruiz et 
al., 2007). These data suggest that impairment of cortical visuoperceptive function is more 
likely to be involved in the pathogenesis of VH in the majority of patients with PD than optic 
pathology, although this may be relevant in individual patients where this has been reported 
(Matsui et al., 2006, Holroyd et al., 2001, Fenelon et al., 2003). Our logistic regression results 
also support the importance of associative visuoperceptive dysfunction, rather than 
constructional visuospatial dysfunction or lower level apperceptive visual agnosia in the 
development of VH. 
 
The findings of impairment of higher cortical function in visual pathways in 
neuropsychological testing were also supported by results of the pathological study. VH 
patients demonstrated higher overall cortical LB density with significantly increased LB 
density in the middle temporal gyrus, anterior cingulate gyrus and particularly the middle 
frontal gyrus and transentorhinal cortices consistent with previous pathological studies 
showing higher LB counts in temporal lobe structures in VH (Harding et al., 2002a, 
Papapetropoulos et al., 2006a). Additionally there was a trend to higher LN density in the 
temporal cortex. On the other hand, in contrast to previous studies, no increased LB density 
was found in patients with VH in the amygdala (Harding et al., 2002a, Harding et al., 2002b, 
Kalaitzakis et al., 2009, Papapetropoulos et al., 2006b) or parietal cortex (Papapetropoulos et 
al., 2006b). Kalaitzakis and colleagues found αS burden in the amygdala to be strongly 
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related to VH but only in those PD cases with concomitant dementia, implicating that αS 
pathology in this region is not related to the presence of VH per se but moreover to dementia.    
 
6.4.2  Sleep-wake regulation and brainstem function 
This study also demonstrated significant impairment of the brainstem-regulated sleep-wake 
cycle with excessive daytime somnolence and increased prevalence of RBD in PD patients 
with VH. This is consistent with previous studies showing higher prevalence of 
polysomnographic abnormalities and RBD in VH (Comella et al., 1993, Manni et al., 2002, 
Nomura et al., 2003). Brainstem locations implicated in REM sleep include the dorsolateral 
tegmental and pedunculopontine nuclei (Kalia, 2006). We have also shown that VH are 
associated with autonomic dysfunction including gastro-intestinal, urinary and cardiovascular 
function. This is consistent with previous studies, where autonomic function has been 
associated with VH (Kitayama et al., 2008, Oka et al., 2007, Williams and Lees, 2005). 
Autonomic impairment in PD can be mediated by central brainstem (LB deposition in and 
degeneration of brainstem nuclei, such as the dorsal vagal nucleus) and peripheral (i.e., 
cardiac sympathetic denervation) mechanisms. Autonomic dysfunction is associated with 
RBD, for example abnormal cardiac scintigraphy has been demonstrated in idiopathic RBD 
(Mitra & Chaudhuri, 2009) and these functions co-localise to similar brainstem locations. In 
our clinical study, presence of RBD and autonomic impairment were significant independent 
predictors in a regression model and this is supportive of greater involvement of brainstem 
function in PD patients with VH. Furthermore, VH in PD resemble the complex peduncular 
(Lhermitte’s) hallucinations (colourful images of people or animals with clear sensorium), 
which have been described secondary to lesions of the rostral brainstem, the thalamus and 
striatocapsular regions (Benke, 2006), particularly cerebrovascular events, and are associated 
with disrupted sleep architecture. Peduncular hallucinations are thought to result from 
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disruption of ascending reticular systems and thalamocortical circuits involved in sleep-
wakes cycle and alertness (Benke, 2006). In our pathological study higher LB or LN densities 
were not demonstrated in the brainstem nuclei sampled (substantia nigra, locus coeruleus and 
dorsal nucleus of the vagus). However, other brainstem nuclei which may be relevant to 
sleep-wake cycle pathology such as lateral tegmental and pedunculopontine tegmental nuclei 
were not examined in this study and further pathological studies in these areas will be 
required to clarify to the role of brainstem LB in the pathogenesis of VH in PD. 
 
6.4.3  Cognitive impairment 
Global cognitive impairment, in the clinical study and retrospective record analysis in the 
pathological study, was associated with VH, consistent with previous literature 
(Papapetropoulos et al., 2005, Merims et al., 2004). In addition, frontal lobe function was 
significantly worse in the group with VH, and was an important contributory factor in a 
regression model to predict presence of VH. This is in keeping with previous 
neuropsychological (Ozer et al., 2007, Grossi et al., 2005), functional imaging (Nagano-Saito 
et al., 2004, Ramirez-Ruiz et al., 2008) and pathological (Papapetropoulos et al., 2006b) 
studies which showed impairment in frontal lobe function in hallucinating patients compared 
to those without VH. Furthermore, the pathological data in this study confirmed higher LB 
density in the frontal cortex in patients with VH than without, as well as higher total cortical 
LB density. 
 
6.4.4  Integrated hypothesis 
In an integrated analysis of all factors studied in the clinical sample, VH in PD were 
associated with, and independently predicted by, impaired higher visuoperceptive function, 
particularly implicating the ventral visual pathway, sleep-wake cycle disruption and 
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autonomic dysfunction implicating brainstem dysfunction, and dysexecutive cognitive 
dysfunction.  Similar to previous cross-sectional studies, medication did not contribute 
further to prediction of occurrence of VH (Aarsland et al., 1999, Fenelon et al., 2000, 
Holroyd et al., 2001, Merins et al., 2004, Fenelon and Alves, 2010), suggesting that other 
factors modify the impact of dopaminergic medication on VH or that this effect is small 
compared to other factors. The pathological study also supported the important role of frontal 
and temporal cortical dysfunction, and particularly the involvement of the areas in the ventral 
visual pathways and areas implicated in reality discrimination.  
 
There are some methodological limitations to this study. The pathological study is limited by 
the retrospective nature the clinical data, and a selection bias is expected in a brain-bank post-
mortem series. However, cases were chosen based on the availability of adequate clinical 
data regarding the presence or absence of VH. Pathological data were not available for all 
areas implicated in visual processing; in particular there was no assessment of retinal 
pathology or regions such as the primary visual cortex.  The role of LB deposition in the 
pathogenesis of PD remains unclear. The proposed sequential staging of topographical 
involvement of LB pathology in PD (Braak et al., 2003) has not been uniformly confirmed in 
pathological series and widespread cortical LB pathology has been demonstrated in elderly 
individuals without neuropsychiatric correlates (Jellinger, 2009, Parkkinen et al., 2008). 
Attributing non-motor symptoms such as VH in PD to regional cortical LB distribution and 
density, in the absence of clearly demonstrated cell death, should be interpreted cautiously 
and requires further clarification (Jellinger, 2009, Parkkinen et al., 2008). VH are associated 
with advanced disease and therefore in the clinical study participants could not be matched 
for disease duration or severity. In order to reduce possibility of alpha errors, strict 
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Bonferroni correction was made in making statistical comparisons. This correction may 
however discount valid weaker associations.  
 
In conclusion, the results support the proposed integrated model of pathogenesis of VH 
through dysregulation in gating of external perception and internal image production, 
aberrant activation of associative visual and frontal cortex, lack of suppression or 
spontaneous emergence of internally generated imagery, intrusion of rapid eye movement 
dreaming imagery into wakefulness and dysfunction of the brainstem filtering capacities 
(Diederich et al, 2005, Goetz et al., 2009). Whilst in individual patients ophthalmic 
abnormalities and medication-related factors may play a role, these were not found to make a 
major contribution to this overall model of VH in PD.   
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Chapter 7 
Pathological Gambling and Impulse Control Disorders in Parkinson’s Disease.  
 
 
7.1  Introduction  
PG is defined by DSM IV criteria (American Psychiatric Association, 2004) as a persistent 
and recurrent maladaptive behaviour. It is classified as an ICD and often leads to severe 
financial embarrassment and breakdown of interpersonal relationships. It occasionally occurs 
in PD and has been associated with its treatment with dopaminergic drugs. PG together with 
hypersexuality, and other impulse control behaviour and stereotyped repetitive activities 
known as punding (Evans et al., 2004) are recognised components of DDS. DDS is 
characterised by the overuse of additional non-prescribed dopaminergic medication despite 
an adequate motor response (“on” state) and is frequently complicated by marked dyskinesia 
and “off” state dysphoria (Giovannoni et al., 2000). The central role of dopaminergic drug 
therapy in these disorders suggests that they share a common neurobiology and that these 
may be different manifestations of an underlying vulnerability to developing an ICD. Specific 
differences in relation to use of dopamine agonists (DA) and demographic characteristics of 
patients with PG compared to those with DDS may provide important insights. The first part 
of this study examined the published literature to determine the demographic characteristics 
and medication profiles of PD patients who pathologically gamble and examined the 
prevalence of other DDS behaviours in this group. In addition, we assessed how the overall 
frequency of each DA used in the PG group related to the prescription of each drug overall 
and specifically whether any particular DA is more implicated in this maladaptive behaviour. 
In the second part of the study, the detailed demographic data, dopaminergic medication 
profile and clinimetric measures available from our cohort of PD patients were used. For each 
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patient the presence or absence of impulse control behaviour or DDS had been recorded on 
the MDS-UPDRS (Part 1.6). Predictive variables for ICD/DDS identified in the initial meta-
analysis (age, sex, dopaminergic medication, and co-morbid psychopathology) and other 
associated features predicted from the literature (for example cognitive impairment and sleep 
disorders) were examined.  
 
7.2  Methods 
7.2.1  Literature review and meta-analysis 
PubMed literature search using term “gambling” and “Parkinson’s disease” or “dopamine 
agonist” or any of individually named DAs was carried out for the period up to March 2007. 
Additional relevant case series referenced by these publications were included (Tyne et al., 
2004, Serrano-Duenas, 2002, Antonini et al., 2006). Sex, age at presentation of PG, age at 
onset of PD, disease duration, type of DA used, total daily levodopa equivalent units (LEU), 
and presence of co-morbid psychopathology, including DDS behaviour, was recorded for 
each. LEU was calculated based on theoretical equivalence used in previous reports (Evans et 
al., 2004). Categorical data were compared using the Chi-squared test and continuous 
numerical data using the unpaired t-test. Odds ratio (OR) and confidence intervals (CI) were 
calculated from available data in retrospective database reviews (Driver-Dunckley et al., 
2003) and prospective screening studies (Antonini et al., 2006, Weintraub et al., 2006, Voon 
et al., 2006, Grosset et al., 2006, Pontone et al., 2006), where overall prescription rates of 
individual DA in the screened population were known (Bland & Altman, 2000), using 
STATA® software (StataCorp LP, USA). 
 
7.2.2  Clinical study on dopamine dysregulation 
Each patient was assessed on the MDS-UPDRS. The MDS-UPDRS Part 1.6 encompasses 
159 
 
DDS and gives instructions to the examiner to consider “involvement in a variety of activities 
including atypical or excessive gambling (e.g. casinos or lottery tickets), atypical or excessive 
sexual drive or interests (e.g. unusual interest in pornography, masturbation, sexual demands 
on partner), other repetitive activities (hobbies, dismantling objects, sorting or organizing), or 
taking extra non-prescribed medication for non-physical reasons (i.e. addictive behaviour)” 
(Goetz et al., 2008). The examiner is also asked to rate the impact of these behaviours on the 
patient’s personal life, family and social relations. For the purposes of analysis, patients who 
scored ≥ 1 on MDS-UPDRS item 1.6 were considered to have DDS and were compared with 
non-DDS group in terms of demographics (age, sex, smoking history), dopaminergic 
medication, disease characteristics (PD duration, motor severity and motor complications 
[UPDRS]), psychiatric symptoms (HDRS, HADS), cognition (ACE, FAB, SCOPA-COG) 
and sleep (PSQI, ESS, SCOPA-sleep), using non-parametric (Mann-Whitney) statistical 
analysis. 
 
7.3  Results  
7.3.1  Prevalence of PG in PD compared to the general population 
Two large North American epidemiological studies using structured interviews based on the 
DSM-IV criteria show a prevalence of PG in the general population of 0.42% (USA national 
survey, N=43,093) (Petry et al., 2005) and 1% (Ontario, Canada, N= 1,030) (Ferris et al., 
1996) respectively. In PD, the prospective screening studies for PG that replicate this strict 
methodology and adherence to DSM-IV criteria, including use of an experienced psychiatrist 
to interview patients (Voon et al., 2006), revealed higher rates of PG than the general 
population. In one study, 4.4% of patients on PD medication and 8.0% on DA fulfilled DSM-
IV criteria for PG (Grosset et al., 2006) and in another, the lifetime prevalence of PG in PD 
was 7.2% in patients using a DA (Voon et al., 2006).  
160 
 
 
7.3.2  Patient characteristics 
28 case series were identified with a total of 177 patients, dating from July 2000 to March 
2007 (Tyne et al., 2004, Serrano-Duenas, 2002, Antonini et al., 2006, Dodd et al., 2005, 
Driver-Dunckley et al., 2003, Weintraub et al., 2006, Voon et al., 2006, Grosset et al., 2006, 
Pontone et al., 2006, Larner, 2006, Seedat et al., 2000, Gschwandtner et al., 2001, Avanzi et 
al., 2004, Bandini et al., 2006, Spengos et al., 2006, Nirenberg & Waters, 2006, Montastruc et 
al, 2003, Ardouin et al., 2006, Kurlan, 2004, Imamura et al., 2006, Drapier et al., 2006, 
Avanzi et al., 2006, Lu et al., 2006, Sevincok et al., 2007, Wong et al., 2007, Voon et al., 
2007, Garcia et al., 2007, Smeding et al., 2007). There was a male preponderance of 118/156 
(75.6%) cases, mean age at diagnosis of PG of 57.3 years (±9.9, range 30-78, N=80), mean 
age at onset of Parkinson’s disease of 49.5 years (±10.3, range 18-72, N=80) and a disease 
duration of 7.8 years (±4.9, range 2-22, N=80). Other psychopathology was reported in 45/70 
(64.3%) with depression in 38/91 (41.8%). Absence or presence of previous gambling 
behaviour was reported in 8 series. The majority, 23/31 (74.2%) did not gamble before 
diagnosis of PD. Previous substance misuse was reported in 6 series. A minority, 14/38 
(36.8%) had previous substance misuse, predominantly alcohol. Information on pre-morbid 
smoking and caffeine use was not given. Previous impulse control disorder (ICD) was 
reported in one series (Weintraub et al. 2006). 36.4% of patients with active ICD had ICD 
behaviour prior to PD compared to 3.5% of controls. 
 
7.3.3  Medication use 
DAs were used in 174/177 (98.3%) of cases, with DA monotherapy in 17/130 (13.1%). This 
included two patients using a combination of two different DA. The three exceptions were a 
case of PG related to use of selegiline (Drapier et al., 2006) and two cases related to the use 
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of L-DOPA monotherapy (Ardouin et al., 2006, Avanzi et al., 2006). L-DOPA was the most 
frequently co-prescribed agent, 110/130 (84.6%). Overall, pramipexole was the most 
commonly prescribed DA 78/177 (44.1%). Other agents were ropinirole in 42/177 (23.7%), 
pergolide in 32/177 (18.1%), bromocriptine in 13/177 (7.3%) and cabergoline in 8/177 
(4.5%). In six series, the number prescribed each individual DA in the screened population 
group was given; overall, pramipexole was the most commonly used DA (43.6%), followed 
by ropinirole (28.9%). In five prospective screening studies, the prevalence of PG in patients 
taking DA ranged from 2.3 to 8.0% (>6% in four series). In one paper (Driver-Dunckley et 
al., 2003), pramipexole was significantly more frequently associated with occurrence of PG, 
compared to ropinirole (P=0.01). However, overall the difference between treatment with 
individual DA does not reach statistical significance. The pooled OR of PG associated with 
pramipexole compared to ropinirole is 1.55, CI 0.88-2.73, P=0.13 (heterogeneity χ2 P=0.32, 
fixed effects model) (figure 7.1) and the OR comparing total non-ergot and ergot DA is 1.78, 
CI 0.89-3.54, P=0.10 (heterogeneity χ2 P=0.088, fixed effects model). The latter calculation 
very nearly approaches statistical heterogeneity, but if a random effects model is applied the 
OR is less statistically significant (OR 1.38, CI 0.49-3.93, P=0.55). 
 
 
  
162 
 
Figure 7.1: Meta-analysis to determine influence of dopamine agonists on prevalence of 
pathological gambling: (a) ergot versus non-ergot dopamine agonists and (b) pramipexole 
versus ropinirole. Forest plots are shown with pooled odds ratio and 95% confidence ratios. 
 
 
 
  
 
 
 
 
163 
 
The mean latency of onset of PG from DA initiation was 23.0 months (±24.6, range 1-84 
months, N=30) and from L-DOPA initiation 86.9 months (±65.1, range 12-216 months, 
N=13).  Some patients had been on DA therapy for relatively long periods (18/30 ≥ 1 year 
and 12/30 ≥ 2 years) with their problem of gambling not becoming clinically evident until 
dopaminergic treatment was increased. In 7/9 cases in one paper (N=9) (Driver-Dunckley et 
al., 2003) PG started within one month of increasing the dose of a DA, which had previously 
been initiated.  
 
The mean total LEU was 909.2 (±621.1) mg and the mean DA LEU was 308.9 (±146.6) mg, 
equivalent to 4.6mg of pramipexole salt content (= 3.1 mg base) or 15.4 mg of ropinirole. 
The pramipexole equivalent of 4.6 mg (salt) exceeds the maximum recommended dose for 
this drug. In cases where individual doses of pramipexole were provided (N=41), 26/41 
(63.4%) were taking ≥ 4.5mg. In cases where individual doses of ropinirole were provided 
(N=23), none exceeded the recommended maximum (24mg) with one patient was taking 
24mg. In total for ropinirole and pramipexole (the two most commonly prescribed non-ergot 
DA) 27/64 (42.2%) were taking the maximum recommended dose or more. In papers where 
individual doses of L-DOPA were recorded (N=74), 38/74 (51.4%) were using <500mg, 
28/74 (37.8%) 500-1000mg and 8/74 (10.8%) >1000mg, the dose range typical of DDS.  
 
7.3.4  Dopamine dysregulation syndrome and psychiatric comorbidity 
In case series on PG, DDS was explicitly reported in 18 patients, specifically excluded in 53 
patients and in the remaining 106 cases DDS was not specifically reported (table 7.1). In 
those with PG, the DDS and no DDS groups were similar in terms of their predominantly 
male sex (P=0.62), early onset of PD (P=0.26), high DA LEU (P=0.42) and overall history of 
psychiatric disorders (P=0.47). However, the DDS group had significantly longer disease 
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duration (P=0.05), and higher total LEU (P=0.003). Directly comparing the non-DDS PG 
group (N=50) with a larger (N=25) representative group of DSS (Evans et al., 2005), disease 
duration was significantly longer in patients with DDS (P<0.0001), DA were used less 
frequently (P=0.001) and L-DOPA more frequently (P=0.003). Both DA LEU (P<0.0001) 
and total LEU (P<0.0001) were significantly more in DDS than non-DDS PG (table 7.2). The 
non-ergot DA (P<0.0001) were significantly less associated with DDS behaviour than ergot 
DA. Gambling in the context of an episode of mania is an exclusion criterion in DSM-IV 
criteria for PG. However, cases of hypomania (Voon et al., 2006, Seedat et al., 2000) and 
psychotic symptoms, such as delusional thought disorder (Dodd et al., 2005) developing after 
the onset of PG were reported, although this was uncommon. 
 
7.3.5  Type of Gambling 
Preferred gambling activities are listed in 17 series (N=75).  These include slot machines in 
25/75 (33.3%), casino attendance (activities unspecified) in 16/75 (21.3%), lottery/scratch 
cards in 12/75 (16%), internet gambling in 15/75 (20%), horse/greyhound racing 
10/75(13.3%), bingo in 4/75 (5.3%), interactive television in 2/75 (2.7%) and stock market in 
1/75 (1.3%). This is consistent with previous reports of a predilection for activities which are 
repetitive, require little higher cortical processing and have high reward uncertainty. 
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Table 7.1 Characteristics of patients with pathological gambling (PG) compared to a representative sample of patients with dopamine 
dysregulation syndrome (DDS). Figures given as mean (±SD) 
 
 Patients with pathological gambling (PG) Patients with 
dopamine 
dysregulation 
syndrome (DDS) 
Evans et al. 
(Previously 
unpublished data) 
Statistical 
comparison 
between patients 
with DDS and 
non-DDS PG 
group. 
 
TOTAL No DDS DDS Statistical 
comparison of 
PG patients with 
and without DDS  
Number (N) 177 50 13 - 25 - 
Sex (males) 118/156(75.6%) 35/50(70%) 10/13 (76.9%) NS  19/25 (76.0%) NS  
Age (years) 57.3 (±9.9) 56.2 (±9.3) 61.5 (±7.5) P=0.04  55.4 (±8.1) NS  
PD Onset (years) 49.5 (±10.3) 49.9 (±8.9) 53.0 (±8.1) NS  42.4 (±8.7) NS  
Duration (years) 7.8 (±4.9) 6.3 (±3.8) 8.5 (±3.4) P=0.05  13.1 (±5.9) P<0.0001  
All dopamine 
agonists(DA) (N) 
174/177(98.3%) 50/50 (100%) 12/13 (92.3%) P=0.05  20/25 
(80.0%) 
P=0.001  
All non-ergot DA (N) 120/177(67.8%) 42/50 (84%) 5/13 (38.5%) P=0.0008  1/25 (4%) P<0.0001 
Pramipexole (N) 78/177 (44.1%) 24/50 (48%) 2/13 (15.4%) P=0.03  0 P<0.0001  
Ropinirole (N) 42/177 (23.7%) 18/50 (36%) 3/13 (23.1%) NS  1/25 (4%) P=0.003  
All ergot DA (N) 53/177 (30.0%) 8/50 (16%) 7/13 (53.8%) P=0.004  7/25 (28%) P=0.004 
Apomorphine (N) 0 0 0 NS  14/25 (56%) P<0.0001  
L-DOPA (N) 110/130 (84.6%) 36/50 (72%) 12/13 (92.3%) NS  25/25 
(100%) 
P=0.003 
Total levodopa 
equivalent daily dose 
(LEDD) (mg) 
909.2  (±621.1) 710.4  (±424.2) 1,581.7 (±857.5) P=0.003 1,993 (±833) P<0.0001  
DA LEDD(mg) 308.9 (±146.6) 307.0 (±105.9) 361.2 (±224.9) NS  706 (±309) P<0.0001  
Ψ history (N) 45/70 (64.3%) 19/33 (57.6%) 9/13 (69.2%) NS  20/25 (80%) NS  
Depression (N) 38/91 (41.8%) 12/33 (36.4%) 9/13 (69.2%) P=0.04 12/25 (48%) NS 
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7.3.6  Management 
Patient management was detailed in 18 case series (N=72). Improvement of PG was reported 
with decrease or discontinuation of DA dose in 29 patients (40.3%), four of whom required 
concomitant increase in L-DOPA to control parkinsonian symptoms. Decrease of both L-
DOPA and DA was required in 5 patients. In three patients L-DOPA was decreased with 
increase of the concomitant DA (cabergoline) in one and with switch from ropinirole to 
pramipexole in another. Eight others improved after switching to an alternative dopamine 
agonist (in 6 cases from pramipexole to ropinirole). In patients that responded to 
dopaminergic dose reduction, 9 needed concomitant psychotherapy and 5 antidepressant 
prescription. One responded to stopping selegiline. Overall 22 (30.6%) had psychiatric input, 
of whom 17 had counselling/psychotherapy, 10 were prescribed antidepressants, and three an 
atypical neuroleptic. One did not respond to psychotherapy and SSRI, ultimately committing 
suicide (Driver-Dunckley et al., 2003). Ten patients required subthalamic nucleus (STN) 
stimulation because dopaminergic medication reduction was not tolerated or unsuccessful 
(N=9), there was no response to behavioural therapy (N=4), no response to SSRI (N=2) or 
clozapine (N=1). PG resolved spontaneously in one person. Of the remainder, there was no 
response to treatment in one (decrease in both L-DOPA and pramipexole, Kurlan, 2004), no 
attempted treatment intervention in three (Nirenberg & Waters, 2006, Avanzi et al., 2006, 
Wong et al, 2007) and no information on management in 5 patients.  
 
7.3.7  Clinical study 
15/94 (16%) scored ≥1 on the MDS-UPDRS Part 1.6, indicating ICD or DDS behaviour. The 
majority exhibiting this behaviour were male, although this did not reach statistical 
significance (table 7.3). As in the published literature, patients with ICD/DDS were younger 
and had significantly earlier age at diagnosis of PD. This was a cross-sectional study and 
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patients were not specifically asked about the onset and duration of their abnormal 
behaviours, however ICD/DDS patients had longer disease duration, consistent with finding 
in the meta-analysis that patients with PG have usually been exposed to dopaminergic 
medication for several years. ICD/DDS was associated with overall DA use, and in particular 
ergot DA use. In this study there was only a trend for higher non-ergot DA use (p = 0.19) but 
patients had significantly higher total LEU and DA LEU doses (table 7.3), suggesting that it 
is not only DA use per se that is important, but there is also a possible dose effect, as 
demonstrated in the meta-analysis. ICD/DDS was also associated with amantadine use. 
Alcohol and smoking history was similar in the two groups. Patients with ICD/DDS were 
more anxious (HADS-anxiety), had a trend to more depression (HDRS), significantly more 
sleep disruption (PSQI and SCOPA-sleep-night) and more drug-related motor complications 
(UPDRS Part IV). There was however no difference in scores on the cognitive scales (ACE, 
FAB, and SCOPA-COG). 
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Table 7.2 Demographic and clinical features associated with Impulse Control Disorders and 
Dopamine Dysregulation Syndrome in PD. 
 ICD/DSS 
(n=15) 
Median (IQR)  
Non-ICD/DDS 
(n=79) 
Median (IQR) 
P value 
Demographics 
Age (years) 64 (57-71) 69 (62-75)  0.076 
Age at diagnosis (years) 50 (46-59) 63 (54-71) 0.007 
Disease duration (years) 10.8 (6.6-17.9) 4.2 (2.3-11.3) 0.020 
Sex (male) 13/15 52/79 0.11 
Smoking (pack years) 1 (0-5) 0 (0-14.5) 0.80 
Alcohol (units/week) 5 (0-10) 5 (0-16) 0.37 
Medication 
Levodopa 13/15 50/79 0.078 
All dopamine agonists 14/15 39/79 0.002 
Non-ergot agonists 10/15 38/79 0.19 
Ergot dopamine agonists 4/15 1/79 <0.001 
MAO inhibitor 3/15 8/79 0.28 
COMT inhibitor 7/15 19/79 0.073 
Amantadine 5/15 7/79 0.009 
Total LEDD 901.5 (601.5-1034.7) 360.0 (100.5-800.0) <0.001 
Dopamine agonist LEDD 268.0 (201.0-320.0) 0.0 (0.0-201.0) <0.001 
Psychiatric co-morbidity 
HDRS 5 (2-8) 2 (1-6) 0.071 
HADS-Anxiety 8 (5-10) 5 (2-8) 0.007 
HADS-Depression 7 (3-10) 5 (3-8) 0.34 
Cognition 
ACE 94 (90-99) 92 (85-96) 0.088 
FAB 16 (15-18) 16 (14-17) 0.51 
SCOPA-COG 28 (22-32) 24 (21-30) 0.18 
Sleep 
PSQI 10 (6-13) 6 (3-8) 0.003 
ESS 12 (9-14) 7 (4-13) 0.051 
SCOPA-Sleep-Night 8 (4-12) 4 (2-7) 0.008 
SCOPA-Sleep-Day 6 (3-8) 4 (2-8) 0.23 
UPDRS 
Part I 4 (2-5) 3 (1-5) 0.20 
Part II 16 (12-22) 14 (8-20) 0.20 
Part III 27 (21-35) 31 (20-38) 0.51 
Part IV 6 (3-10) 2 (1-6) 0.003 
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7.4  Discussion 
There are certain major caveats in this type of review and meta-analysis that limit 
generalization of results. These include lack of robust selection criteria and therefore over-
reliance on case studies rather than systemic analyses. This is likely to result in selection bias 
for young male PD patients, who are felt most likely to exhibit PG. In addition, retrospective 
identification of mood disorders, substance misuse and previous gambling may be biased in 
case control studies, and underestimated in studies where these behaviours are not actively 
sought. Only large prospective studies can overcome these limitations. 
 
7.4.1  Risk factors of Pathological Gambling in Parkinson’s disease 
PG occurs as a rare side effect of treatment of PD in up to 8% of patients on DA. This 
prevalence is considerably higher than in the general population, where the prevalence of PG 
is around 1% (Ferris et al., 1996). Patients are predominantly male and young. Psychiatric co-
morbidity was often present but as many studies were retrospective it is not clear whether this 
is a predisposing factor or consequence of the condition. These findings are consistent with 
population-based observations that link PG to younger age, male gender and high rates of 
psychiatric problems (Potenza et al., 2001). However substance misuse appears to be a less 
frequent risk factor in PD patients compared to PG in the general population. The majority of 
patients have no history of gambling or substance misuse. This may however be an 
underestimate as the majority of studies did not actively screen for these pre-morbid risk 
factors. 
 
7.4.2  Relationship to dopaminergic treatment 
With the exception of one patient on selegiline and two on L-DOPA alone, all the affected 
patients in the meta-analysis were on DA (98.3%). An initial case series of 12 patients 
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(Molina et al., 2000) implicated L-DOPA as a potential aetiological agent for PG, however 
other dopaminergic drugs used (particularly DA) were not listed. Subsequently, several series 
reporting the phenomenon of DA-associated PG were published. Results of this meta-analysis 
confirm treatment with this drug group as the largest independent risk factor. It has been 
suggested that the DA pramipexole is associated with a particularly increased risk of PG. 
Evidence for this includes a high adjusted reporting ratio compared to other DA in an FDA 
audit of adverse events (Szarfman et al., 2006). However, the increased reporting ratio may 
reflect reporting bias in the FDA audit as the first large case series implicated pramipexole as 
the main aetiological agent (Driver-Dunckley et al., 2003). The difference may also reflect 
the relative prescription frequency of pramipexole (overall 43.6%, and >50% of DA 
prescriptions in several reported series (Weintraub et al., 2006, Pontone et al., 2006). 
Comparison of the risk of PG on different DA did not reach statistical significance, 
comparing pramipexole to ropinirole and comparing non-ergot and ergot DA. With further 
prospective studies these differences may become significant; however the OR is likely to 
remain small.  
 
The doses of DA were generally large, with a large proportion of patients taking higher than 
the recommended maximum dose, particularly of pramipexole. The use of L-DOPA in the 
majority of PG patients may suggest cross-sensitization of brain systems mediating reward. 
This is further supported by the observation that many individuals with PG had been on 
stable doses for many months before PG evolved. However, many patients with PD are 
exposed to a large variety of different dopaminergic drugs and only a relative minority 
develop compulsive behaviours indicating that individual factors, including a neurobiological 
predisposition, are highly relevant. 
 
171 
 
The clinical study in the PD patient cohort confirmed an association of DDS with 
dopaminergic medication, and in particular high dopamine equivalent doses of L-dopa and 
DAs. The median DA LEU was 268 mg, equivalent to pramipexole 4 mg (salt) dose. Patients 
with DDS had significantly longer disease and treatment duration (median 10.8 years since 
diagnosis), consistent with the finding in the meta-analysis that patients exhibiting this 
behaviour had been exposed to dopaminergic medication for some time.    
 
7.4.3  Neurobiological Predisposition 
Ventromedial prefrontal cortex (VMPFC) involvement has been implicated in ICD from 
imaging studies. These include an fMRI study of individuals with PG (non-PD) compared to 
controls which showed negative correlation between activation of the VMPFC and ventral 
striatum (an area implicated in drug addiction) and gambling severity (Reuter et al., 2005). 
PET studies in PD patients, un-medicated and with early stage disease, showed significantly 
lower activation in the orbitofrontal cortex (OFC) and amygdala, as well as striatum (Ouchi 
et al., 1999) and a further PET study in medicated PD patients performed whilst doing the 
Iowa Gambling task (Bechara et al., 2005) showed reduced activity in the mesial-frontal 
areas (Thiel et al., 2003). Decreased activity of the OFC has been consistently reported in 
imaging studies of drug-addicts (Volkow et al., 2005) and is consistent with evidence that the 
prevalence of PG is higher in addicts in general (Toneatto & Brennan, 2002). In DDS, PET 
studies have demonstrated sensitization of ventral striatum to dopaminergic transmission, 
which correlates with the trait of L-DOPA “wanting” (Evans et al., 2006). VS sensitization is 
replicated in PET studies after amphetamine administration (Boileau et al., 2006). PG and 
chemical addiction share many similarities, which include difficulty in controlling the 
impulse to gamble/overuse medication and the persistence in these behaviours despite 
negative consequences. Investigation into the biological features of both PD and non-PD 
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subjects with impulse control behaviour provide support for at least an overlapping biological 
substrate. 
 
7.4.4 Relationship to impulse control disorders and dopamine dysregulation 
syndrome  
The patient characteristics of PG in PD are comparable to case series of other impulse control 
disorders in PD such as hypersexuality (Klos et al., 2005). PG also shares a number of 
characteristics of DDS, such as male sex, early age of onset of PD, higher prevalence of 
depression than controls and intake of relatively high doses of DA. However, a number of 
patients with PG have been specifically reported not to have DDS and, conversely, not all 
patients with DDS have PG as part of the syndrome. PG also differs from DDS in that DA 
use is almost invariably associated (98.3%), whereas DDS is associated with high doses of L-
DOPA. In patients with PG, those with DDS have longer disease duration and higher total 
LEU.  
 
There are various hypotheses for the aetiology of dopaminergic medication associated 
compulsive behaviours in PD. It may be speculated that differences between occurrence of 
DDS and PG are due to the shorter duration of action of L-DOPA producing more instant 
effects than DAs in DDS, whereas PG may be an adverse effect relating to more continuous 
dopamine receptor stimulation. However, it is possible that PG represents a dose dependent 
side effect of DA treatment with a different pathophysiology to DDS and overlap with the 
DDS phenotype may represent DA co-prescription in this group. The relative selectivity of 
DA for D3 dopamine receptors, including in mesolimbic areas of the brain, has been 
postulated as a mechanism for their association with impulse control disorders (Dodd et al., 
2005). The differential receptor profile of L-DOPA and DA (including differences between 
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ergot and non-ergot DA) may influence the type of compulsive behaviour that manifests.  
 
7.4.5  Management 
A large proportion of patients with PG were taking higher than the maximum licensed dose 
of DA. This should clearly be avoided, even with good antiparkinsonian benefit. Pre-morbid 
gambling, drug use histories and impulsive sensation seeking personality traits may be 
relevant in identifying at risk individuals. The onset of PG may also occur after the 
introduction of new dopaminergic medications (particularly DA) or dose increases, and at 
these times, and especially in young male patients, particular attention should be given to the 
possibility of this syndrome, although overall only a relatively small minority of patients will 
be affected. In the non-PD population, there is evidence of benefit from cognitive behavioural 
therapy (Sylvain et al., 1997), however long term compliance with self-help groups (Stewart 
& Brown, 1988), particularly in those with co-morbid psychopathology or drug dependency 
is poor. SSRI use has also been shown to be potentially beneficial (Hollander et al., 2000). In 
PD several treatment strategies have been reported to be beneficial but no prospective study 
has been conducted to date. Reduction of DA dose, possibly with increase in L-DOPA to 
alleviate worsening PD symptoms, reduction of all dopaminergic treatments, or switching 
from one DA to another may be successful. However, changes to dopaminergic treatment are 
often not well tolerated and the psychological/cognitive treatments and psychotropic 
medication, used in the non-PD PG population may prove beneficial.  
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Chapter 8 
Clinical Features associated with Apathy in Parkinson’s Disease. 
 
8.1  Introduction 
The clinical syndrome of apathy is found in up to 60% of patients with Parkinson’s disease 
(Oguru et al, 2010). Diagnostic criteria for apathy in PD (Starkstein et al., 2009) include loss 
of motivation relative to pre-morbid function, diminished goal-directed behaviour and 
cognition, and flattened affect and lack of emotional responses, that are severe enough to 
result in significant distress or impact on social or occupational function.  Apathy may be 
associated with depressive disorders (Reijnders et al., 2010; Starkstein et al., 2009) or 
cognitive impairment (Reijnders et al., 2010, Dujardin et al., 2007, Butterfield et al., 2010), 
particularly executive dysfunction (Varanese et al., 2011, Zgaljardic et al., 2007, Dujardin et 
al., 2009), but it can exist as a distinct neurological entity (Kirsch-Darrow et al., 2006). 
However, few data exist on the relative contribution of each of these factors to apathy and its 
relationship with other non-motor features that may influence its occurrence has not been 
examined in detail. We here examined the role of other factors that may lead to reduced goal-
directed behaviour and cognition, loss of motivation, flattened affect and lack of emotional 
responses such as impaired night time sleep, excessive daytime somnolence, fatigue, anxiety, 
motor severity and motor complications (“off” fluctuations and dyskinesias) in addition to 
impaired cognition and depression.  
 
8.2  Methods 
8.2.1.  Patients and clinical measures 
The Lille Apathy Rating Scale (LARS) was administered to all patients (Sockeel et al., 2006). 
The LARS is a 33-item apathy rating scale based on structured clinical interview with several 
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domains (everyday productivity, interests, initiative, novelty seeking, motivation, emotional 
response, concern, social life and self-awareness) which has been validated for use in PD and 
has shown high internal consistency, test-retest reliability and inter-rater reliability (Sockeel 
et al., 2006). A cut-off score of ≥ -16 (scale range: -36 to +36, where higher scores represent 
a greater degree of apathy) had a high degree of sensitivity and specificity in discriminating 
an expert’s judgement of apathy in the original validation study in PD cohort (n=159) and 
healthy controls (n=58) (Sockeel et al., 2006). The LARS has also shown good concurrent 
validity with proposed consensus criteria for apathy in Alzheimer’s disease and other 
neuropsychiatric disorders (Robert et al., 2009). Other clinical measures included the HDRS 
(Schwab et al., 1967), HADS (Upadhyaya and Stanley, 1993), ACE (Larner, 2007), FAB 
(Dubois et al., 2000), SCOPA-COG (Marinus et al., 2003), UPDRS (Fahn et al., 1987), 
SCOPA)-Sleep scale (Marinus et al., 2003b), and FSS (Krupp et al., 1989), 
 
8.2.2.  Statistical analysis 
Based on established cut-off scores on clinical scales, patients were classified as apathetic 
(LARS score ≥ -16 [Sockeel et al., 2006]) and/or depressed (HDRS score ≥ 10, cut-off score 
for screening in PD [Schrag et al., 2007]) and/or cognitively impaired (SCOPA-COG ≤ 24, 
optimal cut-off for screening for PD dementia [Verbaan et al., 2011]). Scores on clinical 
rating scales for motor and non-motor features of PD in apathetic and non-apathetic groups 
were compared using Mann-Whitney U analysis. Multiple regression analysis was performed 
separately with the LARS total score and the four subscores (intellectual curiosity, emotion, 
action initiation and self-awareness) as the dependent variables and clinical factors in the 
univariate analysis (P<0.05), excluding collinear variables, as the independent variables. 
Regression analysis was performed with backward selection, with probability criteria for 
variable removal P>0.10.  
176 
 
 
8.3  Results 
8.3.1  Clinical features associated with apathy 
15 of 94 (16%) patients were defined as apathetic using the LARS cut-off score. Only one of 
15 (7%) had pure apathy, the remainder having depression (5 of 15, 33%) and/or cognitive 
impairment (12 of 15, 80%), with 3 (19%) having both (fig 8.1). In comparison, in the non-
apathetic patients, 6 of 79 (8%) had depression and 34 of 79 (43%) had cognitive impairment. 
There was no significant difference between the apathetic and non-apathetic groups in age, 
disease duration or dopaminergic medication (Levodopa equivalent units, LEU) (table 8.1). 
Patients with apathy had significantly more depression (HDRS, HADS-depression score), 
fatigue (FSS), cognitive impairment (ACE, SCOPA-cognition, FAB), daytime somnolence 
(SCOPA-sleep-daytime), severity of motor symptoms (UPDRS motor score, Part III) and 
motor fluctuations (UPDRS Part IV, table 8.1). In the regression analysis five variables were 
independently associated with apathy in PD: greater depression (HDRS), daytime 
somnolence (SCOPA-sleep-daytime), cognition (SCOPA-cognition), and motor severity 
(UPDRS Part III) and lower motor complications scores (UPDRS Part IV) (table 8.2). 
Predictive variables for the LARS intellectual curiosity subscore were greater depression 
(HDRS), cognitive impairment (SCOPA-cognitive), daytime somnolence (SCOPA-sleep-
daytime) and lower motor fluctuation scores (UPDRS Part IV). Predictive variables for the 
action initiation subscore were greater daytime somnolence, cognitive impairment and motor 
function (UPDRS Part III) scores. Predictive variable for self-awareness subscore was fatigue 
(FSS). No variables allowed significant prediction of the LARS emotion subscore in this 
study.   
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Figure 8.1 Apathy, Depression and Cognition in Parkinson’s Disease 
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Table 8.1 Clinical findings of PD patients with and without apathy 
 Apathetic (N=15) 
Median  
(Interquartile range) 
Non-Apathetic 
(N=79) Median 
(Interquartile range) 
P value 
Demographics 
Age (years) 71.0 (62.0-75.0) 68.0 (62.0-74.0) 0.55 
Disease duration 
(years) 
6.7 (3.1-15.9) 4.8 (2.3-11.6) 0.19 
LEU (mg) 626.7 (300.0-883.5) 400 (100.5-900.0) 0.14 
Sleep and fatigue 
SCOPA-Sleep-Night-
time 
3.0 (1.0-11.3) 4.0 (2.0-8.0) 0.76 
SCOPA-Sleep-
Daytime 
8.0 (3.0-12.5) 4.0 (2.0-6.0) 0.021 
FSS 5.7 (4.5-6.6) 4.1 (2.8-5.2) 0.008 
Depression and anxiety 
HDRS 8.0 (6.0-11.0) 2.0 (1.0-5.0) <0.001 
HADS-Anxiety 3.5 (1.8-7.5) 5.0 (3.0-9.0)  0.20 
HADS-Depression 8.5 (6.0-11.3) 5.0 (2.0-8.0) <0.001 
Cognition 
ACE 85.0 (77.0-94.0) 93.0 (87.0-96.0) 0.021 
FAB 13.0 (12.0-17.0) 16.0 (15.0-17.0) 0.031 
SCOPA-Cognition 20.0 (18.0-23.0) 25.0 (22.0-31.0) 0.003 
-memory 6.0 (5.0-8.0) 9.0 (7.0-12.0) 0.003 
-attention 4.0 (2.0-4.0) 4.0 (4.0-4.0) 0.28 
-executive 8.0 (6.0-9.0) 9.0 (8.0-10.0) 0.038 
-visuospatial 3.0 (2.0-4.0) 4.0 (3.0-5.0) 0.076 
Motor function 
UPDRS Part III  38 (29-48) 28 (19-37) 0.020 
UPDRS Part IV 4 (3-9) 2 (1-6) 0.031 
Abbreviations LEU – Levodopa Equivalent Units, SCOPA – Scales for Outcome in 
Parkinson’s disease, FSS – Fatigue Severity Scale, HDRS – Hamilton Depression Rating 
Scale, HADS – Hospital Anxiety and Depression Scale, ACE – Addenbrooke’s Cognitive 
Examination, FAB – Frontal Assessment Battery, UPDRS – Unified Parkinson’s Disease 
Rating Scale.  
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Table 8.2: Multiple regression analysis of clinical features associated with apathy subscores 
in Parkinson’s disease 
 β-coefficient T score P value 
LARS total score  
SCOPA-sleep-
daytime 
0.59 3.00 0.004 
HDRS 0.73 3.70 <0.001 
SCOPA-
cognition 
 -0.27 -2.44 0.017 
UPDRS Part III 0.12 1.99 0.050 
UPDRS Part IV  -0.47 -2.08 0.041 
Model R
2
 = 0.39 
LARS intellectual curiosity 
SCOPA-sleep-
daytime 
0.09 3.08 0.003 
HDRS 0.12 4.48 <0.001 
SCOPA-
cognition 
-0.04 -2.74 0.007 
UPDRS Part IV -0.06 -1.98 0.051 
Model R
2
 = 0.38 
LARS emotion 
Nil significant 
LARS action initiation 
SCOPA-sleep-
daytime 
0.10 3.60 0.001 
SCOPA-
cognition 
-0.06 3.26 0.002 
UPDRS Part III 0.02 2.32 0.023 
Model R
2
 = 0.37 
LARS self-awareness 
FSS 0.14 1.77 0.080 
Model R
2
 = 0.03 
Abbreviations, LARS = Lille Apathy Rating Scale, SCOPA = Scales for Outcome in 
Parkinson’s disease, HDRS = Hamilton Depression Rating Scale, UPDRS = Unified 
Parkinson’s Disease Rating Scale, FSS = Fatigue Severity Scale. 
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8.4  Discussion 
Our finding that apathy in PD is strongly and independently associated with higher 
depression scores and cognitive impairment is consistent with previous studies (Reijnders et 
al., 2010; Reijnders et al., 2010, Dujardin et al., 2007, Butterfield et al., 2010; Starkstein et 
al., 2009). We could also confirm that considerable overlap exists between these three 
syndromes, although in some patients apathy is not associated with either of these 
comorbidities. Apathy was also significantly associated with fatigue and daytime 
somnolence, which was not fully explained by greater cognitive impairment and depression, 
and not associated with poor night-time sleep, suggesting that this non-motor feature 
additionally contributes to patients’ loss of motivation, and addressing this separately may 
improve patients’ apathy. Greater motor impairment, as measured by UPDRS motor score, 
further contributed mildly to higher apathy scores. This is in contrast to previous studies 
where there was no difference in motor scores between apathetic and non-apathetic patients 
(Starkstein et al., 2009) or this variable did not contribute to the regression model once other 
variables had been accounted for (Oguru et al., 2010).  As this was primarily seen in the 
action initiation subscale, this may reflect patients’ difficulty in physically initiating activities 
due to immobility. Finally, there was a significant greater apathy score in those with lower 
motor complications subscores on the UPDRS, which may reflect lower responsiveness to 
medications. In conclusion, apathy in PD is frequently associated with depressive symptoms 
and cognitive impairment and with greater motor impairment and fewer motor complications 
but also independently with increased daytime somnolence/fatigue, which can potentially be 
addressed directly in clinical practice to improve apathy.  
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Chapter 9 
Conclusions 
 
9.1  Quality of life 
PD is a multisystem neurodegenerative disorder, characterised by dopaminergic neuronal loss 
in the substantia nigra pars compacta. However, a number of other neurotransmitter systems 
are involved and detailed pathology studies have demonstrated involvement of widespread 
extra-nigral locations. The development and widespread introduction of Levodopa therapy 
for PD in the 1970s resulted in a dramatic change in the prognostic outcome and quality of 
life for PD patients with improvement in the characteristic motor features of the disease. In 
subsequent decades, research and development into pharmacological therapies has focused on 
drugs that act on dopaminergic pathways, for example synthetic dopamine agonists and 
medication to potentiate L-dopa function, such as mono-amine oxidase inhibitors (selegiline 
and rasagiline) and catechol-o-methyl transferase inhibitors (entacapone and tolcapone). The 
majority of primary care physicians are able to recognise the typical motor features of PD 
(tremor, rigidity, bradykinesia, and gait disturbance) and have good knowledge of the 
dopaminergic drug therapies available, and feel confident to prescribe and adjust doses in the 
primary care setting. In addition, many patients have access to specialist hospital based care 
(geriatricians, general neurologists and movement disorder specialists), and in many cases are 
seen in clinics with multi-disciplinary input (PD nurse specialists, occupational therapists and 
occupational therapy). Therefore in most cases dopaminergic drug therapy has been 
optimised depending on motor severity and within limits of associated motor complications 
(motor fluctuations and dyskinesias). However, until relatively recently, there has been little 
research into the prevalence of NMS or into the development of novel drug therapies for 
these symptoms; but despite this, NMS have been shown to influence Hr-QOL. Previous 
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studies that have examined the influence of different clinical factors on quality of life have 
concentrated on motor severity and motor complications; where non-motor features have 
been included, this has generally been limited to cognitive function and mood. Cognitive 
scales used have often been generic (for example MMSE) rather than scales specifically 
developed in PD, or scales more sensitive to detect dysexecutive or subcortical cognitive 
function. Depression has consistently been shown to have a significant impact on quality of 
life however other important neuropsychiatric features such as anxiety, apathy and psychosis 
have not been extensively examined. This study aimed to examine a very broad range of 
motor and non-motor symptoms, and to quantify these accurately with validated clinical 
scales. Where possible, scales were used that had been developed specifically for PD, rather 
than generic scales, and also scales that had undergone independent validation by other 
groups and had demonstrated adequate clinimetric scales properties, and good convergent and 
discriminant validity, were used, although this was not possible in all cases. A wide range of 
NMS were assessed including autonomic function, neuropsychiatric features (depression, 
anxiety, apathy, hallucinations and delusions), sleep (nocturnal and daytime sleepiness), 
cognition (including a scales specifically measuring frontal cognitive function), pain, and 
fatigue. This study confirms that NMS are frequent in PD (mean of 11 symptoms per patient, 
on the NMSQ screening questionnaire). As expected, motor features (severity, fluctuations 
and dyskinesia), depression and cognition had statistically significant univariate correlation 
with Hr-QOL scales. The correlation coefficients for these variables, was similar to the 
published literature, with cognition in particular having only modest correlation with quality 
of life indices. However, in this study, autonomic function, sleep, fatigue, pain and psychosis 
also had high univariate correlation with quality of life, and the multivariate analysis 
demonstrated that in optimally treated patients from a motor perspective, depression, 
autonomic features, fatigue and daytime somnolence were most highly correlated with poor 
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Hr-QoL, and motor features were excluded in the final regression analysis. Therefore 
emphasis on the optimisation of motor symptoms is unlikely to be sufficient to have maximal 
impact on Hr-QOL. Treatment options are not available for all non-motor symptoms in PD, 
or have been developed for use in other neurological or non-neurological disorders rather 
than in PD, and therefore these treatments will require further validation in well-designed 
studies. A challenge for the future will be determine the exact role of extra-nigral 
dopaminergic transmission and other non-dopaminergic neurotransmitter systems in the 
aetiopathogenesis of the wide spectrum of motor and non-motor features of PD and the 
development of novel pharmacotherapies to improve debilitating non-motor features. When 
proven therapies for NMS become available, they should have significant impact on patients’ 
functioning. 
9.2  Detection of non-motor symptoms 
This thesis has examined two aspects of physicians’ awareness and recognition of NMS in 
PD. A retrospective case notes analysis of donors with pathologically proven PD, from the 
UK Brain Bank, revealed that the presenting feature in PD can often be non-motor, with pain, 
autonomic symptoms, and disorders of mood being the most common presenting features. 
This is consistent with autopsy studies that have proposed that the pathological changes in PD 
(LB deposition) can begin in extra-nigral locations, particularly brainstem areas implicated in 
mood and autonomic function. This study has demonstrated that primary care physicians are 
less adept at making an early and confident diagnosis of PD, when non-motor features 
predominate, and this has often led to misdiagnosis as musculoskeletal disorders (“frozen 
shoulder”, osteoarthritis, or degenerative disc-vertebral disease), psychiatric problems 
(depression and anxiety), cerebrovascular disease or other non-neurological diagnoses. Many 
patients are thus referred to inappropriate specialists (rheumatology, orthopaedics, psychiatry, 
urology, or stroke) and may undergo unnecessary investigations or interventions. This study 
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highlights the importance of educating primary care and hospital general physicians in the 
recognition and use of NMS, in the early diagnosis of extra-pyramidal disorders; this will be 
of greater importance if disease-modifying therapies in PD are developed, that could impact 
on disease progression, rather than the currently available symptomatic therapies.  
In addition, this thesis examined the documentation of non-motor features in a cross-sectional 
sample of PD patients in specialist movement disorders clinics, using a screening 
questionnaire and compared this to a retrospective case notes audit. Our study found that 
under half of NMS reported in the screening questionnaire had not been documented in the 
medical notes, particularly potentially embarrassing bowel, bladder and sexual dysfunction. 
The majority of NMS however were shown in our analysis to have significant impact on 
disability and Hr-QOL, and specific enquiry for these issues in PD patients and 
implementation of management strategies is likely to result in significant improvement in 
quality of life.  
9.3  Measurement of non-motor symptoms in PD 
PD is a complex disorder and in the time and resource pressures of the out-patient setting it 
would be virtually impossible to question patients on all NMS, assess their severity and 
clinical significance, and to counsel and instigate multi-disciplinary management strategies. 
The MDS-UPDRS has been developed as a global PD scale, and is a substantial revision of 
the original UPDRS, designed to encompass the complete range of motor and non-motor 
symptoms and to quantify their severity, and is an objective measure of change over time or 
response to drug therapies. The MDS-UPDRS consists of a physician’s assessment of 
neuropsychiatric features (cognition, mood, anxiety, apathy, hallucinations and DDS) and a 
detailed examination of motor features and also a patient (or carer) completed questionnaire 
dealing with other motor or non-motor experiences of daily living. We have demonstrated 
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that the MDS-UPDRS Part I (nM-EDL), which normally takes less than ten minutes to 
complete, has high convergent validity with a battery of detailed clinimetric scales for non-
motor features.  
9.4   Neuropsychiatric symptoms 
Psychiatric phenomena are common in PD. VH, in particular, have been proposed as a 
diagnostic marker of LB pathology and already form part of the formal diagnostic criteria for 
DLB. This thesis examined the pathogenesis of VH in PD. Based on an extensive review of 
clinical, psychometric, pathological, functional imaging and polysomnographic studies, an 
integrated hypothesis was proposed implicating altered visual processing, disorder of sleep-
wake cycle and REM sleep dream mentation, cognitive function, and dopaminergic 
medication. In this study, a multiple regression analysis supported this hypothesis, with RBD 
(ICSD-R minimal diagnostic criteria), executive cognitive function (SCOPA-COG-executive 
score) and a measure of higher order cortical visual processing (BORB object decision task) 
identified as independent determinants of VH in our cohort of PD patients. SCOPA-AUT 
score also contributed significantly to the model and is a marker of brainstem dysfunction, 
which is consistent with the integrated hypothesis. As with, previous cross-sectional studies, 
dopaminergic medication did not make a significant contribution to the regression model. A 
post-mortem study was also performed which demonstrated increased LB density in several 
cortical areas (frontal, temporal, cingulate and entorhinal cortices), including areas implicated 
in visuoperception and cognitive function. This study has potential therapeutic implications 
for the treatment of VH. For example, further analysis of the brainstem nuclei involved in the 
sleep-wake cycle and dreaming, and identification of specific neurotransmitters involved, and 
development of drugs that act on these transmitter systems, will help in the development of 
effective treatments for VH. Similarly, development of medication that can improve 
cognitive function (executive and visuoperceptive) is likely to be important.               
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In this thesis, a meta-analysis of published case series of PG, the archetypal ICD in PD, was 
performed and identified characteristic clinical features, including younger age, male sex, 
psychiatric co-morbidity such depression, and in particular dopaminergic medication. ICD 
was highly associated with DA use, particularly at higher doses, and L-dopa has also been 
implicated in the majority of PG patients, suggesting cross-sensitization of brain systems 
mediating reward. In our PD cohort, patients with ICD/DDS had younger age at diagnosis of 
PD, longer disease duration (suggesting more prolonged exposure to dopaminergic 
medication) and were significantly more likely to use DA medication, and had higher doses 
of dopaminergic medication. It was also demonstrated that psychiatric co-morbidity 
(particularly anxiety), disordered sleep (nocturnal insomnia) and motor complications (higher 
UPDRS part IV scores) are associated with DDS. 
This study also examined the relationship of apathy with depression and cognitive 
impairment. Apathy in PD was strongly and independently associated with higher depression 
scores and cognitive impairment, consistent with previous studies. Considerable overlap 
exists between these three syndromes, although in some patients apathy exists as a distinct 
clinical feature. Apathy was also significantly associated with fatigue, increased daytime 
somnolence, higher motor scores (UPDRS Part III) but also fewer motor complications 
(UPDRS Part IV), which may reflect lower responsiveness to medication. These identified 
features could potentially be addressed directly in clinical practice to improve apathy. 
9.5  Conclusions 
This thesis has demonstrated the importance of NMS in PD. NMS can occur in the early 
stages of PD, and their identification can aid early and accurate diagnosis of the disease, but 
alternatively misattribution of these symptoms to other neurological or non-neurological 
disorders, can lead to misdiagnosis, inappropriate specialty referrals or therapeutic 
187 
 
interventions. I have also demonstrated that NMS have a significant impact on Hr-QOL and 
disability, in early and late disease, but can be under-recognised by neurologists. This study 
has also specifically examined neuropsychiatric features of PD, with particular reference to 
VH, apathy, ICD and DDS.      
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